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ABSTRACT 
 
FMS is the receptor for macrophage colony stimulating factor (M-CSF or CSF-1) and is 
essential for the differentiation and survival of most macrophages, microglia and 
osteoclasts    Infiltration of macrophages and high levels of M-CSF in serum are 
associated with poor prognosis in human breast, ovarian and endometrial cancers.     
Consequently, inhibitors of FMS have considerable therapeutic potential for the treatment 
of cancer, as well as macrophage-mediated inflammatory disease and bone disorders 
caused by excessive osteoclastogenesis .   
 
Here I report the identification of four clinically advanced small molecule kinase 
inhibitors which can also target FMS, as shown by various biochemical and cell-based 
assays.  The inhibitors I identified are imatinib, nilotinib, tandutinib and dasatinib 
(IC50s = 600, 250, 400 and 0.5 nM, respectively),  where the IC50 values refer to 
inhibition of FMS-dependent cell growth.  
 
All of these inhibitors effectively inhibited osteoclastogenesis at concentrations 
expected to be achieved in patients and nilotinib was a particularly potent inhibitor 
(IC50 = 50 nM) indicating that nilotinib is a strong candidate for treatment of diseases 
where osteoclasts are over activated such as osteoporosis and osteolytic bone disease.  
Dasatinib was found to be a potent inhibitor of tumour associated macrophages 
derived from ovarian tumour ascites (IC50 = 0.5 nM) which is similar to the 
concentration required to inhibit FMS and within concentrations considered to be 
achieved in vivo. 
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Using these FMS inhibitors I have also confirmed that the downregulation of the FMS 
receptor in response to ligand binding is independent of kinase activity and instead 
requires a structural change in the receptor.  Intriguingly, at least two tyrosine 
autophosphorylation sites of FMS are still phosphorylated in the presence of some of 
these inhibitors and therefore in the absence of FMS kinase activity.  This implies that 
other kinases may be involved in FMS activation. 
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CHAPTER 1.  INTRODUCTION 
 
1.1 Receptor Signalling 
Signalling by cell surface receptors is fundamental to many cellular processes and 
disease states.  Soluble extracellular signalling molecules including hormones, 
cytokines, growth factors, neurotransmitters and pheromones bind to their specific 
receptor, inducing a structural change in the receptor and receptor activation.  This 
activates a cascade of biochemical pathways which can have a great variety of effects 
on the cell including cell proliferation, differentiation, survival, activation and control 
of motility.  These receptors are classified according to the cellular response they 
induce and by their primary structure.  
 
Cell surface receptors can be divided into four main groups: G protein coupled 
receptors, cytokine receptors, ion-channel linked receptors and tyrosine kinase 
receptors.  G protein coupled receptors span the membrane seven times and so are 
also often called heptahelical receptors.  They have a diverse range of ligands 
including light-sensitive compounds, odors, pheromones, hormones, and 
neurotransmitters and represent 30 – 45 % of current drug targets (Drews, 2000; 
Hopkins and Groom, 2002).  G protein coupled receptors are activated by binding to 
their specific ligand and are then able to activate adenylyl cyclase through a linkage to 
G proteins.  Adenylyl cyclase then generates cyclic adenosine monophosphate from 
ATP which is able to activate many kinases to form a signalling cascade. 
 
 Cytokine receptors are receptors for cytokines and usually have associated tyrosine 
kinase activity.  Cytokines are low molecular weight proteins which regulate 
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immunity, inflammation and haematopoiesis and are usually biologically effective at 
very low concentrations and often work in synergy with one another.  Cytokine 
receptors are often linked to immunodeficiency diseases and include various receptor 
families including the interferons, the interleukins and the tumour necrosis factor 
receptor family.  
 
Ion-channel linked receptors are restricted in their expression to electrically excitable 
cells including neurons and muscle cells and are responsive to chemical messengers 
such as Na+, K+, Ca2+ and Cl-.  They are classified into 3 mains groups: Cys-loop 
receptors such as the serotonin receptor, ionotropic glutamate receptors such as 
kainate and ATP-gated channel receptors such as PX2.  Ion channel receptors are the 
main target of anaesthetics and alcohols such as ethanol and are usually located at 
synapses between cells. 
 
Receptor tyrosine kinases (RTKs) are cell membrane receptors categorised by an 
intrinsic tyrosine kinase activity, giving the ability to autophosphorylate tyrosine 
residues within the receptor. Receptor activation occurs when extracellular 
polypeptide ligands bind to ligand binding domains of the receptor on the surface of 
the cell, causing dimerization of pairs of receptor monomers.  A conformational 
change in the receptor is induced and the kinase becomes activate and is able to 
phosphorylate itself and protein substrates.  The activated receptors are then able to 
signal to a complex network of intracellular signalling molecules which can lead to 
many cellular outcomes including cell proliferation, differentiation and migration 
(figure 1.1).  
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Figure 1.1. Schematic diagram of a receptor tyrosine kinase showing the 
extracellular ligand binding domain, the cytoplasmic domain, containing the 
kinase domain and the ATP binding site.  Modified from http://www.multi-
targetedtherapy.com/rtkCancer.asp 
 
The RTK family includes the receptors for many growth factors and colony 
stimulating factors including Epidermal Growth Factor (EGF), Vascular Epithelial 
Growth Factor (VEGF) Nerve Growth Factor (NGF) and the Platelet –Derived 
Growth Factor family.  The receptor tyrosine kinases have been categorised various 
ways and a popular classifiaction based upon the structures of these receptors is 
shown in figure 1.2 which was proposed by (Ullrich and Schlessinger, 1990).  Figure 
1.3 shows an alternative evolutionary tree which includes all of the receptor tyrosine 
kinases and the cytoplasmic tyrosine kinases. 
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I             II            III      IV      V        VI      VII      VIII     IX    
Tyrosine kinase domains
Cysteine-rich domains
Immunoglobulin-like domains
Acid box
Fibronectin type III domains
I EGF Receptor, HER2, HER3, HER4
II Insulin Receptor
III PDGF, M-CSF, KIT and FLT-3 receptors
IV FGF receptors
V VEGF receptor, FLK receptors
VI Met/HGF receptor
VII TrkA, TrkB, TrkC
VIII Ephrin receptors
IX AXL receptor
Figure 1.2.  Structural classification of receptor tyrosine kinases into nine subfamillies proposed by Ullrich and Schlessinger.   
(Ullrich and Schlessinger, 1990)
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Figure 1.3.  The evolutionary tree of receptor tyrosine kinases and cytplasmic tyrosine kinases with the PDGF receptor family highlighted. 
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1.1.2 Signalling by the PDGF Receptor Family 
Receptor tyrosine kinases are divided into subgroups with respect to their sequence 
and structure (figure 1.2).  The Platelet Derived Growth Factor Receptors (PDGFR) or 
Type III RTK family are a closely related family of tyrosine kinase receptors which 
are activated by the binding of their specific ligands.  Figure 1.3 shows an 
evolutionary tree consisting of the receptor tyrosine kinases and the cytoplasmic 
tyrosine kinases with the PDGF receptor family circled in red.  This family consists of 
KIT, FLT3, PDGF α and β and FMS, which bind to Stem Cell Factor (SCF) (Lev et 
al., 1994) FLT3 (Stirewalt and Radich, 2003), PDGF ligands  (Heldin and 
Westermark, 1999; Bergsten et al., 2001; LaRochelle et al., 2001; Li et al., 2000) and 
Macrophage Colony Stimulating Factor (M-CSF) (Yeung and Stanley, 2003) 
respectively.  Ligand binding induces activation and autophosphorylation of the 
receptor and this allows recruitment and binding of other proteins with 
phosphotyrosine recognition domains.  This results in a signalling cascade which 
induces changes in conformation and phosphorylation status of many downstream 
molecules and leads to activation of specific transcription factors.  An example of a 
common, well documented signalling cascade downstream of the PDGF receptor 
family is the ERK/MAPK pathway.  Generally, upon ligand binding, adapter 
complexes which have SH2 and SH3 domains such as the GRB1/SOS complex 
translocate to the membrane and bind to the receptor.   These complexes are able to 
convert Ras-GDP to Ras-GTP by guanine nucleotide exchange.  Ras is then able to 
activate the MAP kinase kinase kinase (MAP3K) family member Raf which in turn 
activates the MAP kinase kinase (MAPKK) family members MEK1 or MEK2.  These 
in turn activate the MAP kinase members ERK 1 and ERK2 which are then able to 
translocate through the nuclear membrane and activate transcription factors such as 
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TCF and Elk1.  This is a simplified view and signalling cascades in fact involve 
interplay between many kinases and phosphatases and crosstalk between a number of 
signalling pathways, including three further MAP kinase signalling pathways, the PI3 
kinase and JAK/STAT signalling pathways.   These pathways regulate many cellular 
effects and therefore deregulation of signal transduction is implicated in many 
diseases.   
 
 All members of the PDGF receptor family have the same basic structure including 
five extracellular immunoglobulin (Ig) domains, a single transmembrane spanning 
helix, an autoinhibitory juxtamembrane region (JMR) and a cytoplasmic kinase 
domain, consisting of an N terminal and C terminal lobe and a characteristically large 
loop region called the kinase insert region (figure 1.4 shows a schematic diagram of 
the FMS receptor).  The PDGF receptor family is most associated with 
haematopoiesis.  The FLT-3 and KIT receptors are important receptors for early 
haematopoietic progenitor cells and can promote their survival and proliferation 
(Simmons et al., 1994; Drexler, 1996).  KIT is also expressed on mast cells and is  
widely expressed during embryogenesis  and in melanocytes and germ cells and is 
known to have  multiple roles in development (Keshet et al., 1991; Lyman and 
Jacobsen, 1998).  The PDGF receptor has many signalling roles in the mesenchymal 
cell lineage in both adults and during development but the haematopoietic role of 
PDGF is less clear although it is an important factor for megakaryocyte differentiation 
and proliferation (Yang et al., 1997).  The FMS receptor is an important receptor for 
the development and differentiation of cells of the monocyte/macrophage cell lineage 
and is also expressed by some cells of the female reproductive tract including 
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trophoblasts and some decidual cells where it has a regulatory role (Wiktor-
Jedrzejczak et al., 1990; Cecchini et al., 1994; Regenstreif and Rossant, 1989). 
 
1.1.3. Activation of the PDGF receptor family 
The structures of  FLT-3 (Griffith et al., 2004), PDGF  (Oefner et al., 1992) and FMS 
(Walter et al., 2007) have been determined  but the mechanisms of activation of the 
KIT receptor are the most extensively characterised, the crystal structure of KIT is 
shown in figure 1.4 (Mol et al., 2003). The kinase domain of this family of receptors 
is able to switch between an inactive and active confirmation upon ligand-binding.  
Kinase activation requires a short 20 to 30 amino acid region called the activation 
segment to rotate around a single aspartate residue (Asp 810) within a highly 
conserved region Asp810-Phe811-Gly812 (DFG) sequence. This allows access to the 
substrate and correct orientation of amino acids for catalysis (Mol et al., 2003).  
Stabilisation of this structure requires that part of the activation loop (amino acids 
LARDI , 813-817) , moves position by some 20 Angstroms and converts from a 
helical or loop structure to a beta strand (known as β9, shown in green in figure 1.4)  
that pairs with the invariant  β6 strand of the kinase domain that is found outside the 
activation segment  (shown in yellow in figure 1.4).  The formation of the β6/ β9 pair 
is important for stabilisation of the active structure of all kinases (Dibb et al., 2004).      
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Immunoglobulin Domains
Cell membrane
Kinase insert region
Y723, Y708
Activation loop 
Y802, Y809
N terminus
C  terminus
Kinase 
domain
Juxtamembrane region
Y569
B CA
   
Figure 1.4. The structure of the FMS and KIT receptors.  (A) Schematic diagram of the FMS receptor showing key tyrosine 
phosphorylation sites (Y = tyrosine). (B,C) Inactive and active KIT kinase crystal structures.  (B) In the inactive conformation the JMR 
inserts into the interface between the N and C-lobes and forms hydrophobic interactions with a ß-sheet from the kinase domain (ß6).  The 
magnified area shows hydrophobic bonds between the amino acids 556-560 from the JMR (pink) and the kinase domain ß6 strand 
(yellow).  The JMR competes with the activation loop for this position, preventing the kinase domain from moving into an active 
conformation.  (C) In the active conformation, the activation loop binds with ß6 from the kinase domain (yellow) and forms ß6/ ß9 which 
is required for kinase activity.  JMR is shown in pink, ß6 strand from the kinase domain in yellow and, b9 from the activation loop in 
green. Modified from (Mol et al., 2004, Dibb et al., 2004). 
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When KIT is in its inactive conformation the juxtamembrane region (JMR) has an 
autoinhibitory role and is inserted into the cleft that the activation loop occupies in the 
active conformation and thereby competes with the activation loop for binding with 
the β6 strand (shown in pink in figure 1.4).  This blocks the activation segment  from 
moving into its active position and this autoinhibitory structure  is maintained whilst 
the JMR is not phosphorylated (Mol et al., 2003; Mol et al., 2004a).  Amino acids 
556-560 of the juxtamembrane region are particularly important for this 
autoinhibitory role as they bind directly with the β6 strand.  
 
There are many oncogenic mutations of KIT which affect the interaction of the β6 
strand and JMR.  Amino acids  QWKVV (556-560) of the JMR are an oncogenic 
hotspot and are frequently mutated in cancers, particularly in Gastrointestinal Stromal 
Tumours (GISTs) (Russell et al., 1987)  Small deletions of this region or single amino 
acid mutations, usually of Val559 to Asp, prevent the inhibitory interaction with β6   
and shift the equilibrium of the receptor towards the active state.  FLT-3 mutations are 
also common in acute myeloid leukaemia (AML) and internal tandem repeat 
sequences in the juxtamembrane region are the most common mutation found.  These 
mutations also disrupt the structure of the JMR and therefore its autoinhibitory 
function, allowing the activation loop access to the β6 strand. 
 
Oncogenic mutations of the activation segment are also common, particularly those 
that stabilise the active conformation of the receptor.  Aspartate 816, which is part of 
the β9 strand on the activation loop is an oncogenic hotspot and is often substituted to 
valine (D816V) in mast cell leukaemia (Longley et al., 1999). Asp β9  mutations are 
usually constitutively activating mutations and may give the Asp β9 sheet a higher 
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propensity to form the β6β9 motif, pushing the equilibrium towards the active state 
(Dibb et al., 2004). Mutations of Asp β9 are resistant to the tyrosine kinase inhibitor 
imatinib, which is able to bind to the inactive, but not to the active kinase 
conformation implying that Asp β9 mutations lock the kinase domain into an active 
structure (Ma et al., 2002).   
 
1.1.4. The FMS Receptor 
The FMS receptor is encoded by the c-fms proto-oncogene and is involved in 
regulation of cell proliferation, differentiation and survival in a variety of cells types 
of the monocyte/macrophage cell lineage and some cells of the female reproductive 
tract.  FMS was first discovered due to its similarity to the v-fms oncogene which is 
found in the Susan McDonough strain of the feline sarcoma virus (Sherr et al., 1985).    
In the haematopoietic system, FMS is expressed early in differentiation of the 
monocyte/macrophage cell lineage and is continuously expressed in a non-dividing 
macrophages and osteoclasts (Rohrschneider et al., 1997).  Valuable insights into the 
function of the FMS receptor came from the nullizygous mouse Csf1op/Csf1op which 
has an inactivating mutation in the M-CSF coding gene mapping to chromosome 3 
and as a result has no endogenous M-CSF (Wiktor-Jedrzejczak et al., 1990). 
Csf1op/Csf1op mice are osteopetrotic, toothless due to bone thickening, have a 
deficiency in tissue macrophages and osteoclasts and have fertility defects and brain 
abnormalities including a reduced number of microglia  (Cecchini et al., 1994; 
Michaelson et al., 1996; Wiktor-Jedrzejczak et al., 1982; Wegiel et al., 1998).  This 
phenotype can be partially corrected when recombinant human M-CSF is 
administered to neonatal animals, giving an almost complete recovery of macrophage 
and their progenitor cells and partial recovery of osteoclasts (Ryan et al., 2001).  
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 M-CSF deficient mice also have a diminished ability to support tumour growth.  The 
growth of subcutaneous injections of Lewis Lung cancer cells is impaired (Nowicki et 
al., 1996) as is the metastatic potential of mammary tumours when Csf1op/Csf1op mice 
are crossed with polyoma middle T mice which are susceptible to breast cancer and 
metastasis (Lin et al., 2001).  Both of these phenotypes are reversed when M-CSF is 
administered.   
 
Along with all other members of the PDGF receptor family, the FMS receptor has the 
capacity to autophosphorylate on specific tyrosine residues.  Four tyrosine residues 
have so far been identified as major autophosphorylation sites by in vitro assays and 
these are  Y699, Y708, Y723 and Y809 (Tapley et al., 1990; van der Geer and Hunter, 
1990; Reedijk et al., 1992) (figure 1.4).  In addition to these, at least three other minor  
sites are known to become phosphorylated upon stimulation of FMS with M-CSF and 
all of these tyrosine phosphorylation sites are known to interact with and provide 
docking sites for at least one other protein once they become phosphorylated (Pixley 
and Stanley, 2004).  The FMS receptor activates a complex network of intracellular 
signalling pathways and in Bac1.2F5 macrophages, around 0.02% of total cellular 
protein becomes phosphorylated upon M-CSF stimulation.  A summary of known 
downstream signalling molecules of FMS is shown in  figure 1.5 and  table 1 
summarises some of the reported downstream effectors of FMS signal transduction 
(Yeung and Stanley, 2003).   
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Figure 1.5. Signal transduction from the FMS receptor is complex and involves activation of various signalling pathways and an 
initial direct association of FMS substrates to the receptor at specific tyrosine residues.  These signalling molecules are able to 
activate their respective pathways and induce various cellular effects including proliferation, survival, differentiation and cell adhesion and 
motility.  Diagram taken from Pixley, F.J & Stanley, E.R. (2004) CSF-1 regulation of the wandering macrophage: complexity in action.  
Trends Cell Biol, 14, 628-38. 
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(Kelley et al., 1999)PI3K/AKT pathway activatorAKT
(Berg et al., 1998)SH2 domain containing phosphataseSHP1 and SHP2
(Bourette and Rohrschneider, 2000)SH2 domain containing proteinSHIP1
(Yeung and Stanley, 2003)Rho family GTP-aseVav
(Heidaran et al., 1992)MAP3K signalling moleculeRas
(Imamura et al., 1990)Protein kinaseProtein kinase C
(Pixley et al., 2001)Focal complex adapterPaxillin
(Bourette et al., 2001)Adaptor proteinSocs1
(Novak et al., 1995)Part of JAK/STAT pathwaySTAT1, STAT3
(Novak et al., 1995)Activator of JAK/STAT pathwayJak1
(Courtneidge et al., 1993)Src family kinaseSrc
(Courtneidge et al., 1993)Src family kinaseYes
(Courtneidge et al., 1993)Src family kinaseFyn
(Bourette and Rohrschneider, 2000)regulatory unit of PI3KP85 PI3K 
(Wang et al., 1996)ubiquitin ligaseCbl
(Lioubin et al., 1994)activator of RasSos1 
(Lioubin et al., 1994)adaptor proteinGrb2 
(Lioubin et al., 1994)adapter proteinShc
ReferenceGeneral functionSignalling molecule
Table 1.1
Table 1.1. Summary of signalling molecules identified downstream of the FMS receptor.  
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Two major FMS signalling pathways are thought to be the phosphoinositide 3-kinase 
(PI3K) pathway and the MAPK/ERK pathways.  PI3K is activated by growth factor 
receptors at the cell surface and subsequently generates inositol 3-phosphorylated 
second messengers which activate AKT (also known as PKB) and stimulate its serine-
threonine kinase activity (Franke et al., 1997).    AKT can then leave the cell 
membrane and inhibit apoptotic elements such as the caspase family.  PI3K activation 
is thought to be important for macrophage survival and inhibition of AKT activity 
causes macrophage apoptosis (Kelley et al., 1999).  In macrophages, AKT is known 
to block caspase-9 activation, so inhibiting apoptosis and promoting cell survival 
(Kelley et al., 1999).  PI3K is recruited both directly to the kinase insert region of 
FMS (Y723)  or in a src dependent manner through phosphorylation of tyrosine 559 
(Lee and States, 2000).  PI3K signalling is also negatively regulated by FMS 
signalling through a feedback system which involves recruitment of the phosphatase 
SH2-domain-containing polyinosital phosphatase-1 (SHIP-1) to the membrane.  
SHIP-1 dephosphorylates important second messengers of PI3K such as 
phosphatidylinositol 3,4, 5-bisphosphate and this downregulates AKT activity (Baran 
et al., 2003). 
 
The MAPK/ERK pathway is thought to have a central role in controlling cellular 
proliferation and in macrophages is involved in cell activation, differentiation and 
proliferation.  Upon FMS activation, Raf is recruited to the receptor via adapter 
proteins and is able to phosphorylate MEK-1 on serine/threonine residues (Howe et 
al., 1992).  MEK-1 is a threonine/tyrosine kinase and once activated can 
phosphorylate and activate ERK-1 and ERK-2 (also known as p42/p44 MAPK) 
(Crews et al., 1992).  The activated ERKs are able to then translocate though the 
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nuclear membrane and regulate transcription factors and therefore cellular outcome.   
In macrophages, the cellular outcome of ERK signalling is determined by many 
complex factors including the duration of signalling and by the cell surface receptor 
from which the signal originates.  For example, various authors have proposed models 
in which the duration of FMS signalling to ERK is important for cellular outcome.  
When ERK is stimulated through the FMS receptor, which has an ERK 
phosphorylation peak of around 5 minutes, cell proliferation is stimulated and 
differentiation is supressed.  In contrast to this, chronic signalling though 
lipopolysaccharide or through the phorbol ester tetradecanoyl-phorbol-13-acetate has 
an ERK phosphorylation peak of around 20 minutes and inhibits cell proliferation and 
induces differentiation (Valledor et al., 2000; Suzu et al., 2007). 
 
1.2. FMS function in haematopoetic cells 
M-CSF is an important growth factor for cells of the monocyte macrophage cell 
lineage and plays an important role in regulating the production of various specialised 
cell types which originate from the monocyte precursor.  Monocytes are derived from 
CD34+ hematopoetic stem cells and are relatively primitive haematopoietic cells that 
can differentiate into many cells types including macrophages (Dewar et al., 2003), 
dendritic cells (Thomas and Lipsky, 1996), microglia (Asheuer et al., 2004) and 
osteoclasts (LaRochelle et al., 2001).  
 
1.2.1 The role of FMS in osteoclast production and function 
 Osteoclasts are capable of absorbing bone matrix and interact with osteoblasts to 
constantly remodel skeletal structures of the body.  Monocytes differentiate into 
osteoclasts in response to M-CSF and Receptor Activator of Nuclear Factor kappa B 
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ligand (RANKL) stimulation and adhere to the bone matrix (Yasuda et al., 1998).  
Once adhered to the bone, osteoclasts secrete acid and lytic enzymes which resorb and 
remodel the bone and are the sole bone absorbing cell of the body (figure 1.6) (Baron 
et al., 1985).  Once differentiated from their precursor cells, osteoclasts acquire novel 
characteristics such as calcitonin receptor and vitronectin receptor expression, tartrate-
resistant acid phosphatase (TRAP), cathepsin K and the ß3 integrin (Fuller et al 1993). 
The process of differentiation is negatively regulated by osteoprotegerin (OPG) and 
downregulation of OPG leads to osteoporosis and excessive bone remodelling 
(Simonet et al., 1997).  FMS signalling through M-CSF stimulation is not only 
essential for their differentiation but also promotes osteoclast motility, spreading, cell 
polarization and promotes cell survival by preventing apoptosis (Fuller et al 1993).   
 
There are many skeletal diseases that can be attributed to excess osteoclast activity 
causing an imbalance of bone resorption and bone synthesis.  These diseases include 
osteoporosis, periodontal disease, rheumatoid osteoarthritis, multiple myeloma and 
metastatic bone cancers (Boyle et al., 2003; Teitelbaum, 2006).   
 
 
Figure 1.6.  Osteoclastogenesis.  Osteoclasts originate from bone marrow precursor 
CD34+ cells which require M-CSF for survival and differentiation into pre-osteclasts.  
At this stage, both M-CSF and RANKL are required to stimulate the preosteoclasts to 
fuse to produce a polykaryon and with further RANKL stimulation a mature 
M-CSF M-CSF 
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multinucleated osteoclasts.  This process is inhibited by OPG.  Modified from (Boyle 
et al., 2003) 
 
Metastasis to the bone is a common secondary cancer and various cancers predispose 
to bone metastasis including renal cancer, lung cancer, thyroid cancer, prostate cancer, 
breast cancer and multiple myeloma (Mundy, 2002).  Bone metastasis can be either 
osteolytic, and associated with excess osteoclast formation or osteoblastic and 
associated with excess bone formation.  Osteoblastic bone metastasis is most 
commonly associated with prostate cancer whereas osteolytic bone metastasis is most 
associated with breast cancer and together bone metastasis is present in 70 % of cases 
of mortality from these two cancers (Coleman and Rubens, 1987; Charhon et al., 
1983).  The distinction between osteolytic and osteoblastic lesions is not entirely 
straightforward as osteolytic cancer is commonly associated with local bone 
formation and osteoblastic cancer is commonly associated with local areas of 
osteolysis and osteoclast formation.  Bone metastasis could therefore be considered to 
alter the balance of normal bone formation and absorption (Stewart et al., 1982).  
Breast cancer metastasis to the bone is well characterised and is thought to be mainly 
due to the release of a peptide from tumour cells called parathyroid-hormone-like-
protein (Guise et al., 1996).  This stimulates osteoblasts to produce high levels of pro-
osteoclastogenic growth factors such as RANKL and in turn promotes excess 
osteoclast formation and therefore bone absorption. In an animal model of osteolytic 
bone metastasis, inhibition of the parathyroid-hormone-like-protein with neutralising 
antibodies significantly decreased the size and number of osteolytic lesions (Guise et 
al., 1996). 
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Osteoclasts and tumour cells are thought to have a mutually beneficial relationship 
and osteoclasts produce many growth factors which promote tumour growth such as 
Transforming growth factor beta and Insulin like growth factor-1.  This results in a 
continuous cycle of tumour production, osteoclastogenesis and bone destruction and 
this is summarised in figure 1.7 (Yin et al., 1999).  It may therefore be possible that 
inhibiting osteoclastogenesis may also decrease tumour burden.  Consistently, in an 
animal model of breast cancer metastasis to the bone, treatment with the 
bisphosphonate osteoclast inhibitor Risedronate effectively inhibited 
osteoclastogenesis and also inhibited tumour cell metastasis to the bone but had no 
effect on metastasis to other soft tissues (Sasaki et al., 1995).  This association is also 
extended to other animal models, and various explanations have been suggested for 
this effect including inhibition of tumour invasion, angiogenesis, tumour cell adhesion 
to the bone and general alterations in the bone microenvironment (Clezardin et al., 
2003; Green, 2003; Green and Clezardin, 2002; Denoyelle et al., 2003).  More 
investigation into this area is needed, but it is clear that osteoclasts are an important 
therapeutic target.  
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Figure 1.7. The interplay between osteoclasts and tumour cells in osteolytic bone metastasis from breast cancer.  Osteoclasts and tumour cells 
create a mutually supportive bone environment which is conducive to osteoclastogenesis and tumour proliferation.  Tumour cells produce 
parathyroid hormone related protein (PTHrP) which stimulates osteoblasts to upregulate production of RANKL.  This stimulates 
osteoclastogenesis and results in bone destruction.  Mature osteoclasts produce growth factors such as TGF beta and IGF1 which promote tumour
cell survival and proliferation.  
Diagram taken from Mundy, G. R. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2, 584-93 
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1.2.2 The role of FMS signalling in microglia activation 
Microglia are important phagocytes of the central nervous system and constitute 
approximately 20 % of the non-neuronal cells.  Microglia exist in the central nervous 
system (CNS) as ‘resting microglia’, which are characterised by low surface antigen 
expression and are small cells with fine processes (Garden and Moller, 2006). 
Microglia can become ‘activated’ when they are stimulated with inflammatory 
cytokines due to CNS injury and stimulation from other inflammatory cells.  The 
main function of microglia is to protect the nervous system by producing neuro-
protective agents and phagocytising cellular debris resulting from injury or disease 
(Imai and Kohsaka 2002). M-CSF is thought to be important in microglia activation 
through an M-CSF/FMS autocrine loop which is stimulated by an inflammatory 
environment.  This results in the production of various inflammatory cytokines  
including Interleukin-1, macrophage inflammatory protein-1-β, Interleukin-6 and M-
CSF and also the release of reactive oxygen species such as nitric oxide (Hao et al., 
2002).  Activated microglia can also contribute to neurodegenerative diseases by 
producing neurotoxic agents which exacerbate the chronic inflammatory environment 
and contribute to neuronal damage (McDonald et al., 1997; Liu and Hong, 2003; 
McGeer et al., 1988).  As a result, inappropriate microglia activation is implicated in 
many diseases of the nervous system such as Parkinson’s disease, Alzheimer’s disease 
and Prion disease (Eikelenboom et al., 2002; Liu and Hong, 2003).  There is strong 
evidence that FMS signalling is responsible for maintaining microglia in their active 
state and also for modulating cell migration and actin cytoskeleton remodelling and 
microglia proliferation in these diseases (Imai and Kohsaka, 2002; Rogove et al., 
2002).  M-CSF production  is often found to strongly correspond to areas of amyloid 
plaque production in Alzheimer’s disease and in mouse models of neurodegeneration, 
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overexpression of FMS leads to an increase in microglia activation and an 
exacerbation of the neurodegenerative phenotype (Mitrasinovic et al., 2001; Murphy 
et al., 2000).   
 
1.2.3 The role of FMS in macrophages and chronic inflammatory diseases 
Macrophages are the most abundant of the cells to be derived from the monocyte 
lineage and play a large part in the innate immune response.  Monocytes in the 
circulating blood migrate through the endothelial wall and enter the tissue in response 
to chemotactic signals from other immune cells at the site of tissue damage.  Once in 
the tissue the monocytes differentiate into macrophages which are able to engulf 
pathogens and debris and secrete a variety of factors including enzymes, complement 
proteins, cytokines and growth factors.  Macrophages destroy invading micro-
organisms by phagocytosis and by releasing cytokines and cytotoxic molecules such 
as reactive oxygen species. This response is pathogenic and causes debilitating tissue 
damage when inflammation is not resolved appropriately as in various chronic 
inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and 
atherosclerosis (Linton and Fazio, 2003).  M-CSF is a major chemoattractant, survival 
and differentiation factor for macrophages and stimulation of macrophages with M-
CSF therefore contributes to many inflammatory diseases (Akagawa, 2002; Chitu and 
Stanley, 2006).   
 
Arthritis is an inflammatory disease which is associated with chronic inflammation in 
the joints and a massive infiltration of immune cells (Kawanaka et al., 2002). 
Macrophages and M-CSF levels are thought to be particularly important in disease 
pathogenesis and this is illustrated in an animal model of collagen-inducted arthritis.  
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This disease can be induced in wild type mice or in M-CSF knockout mice by 
subcutaneous injection of collagen.  This causes joint inflammation and local tissue 
destruction and is considered a good model of disease progression of human 
rheumatoid arthritis (Williams, 2004).  It was shown that M-CSF knockout mice were 
significantly more resistant to monocyte infiltration and joint destruction than their 
wild type littermates in this model (Campbell et al., 2000).   Consistent with this,  
high concentrations of M-CSF in patient joints in human rheumatoid arthritis is 
associated with a more aggressive disease and a poor quality of life (Yang et al., 2006; 
Kawanaka et al., 2002).  In addition to the damage caused by infiltrating macrophages, 
there is commonly a local production of RANKL from stromal cells in the joint which 
acts with M-CSF to promote increased osteoclastogenesis, leading to osteoarthritis 
and localised bone destruction (Danks et al., 2002).     
 
1.2.4 The inflammatory tumour microenvironment 
In 1863 Rudulf Virchow made a connection between sites of chronic inflammation 
and tumourigenesis and since then this connection has become well established 
(Balkwill and Mantovani, 2001).   We now know that infections that cause chronic 
inflammation are known to be responsible for more than 15% of cancers worldwide 
(Kuper et al., 2000).  These infections lead to local areas of chronic inflammation 
which contain large numbers of infiltrating immune cells.  These immune cells 
produce high levels of mutagenic and cytotoxic substances such as reactive nitrogen 
and oxygen species which cause neoplastic changes in the surrounding tissue (Maeda 
and Akaike, 1998). Classical examples of this include the Hepatitis virus which leads 
to hepatocellular carcinoma due to chronic inflammation in the liver, the HIV virus, 
which is associated with Kaposi’s sarcoma and local chronic inflammation in the skin 
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and the bacteria helicobacter pylori which is associated with stomach cancer 
(Coussens and Werb, 2002).   In fact the inflammatory tumour microenvironment is 
important for most tumours regardless of their origin and it is widely thought that 
non-malignant cells, in particular inflammatory cells, can modulate tumour properties 
and play an important role in allowing malignant cells to express their full neoplastic 
phenotype (Pollard, 2004).   
 
These observations have lead to popular a ‘seed and soil’ hypothesis in which 
malignant changes in a cell forms the ‘seed’ but this requires a fertile ‘soil’ which 
consists of a supportive environment of non-malignant cells.  This supportive 
environment is often termed the ‘tumour microenvironment’ and commonly includes 
resident stromal cells, adipocytes and fibroblasts and a large population of 
haematopoietic cells that include mostly macrophages and T cells but also lower 
numbers of mast and dendritic cells (Albini and Sporn, 2007; Hagemann et al., 2006; 
Pollard, 2004). The interactions between these cell types are complex but it is thought 
that many of the non-cancerous cell types contribute to tumour survival, growth or 
metastasis through the production of cytokines, chemokines,  proteases and 
immunosuppressive molecules that together create a tumour supportive environment 
(see figure 1.8) (Albini and Sporn, 2007; Bissell and Radisky, 2001; Karnoub et al., 
2007; Pollard, 2004). 
 38 
1.3 Macrophages in the tumour microenvironment 
Macrophages play a major part in the tumour microenvironment and make up most of 
the non-malignant cell mass (Pollard, 2004).  Macrophages are highly plastic cells and 
can be polarised to become either tumour supportive or tumour destructive by 
cytokines and growth factors in their environment.  Normally, macrophages work as 
part of the innate immune system and can display two distinct phenotypes which are 
involved in both initial inflammatory responses and in wound healing once the 
inflammation has resolved. These two activated macrophage phenotypes are termed 
M1 and M2.  Normally, macrophages become activated towards an M1 phenotype in 
response to bacterial invasion and lipopolysaccharide stimulation or contact with 
cytokines and chemokines released from T cells or NK cells such as interferon γ.   
This leads to production of immunostimulatory cytokines such as tumour necrosis 
factor α and interleukin-6 and results in the production of cytotoxic compounds, 
phagocytosis, antigen presentation and tissue destruction.  In contrast to this, 
macrophages become activated towards an M2 phenotype when they are involved in 
wound healing and resolution of inflammation and are stimulated by anti-
inflammatory molecules such as glucocorticoid hormones, interleukin-4 and 
interleukin-13 and chemokines which support angiogenesis and matrix remodelling 
such as VEGF.  
 
Macrophages that are present in the tumour environment are usually termed tumour 
associated macrophages (TAMs).  In the majority of cancers, TAMs are thought to be 
activated towards an M2 phenotype due to the various immunosuppressive cytokines 
that are released by the tumour, polarizing the macrophages towards a trophic, wound 
healing phenotype (Mantovani et al., 2002).  By creating an immunosupressive 
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environment, the tumour can be seen to ‘educate’ macrophages to display a 
supportive ‘wound healing’, M2 activated phenotype rather than an cytoxic, M1 
activated phenotype which may direct the immune system to target the tumour 
(Mantovani et al., 2002).  Presentation of tumour associated antigens is also inhibited 
by the tumour, mainly though inhibition of mature dendritic cell differentiation, which 
are the main antigen presenting cell of the immune system (Menetrier-Caux et al., 
1998).  Release of growth factors such as M-CSF and IL-6 from both the tumour and 
TAMs are implicated in this aspect of immunosupression and this indirectly also 
prevents recruitment of cells of the adaptive immune system such as T cells which 
may have lead to immune recognition of the tumour, this process is shown in figure 
1.8. 
 
In support of the views described above,  large numbers of infiltrating TAMs 
correlates with poor prognosis in a variety of cancers including most human breast, 
prostate, ovarian and cervical cancers and this also often correlated with high local 
levels of M-CSF (Kacinski, 1997; Lin et al., 2002; Bingle et al., 2002; Smith et al., 
1995).  Overall, 80 % of malignancies are associated with large numbers of 
infiltrating TAMs which give a poor patient prognosis (Bingle et al., 2002) and as 
described previously, mice that are deficient for macrophage production show 
resistance to metastasis (Pollard 2004).    
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Figure 1.8. Interplay between tumour cells and innate immune cells.  Tumours are heavily influenced by their populating immune cells and in 
return the tumour can ‘educate’ these cells to create a tumour supporting environment and evade immune detection.  Many tumour 
microenvironments are rich in growth factors such as M-CSF, IL-4 and TGF β which support tumour growth and angiogenesis through 
appropriately polarised macrophages.  In contrast to this, some tumours are incapable of immune evasion and the tumour becomes a target of 
the immune system mediated through M1 polarised macrophages and mature dendritic cells.
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By contrast, if macrophages were to become activated towards a more classical M1 
phenotype, it would be expected that they may direct the immune system to attack the 
tumour.  There are a few examples of studies which have shown a correlation between 
infiltrating macrophages and good patient prognosis (Shimura et al., 2000; Kerr et al., 
1998).  Because of this various studies have investigated whether ex vivo autologous 
macrophages which had been activated in vitro towards an M1 phenotype could be 
used to target various cancers.  These studies yielded disappointing results and the 
macrophages did little to effect the tumour progression and the authors suggested that 
the tumour environment may have ‘re-educated’ these macrophages to become 
immunosupressed (Andreesen et al., 1998).   
 
1.3.1 Tumour associated macrophages in tumour angiogenesis 
It is well known that tumours require angiogenesis to grow beyond a critical size, due 
to limiting oxygen and nutrient supplies.  This requires that a number of angiogenic 
factors including monocyte chemoattractant protein-1, VEGF, bFGF and TGFβ are 
released and stimulate angiogenesis within the tumour.  Macrophages are capable of 
producing these factors and are in particular known to be key producers of VEGF in 
the tumour environment (Lewis et al., 2000; Leek et al., 2000).  VEGF is the ligand 
for the VEGF receptors and is a key growth factor involved in angiogenesis and 
vasculargenesis.  Hypoxia is a major regulator of VEGF signaling in tumours and as 
the tumour grows beyond the capacity of its vascular supply, hypoxia related 
transcription factors such as HIF cause the production of angiogenic factors such as 
VEGF from macrophages.  This recruits surrounding stromal cells to increase 
vascularisation and thereby allows tumour growth which is unrestricted by its 
vascular supply (Hanahan and Folkman, 1996; Shweiki et al., 1992).  This is 
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supported by a mouse model of cervical cancer in which an inhibitor of MMP-9 was 
used to target macrophages and prevent VEGF production by macrophages.  In this 
model, both tumour volume and vascularisation was significantly reduced (Giraudo et 
al., 2004).  Furthermore, the depth of invasion and angiogenesis of primary cutaneous 
melanoma is thought to be mediated by TAMs (Torisu et al., 2000) and in a study of 
primary invasive breast carcinomas, angiogenesis was associated with  macrophage 
‘hotspots’  which stained positive for the angiogenic transcription factor HIF-2β 
(Leek et al., 2002). 
 
1.3.2 Tumour associated macrophages in matrix remodeling and metastasis 
Tumour associated macrophages are also important in tumour metastasis as they are 
implicated in assisting matrix remodeling and invasion of tumour cells.  One view is 
that infiltrating monocytes and macrophages provide pathways for tumour cells to 
migrate into blood vessels without the need for any matrix remodeling and in effect 
migrate out of the tumour environment following the path that the macrophages made 
to migrate into the tumour (Opdenakker and Van Damme, 1992).  A more popular 
view is that the macrophages behave as a ‘guide’ for tumour cells and that the two cell 
types migrate together whilst secreting proteases and matrix remodeling chemokines 
along the way.  In a mouse model of breast cancer, two paracrine loops were 
established between macrophages and tumour cells.  Macrophages secreted EGF, 
which stimulated chemotaxis in tumour cells through the EGF receptor and in parallel 
to this,  tumour cells secreted M-CSF, which stimulated chemotaxis in the 
macrophages through the FMS receptor (Wyckoff et al., 2004).  Therefore, both the 
tumour cells and the macrophages adopt an exaggerated migratory phenotype and co-
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migrate, allowing the tumour cells to benefit from the matrix remodeling properies of 
the macrophages (Yamaguchi et al., 2006). 
 
1.4 Small Molecule Kinase Inhibitors 
The first link between the oncogenic mutation of cell signalling components and 
human cancer was made in the early 1980s when the sequence similarity between 
EGF receptor and the v-erbB and the PDGF receptor and v-sis retroviral oncogenes 
were noted (Downward et al., 1984; Doolittle et al., 1983).  Shortly after this, Bishop 
and Varmus noted that animal retroviral oncogenes such as v-src and v-ras may have 
oncogenic counterparts in  human cancers and this solidified the idea that cancer was 
in part caused by gain of function mutations in oncogenes (Ullrich et al., 1984; 
Varmus and Bishop, 1986).  Oncogenic gain of function mutations of receptor 
tyrosine kinases or intracellular kinases have since been discovered in many human 
cancers and there has been much success in developing inhibitors which inactivate 
these enzymes. 
 
There are two main types of inhibitor; monoclonal antibodies which target cell surface 
receptors or their ligands and small molecule inhibitors which usually compete with 
ATP to bind to the kinase domains of cell surface receptors or of intracellular 
signalling molecules.  Table 1.2 shows that there are many of these inhibitors 
currently in advanced clinical development against a range of kinases although this 
list is not exhaustive (Dancey and Sausville, 2003). 
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(Procopio et al., 2008)Phase IIISmall moleculeOnyx/BayerSorafenib;  BAY43-9006Raf
(Welch et al., 2007)Phase IISmall moleculeKyowa Hakko KogyoUCN-01PDK1
(2007)Phase IISmall moleculeEli LillyLY333531; RuboxistaurinPKC-β
(El Fitori et al., 2007)Phase IISmall moleculeNovartisPKC412PKC
(Mullen et al., 2004)Phase IIAntisense oligonucleotideIsis PharmaceuticalsISIS 5132Raf
(Alberts et al., 2004)Phase IIAntisense oligonucleotideIsis PharmaceuticalsISIS 2503Ras
(Kantarjian et al., 
2006a)
FDA 
Approval
Small moleculeNovartisNilotinibBCR-ABL
(Druker et al., 2001b)FDA 
Approval
Small moleculeNovartisImatinibBCR-ABL
(Joensuu et al., 2002)FDA 
Approval
Small moleculeNovartisImatinibKIT
(Vogel et al., 2002)FDA 
Approval
Monoclonal antibodyGenentechHerceptinHER-2
(Cohen et al., 2005)FDA 
Approval
Small moleculeOSI-PharmaceuticalsOSI-774; erlotinibEGFR
(Ranson and Wardell, 
2004)
FDA 
Approval
Small MoleculeAstraZenicaGefitinib; IressaEGFR
ReferenceClinical trial 
status
Type of inhibitorCompanyInhibitorTarget
Table 1.2 Table 1.2. Summary of advanced therapeutic agents which target kinases.  
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Imatinib (Imatinib Mesylate; Gleevec; Glivec; STI571) was amongst the first of the 
small molecule tyrosine kinase inhibitors to be used successfully and is now the first 
line treatment for chronic myeloid leukaemia (CML).   Imatinib is an ATP analogue 
which binds to the ABL tyrosine kinase domain of the BCR-ABL fusion protein and 
figure 1.9 shows the crystal structure of imatinib bound to the ABL kinase domain 
( (Schindler et al., 2000).  
 
 
Figure 1.9. Crystal structure of the kinase domain of ABL tyrosine kinase (blue) with 
imatinib bound to the ATP binding pocket (green) (Schindler et al., 2000).   
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 BCR-ABL is the result of a reciprocal translocation between the gene coding for the 
breakpoint cluster region (BCR) on chromosome 22 and the gene encoding for the 
abelson (ABL) tyrosine kinase on chromosome 9.  This chromosome fusion is known 
as the Philadelphia chromosome because it was first discovered in 1960 by Peter 
Nowell in this State and it encodes the constitutively active BCR-ABL tyrosine kinase.  
BCR-ABL is present in nearly all cases of CML and 15-30% of acute lymphoblastic 
leukemia  and is sufficient for the initial development of these leukaemias (Daley et 
al., 1990; Heisterkamp et al., 1990; Kelliher et al., 1990).   
 
Imatinib is also an inhibitor of the PDGF receptor and the KIT receptor (PDGF 
receptor IC50 = 0.25 µM and the KIT receptor IC50=0.1 µM (Buchdunger et al., 
2000).  This is probably a reflection of the striking similarity in the structure of the 
kinase domains of ABL and the PDGF family (Mol et al., 2004b).  As a result 
imatinib has been used to successfully treat gastrointestinal stromal tumours (GISTS) 
which are a tumour of the gastrointestinal tract and are identified by expression of the 
KIT or PDGF receptors.  These kinases have usually suffered deletions of the JMR 
which results in mutant receptors that are fortunately much more sensitive to imatinib 
that the wild type receptor (Chen et al., 2003; Frost et al., 2002; Ma et al., 2002).   
 
FLT-3 and FMS were initially thought to be  insensitive to imatinib despite being 
closely related kinases to the KIT and PDGF receptors (Buchdunger et al., 2000; 
Dewar et al., 2003).  FLT3 is resistant to imatinib due to a phenylalanine residue at 
position 691 which blocks imatinib binding and when this residue is mutated to a 
threonine, the mutant FLT-3 receptor becomes sensitive to imatinib (Bohmer et al., 
2003).    The equivelent mutation of KIT threonine 670  to isoleucine results in an 
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imatinib resistant KIT receptor and is common in GISTS (Tamborini et al., 2006) and 
the same mutation in ABL, T351I is a major cause of imatinib resistance in CML 
(Hofmann et al., 2004).  This conserved threonine is located on the edge of the ATP 
binding pocket and is thought to make critical hydrogen bonds between the kinase and 
imatinib, nilotinib and dasatinib.  When this residue is mutated to an isoleucine, this 
critical stabilising bond is not made and the inhibitor is also sterically blocked from 
binding by the larger side chain of isoleucine (O'Hare et al., 2005a; O'Hare et al., 
2005b).   The corresponding residue in the FMS receptor is a threonine (T663) and 
this residue is conserved in the imatinib sensitive kinases PDGFR (T674), KIT (T670), 
ABL (T315) (Daub et al., 2004).   
 
It therefore seemed unlikely that FMS would be resistant to imatinib considering the 
sequence similarity between the FMS and KIT receptor kinase domain (Dibb et al., 
2004).   We and another group have more recently shown that FMS is in fact sensitive 
to imatinib (Taylor et al., 2006; Dewar et al., 2005a) and Taylor et al found that FMS 
is probably  as sensitive to imatinib as the KIT and PDGF receptors, giving an IC50 
value for inhibition of FMS of 0.3 µM in comparable assays to ABL and KIT.  
 
CML is normally characterised by three main phases of disease; chronic stage, 
accelerated stage and blast crisis (Savage et al., 1997).  The chronic stage lasts for 
several years and is associated with a slow increase in the number of myeloid cell 
precursors in the haematopoetic system.   This is followed by an accelerated phase 
which lasts 4-6 months and during this time, the CML cells become more genetically 
unstable and this results in the accumulation of immature cells with various genetic 
and karyotypic abnormalities (Kantarjian et al., 1988).  This is followed by a blast 
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stage where the haematopoetic system becomes over whelmed by immature blast cells,  
this stage lasts only for one or two months (Calabretta and Perrotti, 2004). 
 
Imatinib is only able to bind to ABL when it is in an inactivated state and it is 
therefore ineffective against mutations which permanently lock the ABL kinase 
domain into an activated position (Schindler et al., 2000).  Resistance to imatinib is 
therefore common in patients who are treated in the more advanced and aggressive 
blast stage of CML where there are excessive numbers of BCR-ABL positive blasts.  
Some of these blasts inevitably carry imatinib resistance mutations due to their high 
number and are selected for by imatinib treatment and clonally expanded.    Patients 
treated in the early chronic phase of the disease on average achieve a 96-97% 
haematological response within 12 months (Hochhaus and La Rosee, 2004) whereas 
for  patients treated in the late accelerated phase of the disease this is reduced to 40% 
(Talpaz et al., 2002) and less than 10% in the more advanced blast stage (Sawyers et 
al., 2002). 
 
This problem with imatinib resistance has stimulated the development of a number of 
other kinase inhibitors which target the common imatinib resistant mutations.  
Nilotinib (AMN107, Tasigna) and dasatinib (BMS-354825, Sprycel) have been the 
most successful in treating imatinib resistance and both of these drugs have FDA 
approval for treatment of imatinib resistant CML (Cortes et al., 2006; Kantarjian et al., 
2006a). 
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1.4.1 FMS Inhibitors 
Recently, there has been interest in developing small molecule inhibitors which target 
the FMS receptor (Irvine et al., 2006; Conway et al., 2005; Murray et al., 2003; Ohno 
et al., 2006; Brownlow et al., 2008a; Brownlow et al., 2008b; Taylor et al., 2006; 
Meegalla et al., 2008).  The FMS receptor is an important signalling molecule for 
macrophages, osteoclasts and microglia and as described above these cell types are 
implicated in a number of diseases, particularly chronic inflammatory diseases and 
tumour metastasis making FMS an interesting target.    One such inhibitor, Ki20227 
has been shown to be useful in treating mouse models of collagen induced arthritis, 
osteolytic bone metastasis and multiple sclerosis progression, mainly by inhibiting 
macrophage and osteoclast survival (Ohno et al., 2006; Ohno et al., 2008; Uemura et 
al., 2008).  Another FMS inhibitor, SU11248 has been tested in a mouse model of 
bone metastasis where it inhibited osteolytic bone destruction and also more 
surprisingly inhibited tumour growth (Murray et al., 2003).   
 
Imatinib has been reported as a FMS inhibitor by us and another group (Taylor et al., 
2006; Dewar et al., 2005a) and has been suggested as a treatment for osteoclast 
related bone diseases due to its potency against osteoclasts (Dewar et al., 2006).  
Consistently, an altered bone and mineral metabolism has been reported in some 
patients who were treated with imatinib for extended periods (Berman et al., 2006) 
and there is also a report of occasional bone thickening in patients who are treated 
with imatinib, based on bone trephine staining.  In this study the authors implicate an 
inhibition of osteoclastogenesis due to inhibition of the FMS receptor and also 
promotion of osteoblastogenesis due to inhibition of the PDGF receptor in osteoblast 
precursor cells (Fitter et al., 2007).   
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Due to the massive success of imatinib and other such small molecule inhibitors in 
targeting kinases, many more of these inhibitors currently being trialled and some 
examples of these are shown in table 1.2.   Most of these inhibitors bind to the ATP 
binding pocket of the kinase domain thereby inhibiting kinase activity.   Many of the 
approximately 500 known kinases have similar structures, particularly around the 
ATP binding pockets so these inhibitors inevitably have other targets than their 
intended primary target (Manning et al., 2002).  The kinase inhibitors which are used 
routinely in the clinic are generally well tolerated by patients and this gives an 
opportunity to treat diseases which are associated with other kinases that are also 
sensitive to these FDA approved kinase inhibitors.  A good example of this in practice 
is imatinib.   Imatinib was originally designed as an inhibitor of the PDGF receptor, 
inspired by the therapeutic importance of this receptor in treating some inflammatory 
diseases.  It was then shown later that imatinib is also a particularly potent inhibitor of 
BCR-ABL and it has since become the front line therapy for treatment of CML (as 
discussed above)  (Druker et al., 1996).  It was later discovered that imatinib also 
targets the KIT receptor and it has also since been very useful for treating GISTS 
where activating KIT mutations are implicated (van Oosterom et al., 2001; Joensuu et 
al., 2001).  As an extension of this, imatinib is currently in clinical trials for treatment 
of a large number of malignancies, a few examples are shown in table 1.3. 
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Table 1.3. Current clinical trials involving imatinib. 
Disease Target 
Head and neck squamous cell cancer PDGF receptor 
Ovarian Cancer PDGF and KIT receptors 
Uterine serous papillary carcinoma PDGF, KIT, ABL 
Rheumatoid arthritis PDGF receptor 
HIV-associated Kaposi’s sarcoma General tyrosine kinase inhibition 
Metastatic breast cancer General tyrosine kinase inhibition 
Information taken from www.clinicaltrials.gov. 
 
So imatinib is a good example of a kinase inhibitor which has proven extremely 
useful in treating several diseases. 
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1.5 Project Aim 
1.  To identify FMS inhibitors.  At the beginning of this project there were no 
commercially available inhibitors which targeted the FMS receptor and therefore the 
main aim of this project was to find some FMS inhibitors and to assess their potential 
to target diseases in which FMS activity is implicated.  Given the ability of imatinib to 
inhibit both ABL and KIT kinases it seemed likely that FMS, which is closely related 
to KIT might be also be a target of imatinib, despite reports to the contrary 
(Buchdunger et al., 2000; Dewar et al., 2003).  I therefore assayed various clinically 
advanced, well tolerated small molecule inhibitors of BCR-ABL and the the FLT-3 
receptor, which is also closely related to FMS.    I found that imatinib (Taylor et al., 
2006), nilotinib (Brownlow et al., 2008a), tandutinib (Brownlow et al., 2008b) and 
dasatinib (Brownlow et al, submitted) are all reasonable inhibitors of FMS as assessed 
by various biochemical and cell based assays. 
 
2.   To assess the potential of these inhibitors to target macrophages and 
osteoclasts.   To do this I needed to develop assays which could be easily used to test 
these inhibitors in vitro upon primary macrophage and osteclast cell types.    I have 
successfully developed various useful assays of osteoclastogenesis, macrophage 
colony formation and tumour associated macrophage production from ovarian cancer 
ascites and used these to assess the therapeutic potential of these inhibitors to target 
these cell types. 
 
3.  To use the kinase inhibitors as research tools to investigate FMS receptor 
activation and downregulation.  I also set out to further establish a previous finding 
that the degradation of FMS is independent of intrinsic receptor kinase activity.  The 
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FMS inhibitors that I identified here proved to be very useful in addressing this 
problem and I have used them to provide evidence that the mechanism of FMS 
degradation is dependent on a structural change in the receptor and not receptor 
kinase activity.   The kinase inhibitors also revealed that at least two tyrosine 
autophosphorylation sites of FMS can still be phosphorylated in the absence of FMS 
kinase activity.  This implies that other kinases may be involved in FMS activation. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell Culture 
2.1.1 General cell culture 
All culture dishes (Invitrogen, Gibco) and flasks (Triple Red) were suitable for tissue 
culture and all serological plugged pipettes were purchased from Costar. All 
experiments were carried out in a Class II flow cabinet and cells were grown at 37°C 
in 5% CO2 (v/v). All adherent cell lines including Rat-2 fibroblasts and N9 microglia 
were grown in Dulbeco’s Modified Medium (DMEM) supplemented with 10% (v/v) 
heat inactivated Foetal Calf Serum (FCS), 50 U/ml penicillin/streptomycin 
(Invitrogen, Gibco) and 200 µM glutamine (Invitrogen, Gibco).  Cells were passaged 
twice weekly by washing in PBS and then incubating with 1 ml of 0.25% trypsin 
(Invitrogen, Gibco) for 5 minutes. The cells were re-suspended in 9 ml of DMEM 
supplemented with 10% (v/v) heat inactivated FCS, 50 U/ml penicillin/streptomycin 
(Invitrogen, Gibco) and 200 µM glutamine (Invitrogen, Gibco) and plated to the 
required density. Suspension cell lines including all FDC-P1 cell lines were grown in 
RPMI 1640 supplemented with 10% (v/v) heat inactivated FCS, 50 U/ml 
penicillin/streptomycin, 200 µM glutamine and 10% (v/v) Wehi 3B conditioned 
medium (containing IL3). Suspension cells were grown in 6 well trays and passaged 
weekly by putting 50 µl, 100 µl and 250 µl into three wells containing 4 ml of  RPMI 
1640 supplemented with 10% (v/v) heat inactivated FCS, 50 U/ml 
penicillin/streptomycin, 200 µM glutamine and 10% (v/v) Wehi 3B conditioned 
medium which contains IL-3.  
 
The cell lines FDC-P1 (Wheeler et al., 1987), FD-cfms (Dibb et al., 1990), FD-V Fms 
(Dibb et al., 1990; Wheeler et al., 1987), FD-D802V (Morley et al., 1999), Rat-2cfms 
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(Baker et al., 1994), Rat-2V Fms (Baker et al., 1994), Rat-2 D802V (Morley et al., 
1999), Rat-2 D802VY708F (Morley et al., 1999), Bac1.2F5 (Morgan et al., 1987), 
K562 (Klein et al., 1976) have been described previously.  Rat-2T633I was made as 
described in section 2.5. 
 
2.1.2 Freezing cell lines 
Cells were grown in T75 flasks until confluent. Adherent cells were incubated with 1 
ml of 0.25% trypsin, and then the trypsin was inactivated by adding 9 ml of DMEM 
with 10% (v/v) heat inactivated Foetal Calf Serum (FCS), 50 U/ml 
penicillin/streptomycin and 200 µM glutamine. The cells were pelleted by spinning 
for 5 minutes and re-suspended in 4 ml of DMEM supplemented with 10% (v/v) heat 
inactivated FCS, 50 U/ml penicillin/streptomycin (Invitrogen, Gibco) and 200 µM 
glutamine (Invitrogen, Gibco) (adherent cells) or RPMI 1640 supplemented with 10% 
(v/v) heat inactivated FCS, 50 U/ml penicillin/streptomycin, 200 µM glutamine 
(suspension cells) with 10% DMSO and aliquoted into freezing vials (0.75 ml per 
vial). The cells were cooled slowly in freezing apparatus containing propan-2-ol at -
80°C overnight then stored in liquid nitrogen.  
 
2.1.3 Cell counting 
Cells were counted using disposable haemocytometers (Hycor Biomed) down a light 
microscope (Olympus CK2).  This value was converted into cells per ml based on the 
volume of the counting chamber.  Each experiment was done in triplicate. 
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2.1.4. Primary cell assays 
2.1.4.1 Isolation of non adherent progenitor cells from mouse bone marrow 
Hind legs from 8 week old Black 6 mice were kindly donated by A. Chandrashekran. 
The femur and tibia were removed, excess muscle tissue removed and bone marrow 
was aspirated with alpha MEM (Invitrogen, Gibco) and a 25 gauge needle (Hycor 
Biomedicals).  The bone marrow was collected, strained using a 70 µM Nylon Cell 
Strainer (Beckton Dickinson) and spun at 1000 rpm for 5 minutes.  The bone marrow 
cells were then incubated in alpha MEM with 10% (v/v) heat inactivated FCS, 50 
U/ml penicillin/streptomycin, 200 µM glutamine and 5000 U/ml M-CSF to deplete 
fibroblasts or mature macrophage and non-adherent mononuclear cells were re-plated 
after 24 hours.  
 
2.1.4.2 Normal human and mouse osteoclasts 
Normal human osteoclasts were produced from G-CSF mobilised human peripheral 
blood which was obtained from Hammersmith Hospital Stem Cell facility with 
informed consent and was a kind donation from S. Marley and M. Gordon.  
Mononuclear cells were purified from total peripheral blood using lymphoprep tubes 
(Axis-Shield) as per manufacturer’s protocol.  1 X 106 mononuclear cells were 
cultured overnight in alpha-MEM + 10 % FCS and 50 IU/ml penicillin/streptomycin 
and 200 µM glutamine on tissue culture plastic in 24 well trays and adherent cells 
were discarded.  Primary mouse progenitor cells which contain monocytes were 
obtained as described above (section 2.1.4).  For normal human and mouse osteoclast 
cultures, 5 x 106 mononuclear cells per well in a 24 well tray or 1 x 106 cells were 
cultured in a 96 well tray with or without dentine slices in the bottom of each well.  
Both human and mouse primary osteoclasts were cultured in alpha Modified Eagles 
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Medium (Invitrogen, Gibco) with 10% FCS and penicillin/streptomycin, 50 IU/ml and 
glutamine 200 µM. This media was supplemented with 5000 U/ml rHuM-CSF (First 
Link) and 40 ng/ml rHuRANKL (First Link) and changed every 3 days for 2 weeks.   
 
2.1.4.3. Macrophage colony formation 
Primary mouse and normal human macrophages were produced by culturing 
mononuclear cells as described above in methylcellulose semi-solid media (Stem Cell 
Technologies) with 10% FCS, 200 µM L-Glutamine and 5000 U/ml RHuM-CSF for 
assessment of macrophage colony formation.  Macrophage colonies were counted 
after 2 weeks and identified based on their morphology with advice from S. Marley 
(Hammersmith Hospital Haematology Dept.). 
 
2.1.4.4 Tumour associated macrophages and osteoclasts 
For experiments in which human ovarian cancer ascites was used, 2mls of total ascites 
was cultured overnight in 24 well trays and adherent cells were used as precursor cells 
for both macrophages and osteoclasts.  Osteoclasts were produced from this material 
after 3 weeks of culture with alphaMEM with 10% FCS and 50 IU/ml 
penicillin/streptomycin, and 200 µM glutamine. Osteoclasts were identified based on 
TRAP staining and each cell containing more than 3 nuclei.   TAMs were produced 
by culturing this material with 5000 U/ml rHuM-CSF for 1 week.  Tumour associated 
macrophages were identified based on immunofluorescence staining with the 
macrophage marker CD 68 and normally a ~ 99 % pure cell population was achieved 
in this system. 
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2.1.5 FDC-P1 and K562 Growth Assay 
Various FDC-P1 or K562 cell lines were grown in RPMI media supplemented with 
10% FCS and 200 µM L-Glutamine, 50 IU/ml penicillin/streptomycin and FDC-P1 
cells were also cultured with 10% (v/v) Wehi 3B conditioned medium as a source of 
IL-3.  FDC-P1 cells that expressed the FMS receptor as a result of retroviral infection 
(Dibb et al., 1990) could be grown with either IL-3 or M-CSF.  These cells were then 
seeded into 24-well plates at 1x104 cells/ml with increasing concentrations of the 
appropriate inhibitor with or without M-CSF (5000 U/ml). Cells were grown for 1 
week at 37 °C, 5% CO2 and were counted using a haemocytometer.  
 
2.2 Staining 
2.2.1 TRAP assay 
Primary osteoclasts were fixed in 4% paraformaldehyde (Fluka) diluted in PBS for 20 
minutes and stained for Tartrate Resistant Acid Phosphatase (TRAP) using the TRAP 
kit from Sigma Aldrich.  TRAP solution (made according to manufacturers protocol, 
see section 2.7.2) was heated to 37 °C and added to fixed cells for 1 hour at 37 °C.  
After this period the cells were washed in PBS and mounted in water based mount 
(DAKO faramount) by placing a 13 mm2 coverslip over the cells.  The exposed edges 
were sealed with clear nail varnish.   
 
2.2.2 Pit assay 
Primary osteoclasts were grown on dentine discs (IDS Ltd) in the bottom of 96 well 
trays.  After 3 weeks of culture the discs were removed and placed in an eppendorf 
tube with 1ml of water and sonicated for 10 seconds.  The slices were then stained for 
10 minutes with 0.5% (w/v) toluidine blue and washed with water.  The pits were 
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viewed using a Nikon Eclipse E600 microscope with a Nikon Digital camera 
DXM1200.  The pit area was measure using the ‘measure area’ function on the Lucia 
G V.4.61 software.   
 
2.2.3 Bone trephine staining 
Bone trephines were stained by the histopathology department, Hammersmith 
Hospital using a standard Masson trichrome stain. Trephine width was measured 
blindly at 10 random places and the distance between two points was measured using 
the ‘measure width’ function on the Lucia G V.4.61 software.   
 
2.2.4 Phalloidin and Giemsa staining 
For phalloidin and giemsa staining of transformation assays, Rat-2  fibroblasts were 
grown on glass coverslips to 70% confluence, treated with the appropriate inhibitor 
for 24 hours and fixed with 4% w/v paraformaldyhyde (Fluka) for 20 minutes, washed 
in PBS and incubated at room temperature in either TRITC labelled phalloidin 
(1:1000 dilution in PBS) (Sigma-Aldrich) or Giemsa stain (1:10 dilution in PBS) 
(BDH biosciences).  The coverslips were washed in PBS and mounted in aqueous 
mounting media (DAKO faramount,).  
 
2.2.5 TUNNEL apoptosis assay 
For TUNEL apoptosis assays, mature osteoclasts were cultured on 13 mm diameter 
glass coverslips and were fixed in 4% (w/v) paraformaldehyde (Fluka) for 20 minutes 
and DNA strand breaks were labelled using an in situ cell death detection kit (Roche) 
according to the manufacturer’s protocol. The assay is based on the preferential 
binding of the FITC-dUTP to terminal deoxynucleotidyl transferase to 3' OH ends of 
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the DNA.  The coverslips were mounted in Vectashield mount with antifade and 
DAPI (Vector laboratories).  The number of apoptotic nuclei (within an osteoclast if 
applicable) and total nuclei were counted in 3 fields of view at x 200 magnification 
using a Nikon Eclipse E600 microscope.  The number of apoptotic nuclei was 
calculated as a percentage of total nuclei. 
2.2.6 Flow cytometry 
Flow cytometry was carried out by C. Hayford.  Ascites samples were centrifuged at 
1000 g for 10 minutes and the supernatant was discarded. The cell pellet was diluted 
in culture media (RPMI 1640 + 10% FCS + Pen/ Strep and Glutamine) and the 
mononuclear cells were isolated using Histopaque-1077 (Sigma Aldrich).  FACS 
analysis was performed by using direct FITC-labelled antibody against CD14 (AbD 
Serotec; 1:50 dilution).  Cells were analysed by flow cytometry (FACS Canto, BD 
Biosciences) using FlowJo software (Ashland, United States). Large granular cells 
were gated and analysed for expression of the monocyte/macrophage marker CD14.    
 
2.2.7 Fluorescence Microscopy 
 
Cells were grown on 13 mm  diameter glass coverslips (VWR) in the bottom of a 24 
well tray overnight.  After the appropriate drug treatment, the cells were fixed with 
4% paraformaldehyde for 20 minutes, permeabilzed with 5% Triton X-100/PBS for 5 
minutes, washed in PBS and blocked for 20 minutes in the appropriate blocker (see 
section 2.7.1).  The primary antibody (see section 2.7.1) was diluted in the same 
blocker and incubated with the cells for 1 hour at room temperature.  This was washed 
and incubated with the appropriate Alexa-fluor conjugated secondary antibody in the 
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dark diluted in blocker for 1 hour.  The coverslips were then washed in PBS for 5 
minutes, removed from the 24 well tray, dipped once in deionised water and mounted 
onto a glass slide using vecta shield mountant with DAPI and antifade (Vector 
Laboratories).  These slides were then visualised using a Zeiss fluorescent microscope. 
 
2.3 Conditions used for inhibitors 
 
For both western blotting and immunofluorescence studies, kinase inhibitors were 
incubated with live cells at 37 °C for 3 hours.  Imatinib was stored in deionised water 
at 10 mM.  Nilotinib (Novartis), tandutinib (Millennium pharmaceuticals), Dasatinib 
(Bristol Myers Squib), SU6656 (Calbiochem) and Staurosporine (Calbiochem) were 
diluted in DMSO to a stock concentration of 10 mM.  Methylamine was diluted in 
deionised water to a stock concentration of 1M.  All inhibitors except for 
methylamine were stored at -20 °C.   Methylamine was stored at 4 °C. 
 
2.4 Protein Assays  
2.4.1 Sample preparation   
For both immunoprecipitation and western blotting assays, Rat-2  fibroblasts, N9 
microglia or Bac1.2F5 macrophages were plated into 10 cm diameter plates and 
grown for 48 hours or until confluent.  Cells were washed in 1 x PBS then lysed in 
1ml of RIPA (see section 2.7.2) directly on the plate.  Using a scraper, the lysates 
were transferred into eppendorfs and pelleted at 13 000 x g in a microfuge for 5 
minutes at 4 °C and pellets were discarded.   50 µl Laemlli lysis buffer (see section 
2.7.2) was added to each western blotting lysate.  Samples were stored at -20 °C.   
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2.4.2 Immunoprecipitation of the FMS receptor 
Samples lysed in RIPA were thawed and spun for 5 minutes at 4°C and 13000 x g in a 
microfuge, and the supernatant was added to 10 µl of FMS (prep792) rabbit 
polyclonal antibody, that was raised against a C-terminal peptide. The lysates were 
transferred into new eppendorfs which were rolled at 4 °C for 1.5 hours. The samples 
were again spun for 5 minutes at 4°C  and 13000 x g in a desktop microfuge and the 
supernatant was added to 20 µl of protein-A-beads (Autogen bioclear) and rolled for 2 
hours at 4 °C. The beads were washed three times in 1 ml of RIPA (see section 2.7.2). 
After the third wash the beads were re-suspended in 10 µl of laemlli lysis buffer and 
stored at -20 °C.   
 
2.4.3 SDS-PAGE  
Cell lysates which were to be probed for FMS or phospho-FMS were run on a 8% 
(w/v) resolving and 4% (w/v) stacking acrylamide gel (see section 2.7.2) and lysates 
to be analysed for MAPK or AKT were run on a 12% (w/v) resolving and 4% (w/v) 
stacking acrylamide gel (see section 2.7.2). Glass plates (18.5cm x 20cm) were 
assembled using 1 mm spacers at the sides and the bottom.  These were held together 
using bulldog clips and sealed using 1% molten agarose. The gel was placed into a 
vertical gel slab apparatus. The bottom and top atrium of the tank were filled with 1 x 
running buffer (see section 2.7.2). The gel was run at 100 volts for 1 hour then 150 
volts for 5 hours. 
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2.4.4 Western blotting transfer system  
Gels were transferred using a wet-blotting system (Biorad).  The gels were taken out 
of the apparatus and the glass plates were carefully removed. The gel was layered in 
to the apparatus with a sponge layer, then 2 sheets of Whatman chromatography paper, 
then the nitrocellulose sheet (0.2 µm pore size) (Amersham), then the gel, then a 
further 2 sheets of whatman blotting paper (Whatman) and finally another sponge 
layer. The whole sandwich of layers was soaked in a dish filled with transfer buffer 
(see section 2.7.2) and a stripette was rolled across the sandwich to remove air 
bubbles. The apparatus was closed and slotted into the transfer tank, which was filled 
with transfer buffer. The proteins were then transferred for 5 hours at 200 mA.  
 
2.4.5 Immunoblotting 
Nitrocellulose membrane was stained with Ponseau S (see section 2.7.2) to see the 
total protein loading.  This membrane was scanned and saved for record.  The 
membrane was then washed in 1XTBS / 0.15 %TWEEN-20 (TBS-T) for 10 minutes 
and blocked in the appropriate blocker (see section 2.7.1) for 30 minutes and 
incubated in the appropriate primary antibody (see section 2.7.1) diluted in blocker for 
12 hours at 4 °C.   The membrane was then washed in TBS-T for 15 minutes with 1 
change and then the appropriate secondary antibody was added (see section 2.7.1) for 
2 hours at room temperature.  After this incubation the membrane was again washed 
in TBS-T for 15 minutes with 1 change. 
 
All membranes were developed using an ECL plus system (Amersham).  The ECL 
plus was left on the membrane for 5 minutes before wrapping the membrane to cling 
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film and placing in a film case. The membrane was developed to GRI biomax film 
using a film developing machine (Kodak). 
 
2.4.6 In vitro kinase Assay 
FMS was immunoprecipitated from Rat-2 cfms cells using the FMS792 antibody as 
described above.  The precipitated FMS receptor was washed 3 times in RIPA (see 
section 2.7.2) and, following this washed 3 times in 50 mM Tris pH7. The 50mM Tris 
pH7 was then aspirated using a 20 gauge needle and resuspended in 17 µl of kinase 
buffer (see section 2.7.2) per tube.  This mixture was then incubated with 0.5 µl 
(0.185 MBq per reaction) of gamma ATP32  and incubated at 30°C for 20 minutes.  
The reaction was stopped by adding 20 µl of Laemmli buffer (see section 2.7.2) and 
the tubes were stored at -80 ºC in a Perspex box.    
 
2.5 Molecular Biology Techniques 
2.5.1 Site-directed mutagenesis  
The FMS T633I mutant was made by oligo-directed mutagenesis following the 
scheme shown in figure 2.1. Vsn-2 c-fms is a retroviral construct containing the entire 
cDNA of 3.1 Kb human c-fms cloned into the retroviral vector vsn-2 (Dibb et al.,1990; 
fig 2.1).  
 
Initially, two short fragments were amplified by PCR by using the following primer 
pairs; forward primer and mutant primer 2 and reverse primer and mutant primer 1 
(see section 2.5.3 for primer sequences).  Product 1 contained a Xho1 restriction site 
and the T633I mutation and product 2 contained a BsrG1 restriction site and the 
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T633I mutation.  These 2 products were E gel purified and ethanol precipitated and 
resuspended in 30 µl of TE buffer (see section 2.7.2).  1 µl of each of these initial 
products was used in a second PCR reaction using the forward and reverse primers 
(see section 2.5.3 for sequences) which generated a larger product which contained 
both of the restriction sites, Xho1 and BsrG1 and the required mutation. This product 
was again E gel purified and ethanol precipitated and resuspended in 30 µl of TE 
buffer.  2 µl of this product and 1 µg of the original vsn-2 c-fms plasmid were 
restriction digested with Xho1 and BsrG1.  These products were again E gel purified 
and ethanol precipitated and resuspended in 10 µl of TE buffer and then ligated to 
reform a circular plasmid which contained the required mutation.  The plasmid was 
transformed into DH5 alpha E. coli and 12 plasmid mini preps were made and 
sequenced to confirm the presence of only the required mutation. 
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MSV LTR                                      cfms cDNA ORF      SV40        Neomycin        Mo LTR
Forward primer        Mutant primer 1
Mutant primer 2     Reverse primer         
Vsn-2 c-fms
First stage PCR
Reaction 1: 
•Forward primer and mutant primer 2
•E gel purification of product 1
Reaction 2: 
•Reverse primer and mutant primer 1
•E gel purification of product 2
Second stage PCR
PCR product 1 PCR product 2
Forward primer
Reverse primer
Final PCR product
Xho 1 restriction siteBsrG1 restriction site
MSV LTR                                    Mutant cfms cDNA ORF SV40        Neomycin        MoLTR
•E gel purification of final product
•Double Restriction digestion of vsn-2 c-fms and final PCR product with BsrG1 and Xho1 
•E gel purification of required products
•Ligation of digested product and vsn-2 c-fms
Xho 1 restriction siteBsrG1 restriction site
 
Figure 2.1. Schematic diagram of cloning strategy used to make FMS T663I 
mutation.   
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2.5.2 Designing oligonucleotides for mutagenesis 
Forward and reverse primers were complementary to the vsn-2 c-fms sequence except 
for the required base mutations. Primers were also designed upstream and 
downstream of the mutation encompassing enzyme sites that were then used to clone 
the fragment back into the vsn-2 cfms construct (Figure 2.1). The primers were 
designed between 18-40 bases in length.  
 
2.5.3 PCR primer sequences 
Mutant Primer 1 (forward): GTACTGGTCATCATCGAGTACTGT 
Mutant Primer 2 (reverse): ACAGTACTCGATGATGACCAGTAC 
Forward Primer (ND218):ATCGGAATTCCGGGCCGTCCATCCTCCTT 
Reverse Primer (ND206):  AGGTGACGGTCCATAGCCTGCTG 
Sequencing primer 1(ND97): GAGCCCTTCTACAAGGTGACG 
Sequencing primer 2(ND220): TGCGAATTCCGGAGCAGATCTGCTGGAAGGT 
2.5.4 Polymerase Chain reaction (PCR)  
All PCR cycling was carried out on a Hybaid PCR express machine. The following 
conditions were used for all PCR reactions (primers had similar annealing 
temperatures): 
 
94 °C – 3 mins (denaturing) 
60 °C – 30 secs (annealing)  
72 °C – 1 min (extension)              30 cycles 
94 °C – 30 secs (denaturing) 
Hold – 4 °C 
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Each PCR reaction was carried out in 20µl of water and contained 5 µM  forward and 
reverse primers (stock solutions at 100 µM); 1µg of vsn-2 cfms (or 1µl of each of the 
first round DNA fragments); 0.2 mM dNTP’s (Abgene); 2µl of 10x PCR buffer with 
MgCl2 (Roche) and 0.8 µl of Taq polymerase (Expand TM High Fidelity PCR system, 
Roche). With each reaction a positive and negative (primers alone) control, no taq 
polymerase, and one control with no template DNA was used.  
 
2.5.5 TBE agarose electrophoresis 
TBE agarose gels were routinely used for checking PCR product sizes as well as 
restriction enzyme digestions of maxi and mini preps (see below). Agarose was 
dissolved in 1x TBE (see section 2.7.2) by heating the solution in the microwave and 
left to cool slightly before adding 0.1µg/ml ethidium bromide (Sigma-Aldrich). The 
concentration of the agarose gels varied from 0.7 to - 2% (w/v) depending on the size 
of the DNA fragments. The cooled agarose was poured into a small horizontal gel 
tank (Flowgen). Once the gel had set the metal plates were removed and the tank was 
filled with 1x TBE. The samples were prepared by adding 1/10th the volume of orange 
loading dye (5 x orange G, see section 2.7.2) and then loaded into the wells of the gel 
with a 1 Kb ladder (Gibco-BRL) to assess the size of the DNA bands. Gels were run 
at 50 volts for 1-3 hours. The bands were visualised using a UV light box.   
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2.5.6 Preparation of inserts and vectors for cloning by restriction enzyme 
digestion 
Restriction enzyme digests were performed using NEB restriction enzymes (Biolabs) 
in the recommended buffers and at the recommended reaction temperatures. The 
reactions were carried out in a final volume of 20µl and contained 1µl of plasmid prep 
DNA (2µg) or 5µl of PCR product, 2µl enzyme buffer and 1µl enzyme and were 
incubated for a minimum of 1.5 hours at the suggested temperature.  The reactions 
were stopped by adding orange loading dye (5 x orange G) and the DNA fragments 
isolated on an E-gel (see section 2.5.7).  
 
2.5.7 E-Gel extraction and ethanol precipitation 
Digested DNA samples intended for isolation were run onto thin (3 mm x 75 mm x 75 
mm) 1% (w/v) agarose TAE gels (containing 0.1µg/ml ethidium bromide).  Sample 
loading buffer (5 x orange G) was added to each of the digested DNA samples then 
loaded into the E-gel leaving a lane between each sample. Gels were run at 30 volts 
for two to three hours in 1x E-buffer. To isolate the required fragment, a cut was made 
in the gel under the DNA band using the UV light box to visualise the DNA. The gel 
was the placed back in the tank on a raised block. All the empty wells were filled with 
E-buffer. The hole was filled with about 40µl of 1x E buffer and the gel was run for 
15 seconds (small DNA fragment) or 20 seconds (larger DNA fragment) at 150volts.   
During this step the DNA enters the cut well and can be removed by using a 
pipetteman.  This step was repeated four times until all the required DNA was 
removed as seen under UV light. The tube was spun for 2 minutes and the supernatant 
removed to a fresh tube. The DNA was ethanol precipitated by adding 1/10th of the 
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volume of NaAc pH 5.2 and 2.5 times the volume of ethanol (-20°C) and  the samples 
were left on ice for 30 minutes (or overnight at -20°C) and spun for 10 minutes at 
13000g in a microfuge. The supernatant was removed and tubes washed with 70% 
ethanol (room temperature). Pellets were air dried before being re-suspended in 30µl 
of TE buffer (see section 2.7.2).  
 
2.5.8 Ligation of inserts into vectors 
Ligation reactions were set up in 1.5ml eppendorf tubes as follows; 
 
 1 2 3 4 5 
Digested vector DNA 1µl 1µl 1µl 1µl - 
Digested insert DNA - - 1µl 3µl 1µl 
T4 DNA ligase - 0.5µl 0.5µl 0.5µl 0.5µl 
10 x 1igase buffer 1µl 1µl 1µl 1µl 1µl 
Water 8µl 7.5µl 6.5µl 4.5µl 7.5µl 
 
The tubes were left at room temperature for 5 hours before transforming into 
competent DH5α cells (see section 2.5.11). 
 
2.5.9 Small scale/ large scale plasmid purification 
Plasmids were purified after transformation of the appropriate plasmid into DH5 
alpha E.coli (see section 2.5.11).  For small scale plasmid purification, colonies of 
transformed E. coli were inoculated into 1 ml of LB media containing 100 µg/ml 
ampicillin and placed in a heated shaker overnight.  E coli were spun at 13 000 x g for 
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5 minutes.  Plasmids were purified using the QIAprep miniprep plasmid Purification 
Kit following manufacturers guidelines (Qiagen).     
 
For large scale plasmid purification, DH5 alpha cells which had been transformed 
with the appropriate plasmid and grown on an agar plate containing 100 µg/ml 
ampicillin overnight were scraped into 250 mls of TY media containing 100 µg/ml 
ampicillin.  This was placed in a 37 °C shaker overnight and the plasmid was 
harvested by spinning down the E. coli at 13 000 x g for 10 mins and using the 
QIAGEN Maxi plasmid purification kit following manufacturers guidelines (Qiagen). 
The OD260 was measured and the DNA concentration was adjusted to 2 mg/ml. 
 
2.5.10 Sequencing double stranded DNA to screen for mutations 
Plasmids were checked for the appropriate mutation by sequencing with a suitable 
primer. Sequencing reactions were prepared in microtubes as follows: 1µl (maxi prep) 
or 2µl (mini prep) DNA, 1µl primer (100 µM), 8µl Big Dye terminator (Applied 
Biosystems) and made up to 20 µl with water. The samples were run on a PCR 
machine with a program of 95°C for 1min then 95°C for 10 seconds, 50°C for 5 
seconds and 60°C for 4 minutes (35 cycles). These reactions were cleaned by an 
isopropanol precipitation method. 80µl of 75% isopropanol was added to each 
reaction, mixed and left at room temperature for 15 minutes. These tubes were then 
spun at 13000g in a mircocentrifuge for 15 minutes after which the supernatant was 
removed. Next, 100µl of 70% isopropanol was added, mixed and incubated at room 
temperature for 10 minutes. The tubes were spun at 13000g for 10 minutes, the 
supernatant removed and the precipitates left to air dry for 30 minutes. These were 
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then stored at –20°C until ready to be sequenced by the in house service at the IRDB. 
Samples were reconstituted back into 30 µl of Hi-dye then denatured for 5 minutes at 
96°C and left on ice.  Sequences were analyzed using the 3100 Genetic analyser, 16 
capillary model (Applied Biosystems) using standard programmes for DNA 
sequencing.  Data was collected automatically using the DNA sequencing analysis 
software version 3.7 (Applied Biosystems).   This system can successfully read 
sequences of up to 560-600 bases. 
 
2.5.11 Transformation of DH5α cells with plasmid DNA 
Competent DH5 alpha cells were transformed with 1-10 ng of plasmid DNA. DNA 
was added to 100µl of cells and the tubes were placed on ice for 45 minutes before 
being heat shocked for 90 seconds at 37°C. Cells were transferred to tubes containing 
1 ml of 2 x TY and shaken for 30 minutes at 37°C. Following this 100 µl of each 
culture was plated onto TY agar plates containing 100 µg/ml ampicillin and incubated 
at 37°C overnight in an inverted position.  
2.5.12 Stable retroviral transfection 
Rat-2  fibroblasts were grown to approximately 40% confluence in T25 flasks. 
Polybrene (Sigma) was added to the flask to a final concentration of 4ng/µl and 
incubated for 1 hour at 37°C, 5% CO2. During this incubation supernatant containing 
the virus was removed from the previously transiently transfected (see section 2.5.13) 
PA317 cells and filtered through a 0.45 micron filter into a 50ml tube and stored in 
the fridge. After the hour the media was removed from the cells and 1.5ml of viral 
supernatant was added along with polybrene (final concentration of 4ng/µl). After 24 
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hours, fresh DMEM supplemented with 10% (v/v) heat inactivated Foetal Calf Serum 
(FCS), 50 U/ml penicillin/streptomycin (Gibco) and 200 µM glutamine (Gibco) was 
added to the cells containing G418 to a final concentration of 1mg/ml.  
 
2.5.13 Transient transfection  
The cell line to be transfected was grown to 80 % confluence and the growth media 
was changed to DMEM with penicillin/streptomycin (Gibco) 50 IU/ml and glutamine 
(Gibco) 200 µM.  Cells were transfected with ESCORT V lipid based transfection 
reagent as per manufacturer’s protocol.  Briefly, for transfection of plasmid DNA 
into a 6 well plate, 300 µl of Escort V buffer was mixed with 3.5 µg of plasmid and in 
a separate tube, 300 µl of Escort V buffer was mixed with 10 µl of Escort V 
transfection reagent.  These two mixtures were combined, inverted 3 times and 
incubated at room temperature for 25 minutes.  The mixture was added to cells drop 
wise and incubated for 48 hours before assaying.   
2.6 Molecular modelling    
Molecular modelling of nilotinib was carried out by J. Murray and the modelling for 
dasatinib was carried out by C. Mol.  The molecular model for the kinase domain of 
FMS was constructed from the homologous (72% amino acid identity) kinase domain 
of activated c-Kit (PDB code: 1PKG (Mol et al., 2003) by manual replacement of 
non-homologous residues, and visual inspection of the model using the XtalView 
molecular graphics program (McRee, 1999). This model structure was energy-
minimized using REFMAC (Murshudov et al., 1997) within the CCP4 suite of 
programs. A model for the binding of dasatinib or Nilotinib to active FMS was 
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derived by superposition and comparison with the crystal structure of dasatinib bound 
to active Abl kinase (Tokarski et al., 2006).   
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2.7 Reagents 
2.7. 1. Antibodies 
Antibody Source Application  Dilution Blocker 
Rabbit anti-FMS C-
Terminus polyclonal 
(Ab792) 
N. Dibb WB, IP 1:1000 5% non fat 
milk/TBS 
0.15% TWEEN 
20 
Rabbit anti-phospho-
Tyrosine723 
Cell 
Signalling 
WB 1:1000 5% BSA 
fraction V 
/1mMNaVO3/T
BS 0.15% 
TWEEN 20 
Rabbit anti-phospho-
Tyrosine708 
polyclonal 
Santa Cruz 
Biotech. 
WB 1:1000 55% non fat 
milk/1mMNaV
O3/TBS 0.15% 
TWEEN 20 
Mouse anti-phospho-
AKT monoclonal 
Cell 
Signalling 
IF, WB 1:100 (IF) 
1: 1000 
(WB)  
10% FCS/ PBS 
5 % milk/TBS-
T 
Rabbit anti-phospho-
MAPK polyclonal 
Cell 
Signalling 
IF, WB 1:100 (IF) 
1: 1000 
(WB) 
10% FCS/ PBS 
5 % milk/TBS-
T 
Rabbit anti-FMS N-
Terminus (3-4A4) 
Mouse/rat specific 
Santa Cruz 
Biotech. 
IF 1:100 10% FCS/ PBS 
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Mouse anti-FMS N 
terminus clone AFS98 
Human specific 
Ebioscience IF 1:100 10% FCS/ PBS 
Alexa 488 conjugated 
Goat anti- Rabbit IgG 
Invitrogen 
Molecular 
Probes 
IF 1:500 10% FCS/ PBS 
Alexa 568 conjugated 
Goat anti- Mouse IgG 
Invitrogen 
Molecular 
Probes 
IF 1:500 10% FCS/ PBS 
Peroxidase 
conjugated Goat anti-
mouse IgG 
Sigma 
Aldrich 
WB 1:10 000 5% non fat 
milk/TBS 
0.15% TWEEN 
20 
Peroxidase 
conjugated Goat anti-
rabbit IgG 
Sigma 
Aldrich 
WB 1:10 000 5% non fat 
milk/TBS 
0.15% TWEEN 
20 
Mouse anti-CBL (A-
9) 
Santa Cruz WB 1:1000 5% non fat 
milk/TBS 
0.15% TWEEN 
20 
Mouse anti CD68 
(KP1) 
Santa Cruz IF 1:1000 10% FCS/ PBS 
Western blotting(WB), Immunoprecipitation (IP), Immunofluorescence (IF) 
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2.7.2. Table of commonly used solutions.  
 
Laemmli lysis buffer 
20%   Glycerol 
2%   SDS 
0.1M  Tris pH 6.8 
10%   ß-Mercaptoethanol 
7M   Urea 
10x Running Buffer 
121g   Tris base 
578g   Glycine 
40g   SDS 
Water to 4 litres 
 
Coomassie Stain 
0.25% Coomassie Brilliant Blue 
45% Methanol 
10% Acetic Acid 
Made in water 
Kinase Buffer 
10mM MnCl2 made in 20mM 
HEPES/20mM PIPES buffer 
 
Fixer for radioactive gels 
10%   MeOH   
5%   Glycerol  
Made in water. 
 
10x PBS 
(1) 0.5M NaH2P04 (30g/500ml)  
(2) 0.5M Na2HP04 (35.5g/500ml) 
Add (2) to (1) until pH 7.2 this gives 
stock solution. Take 200ml of this 
stock and add 8.76g NaCl and make up 
to 1 litre with distilled water. 
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RIPA/SDS 
1%   Nonidet P-40 
1%   Triton X-100 
1%   Sodium deoxycholate 
0.1%   SDS 
150mM  NaCl 
10mM  Tris pH 8.0 
2nM   NaF 
RIPA/SDS was stored at 4°C and 10µl per 
ml of protease inhibitor mix and 
Aprotinin was added before use 
 
Protease inhibitor mix 
20mg/ml  phenyl methyl sulfonyl 
fluoride (PMSF) 
20mg/ml  1-10 phenanthroline 
20mg/ml  Benxamine 
Dissolved in ethanol and stored at -
20°C 
Transfer Buffer 
25mM  Tris base 
0.2M   Glycine 
20%  Methanol 
0.05%  SDS 
TRAP Solution 
44ml Water 
2 ml Acetate solution (Sigma cat 386-
3) 
2ml Naphthol AC-BI Phosphoric acid 
(Sigma cat no. 386-4 
2ml Tartrate solution (Sigma Cat No. 
386-2) 
1 capsule Fast Garnet GBC Salt 
(Sigma Cat 386-15) 
Filter through Whatman No.54 before 
use. 
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Polyacrylamide 8% gel  
16.95 ml     Deionised water 
13.4 ml       30% Acrylamide / 
                    Bis solution (Biorad) 
18.75 ml      1 M Tris (pH 8.8) 
0.5 ml          10 % SDS     
0.5 ml          10 % APS 
30 µl            TEMED    
Polyacrylamide stacking gel 
6.8 ml     Deionised water 
1.7 m      30% Acrylamide / 
               Bis solution (Biorad) 
1.25 ml   1 M Tris (pH 6.5) 
0.1 ml     10 % SDS     
0.1 ml     10 % APS 
10 µl       TEMED    
Polyacrylamide 12% gel  
10.15 ml     Deionised water 
20 ml          30% Acrylamide / 
                    Bis solution (Biorad) 
18.75 ml      1 M Tris (pH 8.8) 
0.5 ml          10 % SDS     
0.5 ml          10 % APS 
30 µl            TEMED    
TBE 
432 g Tris 
220 g Boric acid 
37.2 g EDTA 
Water to 3 litres 
2xTY 
16g   Tryptone 
10g   Bacto-yeast extract 
5g   NaCl 
Water to 1 litre 
2xTY + AGAR 
Same as 2xTY but with 15g of Bacto-
agar add per litre. 
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10x TBE 
432g   Tris 
220g  Boric acid 
37.2g   EDTA 
Water to 4 litres 
20x TAE (E-Buffer) 
0.8M    Tris 
0.4M    Sodium acetate 
20mM   EDTA 
pH 8.0 with glacial acetic acid 
TE Buffer 
10 mM Tris-HCL pH 7..4 
1 mM EDTA 
 
Ponceau S 
0.2 % Ponceau Red 
5 % Acetic acid 
5 X Orange G loading buffer 
0.1 % Orange G powder (SigmaAldrich) 
Dissolved in TAE buffer. 
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CHAPTER 3. Imatinib and Nilotinib inhibition of the FMS receptor and human 
osteoclastogenesis. 
 
3.1 Introduction 
Many diseases are linked to the over activation or aberrant signalling from kinases, 
ranging from cancer to inflammatory diseases.  Over the past 15 years there has been 
much success in treating these diseases with various kinase inhibitors which compete 
with ATP for binding to the kinase domain.  One of the first of these inhibitors was 
imatinib mesylate (Gleevec, Novartis).   Imatinib has been very successful in treating  
Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and is 
currently the first line treatment after having a significant impact on outcome in 
patients newly diagnosed with CML (Branford et al., 2003; Kantarjian et al., 2003; 
O'Brien and Deininger, 2003).   Patients treated in an advanced stage of the disease do 
however tend to develop resistance to imatinib (see introduction, page 48).  
 
This problem has led to the development of a second generation of kinase inhibitors 
against BCR-ABL with the view to overcome imatinib resistance.  Nilotinib 
(AMN107, Tasigna, Novartis) is a new derivative of imatinib that has greatly 
enhanced affinity for the ATP binding site of the Bcr-Abl kinase (Manley et al., 2005).   
It is more potent against CML cells in vitro than imatinib and it is also active against 
32/33 mutations of ABL that confer resistance to imatinib in cell lines (Weisberg et 
al., 2005).  In a phase 1 trial of patients who had previously been treated with imatinib 
and become resistant, 75 percent of patients with the accelerated phase and 39% in the 
blast crisis achieved complete haematological response (Kantarjian et al., 2006a).  
Despite this success, the problem of drug resistance remains as treatment with 
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nilotinib simply further selects for mutations which are resistant to both imatinib and 
nilotinib.  A  particularly common mutation of this class is a mutation of a threonine 
residue at the ‘gatekeeper position’ (see chapter 1, Introduction) in the ATP binding 
site which is particularly necessary for both imatinib and nilotinib to bind to ABL 
(Gorre et al., 2001). 
 
 Imatinib was developed from an inhibitor of the PDGF receptor (Buchdunger et al., 
1996; Buchdunger et al., 1995) and both imatinib and nilotinib are also active against 
other members of this receptor family including KIT but not FLT-3 (Buchdunger et 
al., 2000; Bohmer et al., 2003; Dewar et al., 2005a; Taylor et al., 2006; Lacey et al., 
1998; Manley et al., 2005) although the increased sensitivity of ABL to nilotinib 
compared to imatinib does not correspond to an increased sensitivity to the PDGF 
receptor family (Weisberg et al., 2005).   Imatinib is particularly active against KIT 
receptors that have oncogenic juxtamembrane mutations (Longley et al., 2001; Frost 
et al., 2002) and this provides a novel and effective treatment for patients who have 
gastrointenstinal stromal tumours (GISTs) where this oncogenic mutation is common 
(Joensuu et al., 2002).    However, imatinib is ineffective against another common 
oncogenic mutation of the PDGFR family that changes an Asp residue to a 
hydrophobic amino acid (usually Val) within the  kinase domain of this receptor 
family (Frost et al., 2002; Ma et al., 2002).  This oncogenic mutation is found at high 
frequencies in mast cell leukaemia, acute myeloid leukaemia, testicular cancer and a 
subset of GISTs (Dibb et al., 2004).   There are conflicting reports regarding the 
sensitivity of nilotinib to this mutation (Verstovsek et al., 2006; von Bubnoff et al., 
2005). 
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 Imatinib is well-tolerated by most patients with CML although it has been observed 
that some patients who were treated with higher doses of imatinib showed an 
association with altered bone and mineral metabolism (Berman et al., 2006; Joensuu 
et al., 2002; Joensuu and Reichardt, 2006).  These findings  indicate a reduction in 
osteoclast number or function due to imatinib treatment. 
 
Here we use a number of assays to show that both imatinib and nilotinib are effective 
inhibitors of FMS signalling at concentrations above 600 nM and 250 nM respectively.   
In confirmation of this we found that mutation of Asp 802 to Val described above, 
conferred resistance to both imatinib and nilotinib.   In the majority of FMS-based 
assays, nilotinib was only a slightly more effective inhibitor of FMS signalling 
compared to imatinib, however we observed that nilotinib (IC50 50 nM) was a 
notably more effective inhibitor than imatinib (IC50 > 500 nM) of human osteoclast 
production in primary cultures.  The therapeutic implications of these results are 
discussed at the end of this chapter. 
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3.2. Results 
The proliferation of the haemopoietic cell line FDC-P1 is normally dependent upon 
IL-3 (Dexter et al., 1980; Hapel et al., 1984), however, M-CSF can also be used to 
stimulate the growth of cells that express recombinant FMS (Rohrschneider and 
Metcalf, 1989; Dibb et al., 1990) .  FDC-P1 cells which express the oncogenic FMS 
receptors V-Fms (Dibb et al., 1990) and FMS D802V (Glover et al., 1995)  proliferate 
independently of IL-3 and M-CSF due to the constitutively active FMS receptor.     
 
Figure 3.1 shows that both imatinib and nilotinib inhibited FMS receptor stimulated 
cell proliferation and that a mutation of Asp 802 to Val (D802V) conferred resistance.  
This is in accordance with previous reports of imatinib and nilotinib inhibition of the 
equivalent mutation of the KIT receptor (Frost et al., 2002; Verstovsek et al., 2006) 
although contrary to another report which shows that KIT D816V is sensitive to 
nilotinib (von Bubnoff et al., 2005).  Figure 3.1A shows that the growth of FD cfms 
cells was fully inhibited at 2 µM by imatinib (figure 3.1A; stripes) and accordingly 
the growth of FD V Fms was also fully inhibited at this concentration (figure 3.1A; 
Black).   The IC50 for imatinib inhibition of the FMS receptor was calculated to be 
0.6 µM from this figure.  In contrast, the proliferation of FD D802V was resistant to 
imatinib (figure 3.1A; no fill).  The growth of FD-CP1 cells with IL-3 was unaffected 
by imatinib as expected (data not shown).  In accordance with these results, the 
murine macrophage cell line Bac1.2F5, which expresses endogenous FMS receptor 
and is dependent on M-CSF for survival and proliferation (Boocock et al., 1989) was 
sensitive to imatinib (figure 3.1B; circles).  Infection of these cells with a retrovirus 
expressing FMS D802V conferred resistance to imatinib in this cell line (figure 3.1B; 
squares).   
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Figure 3.1.  Imatinib and nilotinib inhibit FMS dependent cell proliferation and 
a mutation of asp 802 to val confers resistance. (A) FDC-P1 cells that express FMS 
(FD c-fms) V-fms (FD v-fms) or D802V (FD D802V) were plated at 1x104 cells/ml 
in RPMI + 10% FCS in 24-well plates and grown for 7 days in the indicated 
concentrations of imatinib. FD c-fms cells were grown with 5000 U/ml M-CSF. (B) 
Bac1.2F5 macrophage cell line grown with M-CSF (diamonds) or expressing 
oncogenic FMS receptor FMS D802V (squares) grown with increasing concentrations 
of imatinib.  1 x 104 Bacl.2F5 cells were plated in DMEM+10% FCS+5000 U/ml M-
CSF in 24-well trays and grown for 4 days in the indicated concentrations of imatinib. 
(C)  FD c-fms cells were grown in either 10 ng/ml IL-3 (squares) or 5000 U/ml M-
CSF (circles), along with the indicated concentrations of nilotinib.  FD D802V were 
grown in the absence of both M-CSF and IL-3 (triangles), and cell numbers were 
counted after 5 days. (D) Rat-2 fibroblasts expressing V-fms, (Rat-2 V-Fms) FMS 
(Rat-2 cfms) and FMS D802VY708F (Rat-2 D802VY708F) were plated in DMEM 
10% FCS and grown for 5 days in the indicated concentrations of imatinib. All 
experiments were repeated at least 3 times and done in triplicate each time.  Viable 
cell numbers were counted using a haemocytometer and triplicate assays were 
averaged.  Error bars show standard error of the mean (SEM).  (A) Courtesy of J. 
Taylor. 
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A similar result was also shown with nilotinib inhibition of FMS.  Figure 3.1C shows 
that M-CSF  dependent proliferation of FD cfms cells was totally inhibited by 
nilotinib at 0.8 µM (figure 3.1C; circles) and the IC50 value was calculated from 
figure 3.1C as 0.3 µM.   The D802V mutation confers marked but not complete 
resistance to nilotinib, shown in figure 3.1C (triangles).  The growth of FDC-P1 cells 
with IL-3 was unaffected by nilotinib as expected showing that the inhibition of 
proliferation seen in this assay is specific to the FMS receptor pathway (figure 3.1C; 
circles). 
 
I next assessed the ability of imatinib and nilotinib to inhibit Rat-2 fibroblast 
transformation. Normally, these cells proliferate when grown in media with FCS but 
show contact inhibition when they become confluent.  When they ectopically express 
the FMS receptor and are stimulated with M-CSF they become transformed, lose 
contact inhibition and grow to a higher cell number (Baker et al., 1994; Roussel et al., 
1987).  Figure 3.1D shows that when Rat-2  c-fms cells were stimulated with M-CSF , 
the final cell number increased by about 75% (figure 3.1D; open versus closed circles).  
This effect was inhibited by 1 µM imatinib treatment, which resulted in similar cell 
numbers to Rat-2 cfms grown without M-CSF or imatinib (figure 3.1D).    Similarly, 
proliferation stimulated by the oncogenic receptor V-Fms was also inhibited by 
imatinib (figure 3.1D; closed squares).  Expression of FMS D802V only partially 
transforms Rat-2 fibroblasts and only when combined with a second mutation of Tyr 
708 to Phe.  This is due to an enhancement of receptor stability (Morley et al., 1999).  
In accordance with this; proliferation of Rat-2 D802VY708F (figure 3.1D; open 
squares) is enhanced compared to Rat-2 cfms alone but not to the extent of Rat-2 V-
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Fms proliferation (figure 3.1D; closed squares).  The transforming effect of FMS 
D802VY708F, was less inhibited by imatinib, in accordance with Figures 3.1A-C.     
 
The data in figure 3.1D is confirmed in figure 3.2 which shows that both imatinib and 
nilotinib inhibited the morphological transformation of Rat-2 fibroblasts that is caused 
by FMS signalling.  Figure 3.2A and 3.2C, show the transformed morphology of Rat-
2 V-Fms fibroblasts and figure 3.2B, D show that this was suppressed by both 1 µM 
imatinib (figure 3.2B) and 1 µM  nilotinib (figure 3.2D) and that contact inhibition is 
restored.  Figure 3.2E, F shows that the transformed morphology of Rat-2 FMS 
D802VY708F was resistant to imatinib.   Figure 3.2G and 3.2I show F-Actin staining 
of Rat-2 -cfms cells, which illustrates the presence of extended actin cables.  This 
feature was suppressed by both 1 µM imatinib (figure 3.2H) and 1 µM nilotinib 
(figure 3.2J) as expected.  The specificity of imatinib to the FMS signalling pathway 
in these cells is demonstrated by Figure 3.2K-N.  Figure 3.2K shows Rat-2 V-Src 
cells which have a similar transformed morphology to Rat-2 V Fms (figure 3.2A, C).   
However, 1 µM imatinib was unable to reverse the v-Src induced transformation 
(figure 3.2L) of Rat-2 fibroblasts but transformation was reversed by the Src kinase 
inhibitor SU6656 at 1 µM (figure 3.2N). 
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Figure 3.2.  Imatinib and nilotinib 
both inhibit Rat-2  fibroblast 
transformation by FMS.  (A-F) 
Giemsa staining of Rat-2 V Fms or 
Rat-2 FMS D802VY708F treated 
overnight with or without imatinib or 
nilotinib.  (A) Rat-2 V Fms (B) Rat-
2 V Fms + 1 µM imatinib (C) Rat-2 
V Fms (D) Rat-2 V Fms + 1 µM 
nilotinib(E) Rat-2 FMS 
D802VY708F (F) Rat-2 FMS 
D802VY708F+ 1 µM imatinib. (G-J) 
Phalloidin staining of F-Actin of 
Rat-2 V Fms treated with or without 
imatinib or nilotinib overnight. (G) 
Rat-2 V Fms (H) Rat-2 V Fms + 
1µM  imatinib (I) Rat-2 V Fms (J) 
Rat-2 V Fms + 1 µM  nilotinib. (K-
N).  Giemsa staining of  Rat-2 V-Src 
treated with or without imatinib or 
SU6656 overnight. (K) Rat-2 V-Src 
(L) Rat-2 V-Src + 1 µM imatinib (M) 
Rat-2 V-Src (N) Rat-2 V-Src + 1 µM 
SU6656. Ruler = 100 µm. 
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Figure 3.3A shows that M-CSF addition caused the phosphorylation of the mature 
form of human FMS expressed by Rat-2 fibroblasts (compare figure 3.3A; lanes 1 and 
2) and that pre-treatment with 0.25 or 0.5 µM nilotinib largely inhibited this process.  
The major phosphorylated band of figure 3.2A is the mature FMS receptor and the 
higher molecular weight smearing is due to receptor ubiquitination (Taylor et al., 
2006).  The antibody used for the immunoprecipitation is shown as a loading control 
(3A; lower panel).   Unlike normal FMS, both the immature and mature forms of the 
oncogenic receptor FMS D802VY708F are phosphorylated in Rat-2 fibroblasts and 
this occurs constitutively in the absence of M-CSF (Morley et al., 1999).  Figure 3.3B 
shows that the phosphorylation of FMS D802VY708F was not inhibited by nilotinib.  
Ponceau staining of part of the nitrocellulose membrane is shown as a loading control 
(figure 3.3B; lower panel).   Similarly, FMS D802VY708F also showed greater 
resistance to nilotinib than wild type FMS in an in vitro kinase assay (figure 3.2C,D).  
Densitometry readings of kinase assays are shown in figure 3.3D.  Similar results for 
imatinib inhibition of FMS receptor phosphorylation and kinase activity were found 
(data not shown) (Taylor et al., 2006). 
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Figure 3.3 Nilotinib inhibits M-CSF induced FMS phosphorylation and the FMS 
D802VY708F mutation confers resistance. (A) Phosphotyrosine blot of FMS 
expressed by Rat-2 fibroblasts that were pretreated with the indicated concentrations 
of nilotinib for 1 h before the addition of 5000 U/ml M-CSF for 5 mins. Total lysates 
were immunoprecipitated with an FMS-specific rabbit polyclonal (FMS Ab 792) and 
blotted with the anti-phosphotyrosine antibody PY99. (B) Phosphotyrosine blot of 
Rat-2 FMS D802VY708F treated similarly to (A), except that total lysates were 
western blotted with an antibody specific to FMS phosphotyrosine 723. (C) In vitro 
kinase assays of immunoprecipitated FMS or FMSD802VY708F receptors 
subsequently treated with the indicated concentrations of nilotinib. Densitometry 
readings of the in vitro kinase assays are shown for FMS (diamonds) and 
FMSD802VY708F (squares). 
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I also assessed the ability of imatinib and nilotinib to inhibit two downstream 
signalling molecules of the FMS receptor; p42/p44 MAPK (ERK) and AKT (figure 
3.4).  Figure 3.4A shows that imatinib inhibited M-CSF induced p42/p44 MAPK 
phosphorylation in the FD cfms cell line.  When these cells are starved of Foetal Calf 
Serum (FCS), background p42/p44 MAPK phosphorylation is reduced (figure 3.4A; 
upper panel, lane 1).  Phosphorylation of MAPK can be stimulated through the FMS 
receptor by adding M-CSF (figure 3.4A; lane 2).  MAPK phosphorylation was 
completely inhibited at 2.5 µM imatinib (figure 3.4A; upper panel).  Figure 3.4A, 
lower panel shows total p42/p44 MAPK protein loading.  Similarly, figure 3.4B, 
upper panel shows that starving Rat-2cfms fibroblasts of FCS for 5 hours reduces 
AKT phosphorylation considerably and that this can be re-stimulated by adding M-
CSF (figure 3.4B; upper panel, lane 1).  Phospho-AKT was completely inhibited at 
2.5 µM imatinib and figure 3.4B, lower panel shows total AKT as a control for even 
loading.    Comparable results were obtained for nilotinib inhibition of p42/p44 
MAPK and AKT phosphorylation in Rat-2 cfms fibroblasts (figure 3.4 C-J).  Figure 
4C and 4G show an absence of p42/p44 MAPK phosphorylation and Akt 
phosphorylation respectively when Rat-2c-fms fibroblasts were starved of FCS for 24 
hours.  Phosphorylation of both p42/p44 MAPK (figure 3.4D) and Akt (figure 3.4H) 
was stimulated by M-CSF and partially inhibited at 0.5 µM nilotinib (figure 3.4E, 3.4I) 
and totally inhibited at 1 µM nilotinib (figures3.4F, 3.4J). 
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Figure 3.4. Imatinib and nilotinib inhibit M-CSF induced p42/44 MAPK and 
AKT phosphorylation. (A,B) 5 x 106 FDc-fms cells were starved of FCS for 5 h and 
then incubated with the indicated concentrations of imatinib for 3 h and then 
stimulated with 5000 U/ml M-CSF for 2 mins.  Cell lysates were analysed by Western 
blotting and probed with antibodies to p42/44 MAPK, Phospho-p42/44 MAPK, Akt 
or Phospho-Akt as indicated. (C-J) Rat-2 cfms cells were grown to semi-confluence 
on 1 cm diameter glass coverslips in DMEM and then starved of FCS for 24 hours 
and pre-treated with nilotinib for 1 hour prior to stimulation with M-CSF (5000 U/ml) 
for 2 minutes.  Coverslips were probed with antibodies for either phospho-p42/44 
MAPK (C-F) or phospho-AKT (G-J) and visualised with a fluorescent secondary 
antibody.  Panels to the right show DAPI staining of the nucleus. No treatment (C, G); 
M-CSF stimulation only (D, H); M-CSF + 0.5 µM nilotinib pre-treatment  (E, I);  M-
CSF + 1 µM nilotinib pre-treatment  (F, J) Ruler = 100 µm.  (A,B) Courtesy of J. 
Taylor. 
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I also investigated the inhibitory effect of imatinib and nilotinib upon 
osteoclastogenesis from human mononuclear progenitor cells mobilised from bone 
marrow.   Osteoclasts can be readily generated from peripheral blood samples of 
patients who have had their bone marrow mobilised by G-CSF for the purpose of 
bone marrow transplantation.  These samples were collected with the appropriate 
informed consent. Osteoclasts generated in this system are dependent on stimulation 
by both recombinant M-CSF and RANKL which is replenished in the media every 3 
days.  No osteoclasts were formed in media lacking M-CSF and RANKL in 
agreement with previous findings (Susa et al., 2004; Matsuzaki et al., 1998).   Table 
3.1A shows that nilotinib inhibited osteoclastogenesis completely at 500 nM with an 
IC50 value of 50 nM, similar IC50 values were obtained in two further experiments.  
By contrast, in the same experiments imatinib had an IC50 value of 600 nM for the 
inhibition of osteoclastogenesis (Table 3.1), which is in accord with a previous report 
(Ando et al., 2006).    
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9.0 ± 2.01000
264 ± 20.8500
272 ± 23.4100
295.6667 ± 48.00
Imatinib (nM)
01000
0500
14.0  ± 3.5250
16.0 ± 2.1125
52.3 ± 8.462
79.7 ± 3.731
125.3 ± 14.20
Nilotinib (nM) Mean osteoclast number ± SEM
Table 3.1. Osteoclastogenesis from human mobilised peripheral blood. 
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  Figure 3.5A shows a representative photograph of human osteoclasts which can be 
seen to have characteristic multiple nuclei and a distinctive actin ring.   Figure 3.5B 
shows tartrate resistant acid phosphatase (TRAP) staining of osteoclasts which is a 
marker of mature osteoclasts (Minkin, 1982) and figure 3.5C illustrates the inhibitory 
effect of 1 µM nilotinib upon osteoclast formation.  Figure 3.5D shows that human 
osteoclasts cultured upon dentine slices cause pit formation as shown by toluidine 
blue staining and figures 3.5E, F show that pit formation was completely inhibited by 
1 µM nilotinib or imatinib, as expected.   The inhibitory potential of both imatinib and 
nilotinib on macrophage colony formation was also investigated using murine bone 
marrow.  Macrophage colonies formed in methylcellulose semisolid media when 
stimulated with M-CSF.  Figure 3.5G shows that imatinib and nilotinib had similar 
profiles of inhibition of macrophage colony formation in response to M-CSF with 
IC50 values of approximately 0.5 µM  This is in agreement with a previous report 
(Dewar et al., 2003).   
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Figure 3.5.  Imatinib and nilotinib inhibit osteoclastogenesis from human 
mononuclear cells and also inhibit murine macrophage colony formation (A-F) 
Human mononuclear cells were cultured with 5000 U/ml rHuM-CSF and 40 ng/ml 
rHuRANKL (2GF) for 3 weeks in alpha MEM with 10% FCS. (A) Representative 
photograph of the osteoclasts with  F-Actin staining shown in red and DAPI stained 
nuclei shown in blue.   (B-E)  BMM were cultured as above with (C,E) or without 
(B,D) 1 µM nilotinib on either tissue culture plastic (B,C) or dentine slices (D,E).  
After the culture period the cells were stained for TRAP to show TRAP positive 
osteoclasts (B,C) or stained with Toluidine blue to show pit formation (D,E).  Pit area 
was measured using the Lucia G V.4.61 software (F).  (G)  Murine bone marrow was 
cultured in methylcellulose with 10 % FCS and 5000 U/ml  rHuM-CSF for 2 weeks 
with 0.5 or 1 µM nilotinib or imatinib.   Macrophage colonies were counted after 2 
weeks.  Scale bars = 50 µM
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Nilotinib was able to induce mature osteoclast death by apoptosis, this is shown in 
figure 3.6 by tunnel staining of DNA fragmentation.  Figure 3.6A, 1st panel shows that 
before nilotinib was added, there are no apoptotic nuclei and figure 3.6B, 1st panel 
shows many apoptotic nuclei after a 24 hour incubation with 1 µM nilotinib.  Figure 
3.6C shows the number of apoptotic nuclei compared to non apoptotic nuclei at 
various concentrations of nilotinib and at 1 µM nilotinib 35% of the nuclei within 
osteoclasts was apoptotic. 
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Figure 3.6.  Nilotinib induces apoptosis of mature osteoclasts.  Mature osteoclasts 
were incubated overnight with the indicated concentrations of nilotinib and the 
number of apoptotic nuclei contained within an osteoclast was counted based on 
TUNNEL staining and a percentage of apoptotic compared to non-apoptotic nuclei 
was calculated.  (A,B) Representative photographs showing TUNNEL staining in 
green and DAPI stained nuclei in blue.  (A) Untreated, (B) 1 µM nilotinib (C) 
Quantization of apoptotic nuclei.  Ruler = 100 µm 
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     Figure 3.7 models the docking of nilotinib into the recently determined structure of 
the inactive kinase domain of FMS (Schubert et al., 2006).  This model is supported 
by the fact that it predicts hydrogen bond interactions between nilotinib and the kinase 
domain of FMS that are similar to those seen between imatinib and KIT (Mol et al., 
2004a), which is to be expected as there is extensive overlap between the structures of 
nilotinib and imatinib and between the structures of KIT and FMS (Mol et al., 2004a; 
Schubert et al., 2006; Cowan-Jacob et al., 2007).    Molecular modelling was done by 
J. Murray. 
 
 
 
 
 
 
Figure 3.7. Docking model of nilotinib in FMS kinase domain.   The protein 
backbone trace is shown in the region of the active site with residues Glu633, Thr663- 
Cys666 (Hinge region), and Asp796-Gly798 (DFG loop) depicted in stick 
representation.   The co-ordinates from the crystal structure of FMS (RSCB code 
2i1m) were used (25).   Nilotinib is shown in stick representation with carbon atoms 
coloured orange. Dashed lines indicate hydrogen bond interactions. Numbering is 
based on Genebank NM_005211. Courtesy of J. Murray. 
 100 
3.3. Discussion  
Both imatinib and nilotinib inhibited the phosphorylation and kinase activity of the 
normal FMS receptor and its activation of the downstream signalling molecules Akt 
and p42/44 MAPK.  In confirmation that imatinib and nilotinib are specific inhibitors 
of FMS activity, I found that neither inhibit IL-3 dependent growth of the FDC-P1 
cell line (figure 3.1, data not shown) and that a mutation of Asp 802 to Val of FMS 
confers resistance (figure 3.1A).  This is in accord with reports that the equivalent 
mutation of the KIT receptor,  KITD816V is not sensitive to either imatinib or 
nilotinib (Frost et al., 2002; Verstovsek et al., 2006).   The IC50 values for the 
inhibition of M-CSF dependent growth of FDc-fms by nilotinib and imatinib are 0.3 
and 0.6 µM respectively (figure 3.1;(Taylor et al., 2006)).  This agrees with previous 
reports that the >20 fold increase in inhibition of Bcr-Abl by nilotinib compared to 
imatinib is not accompanied by a similar increase in the inhibition of the PDGF or 
KIT receptors (Weisberg et al., 2005).  
 
Imatinib and nilotinib inhibited Rat-2 fibroblast transformation induced by V-Fms 
(figure 3.2A-D) but not FMS D802VY708F (figure 3.2E-F) or by V-Src induced 
transformation (figure 3.2K-L), showing specific inhibition of the FMS signalling 
pathway in fibroblasts.  Nilotinib inhibited FMS phosphorylation with an IC50 value 
of 0.2 µM (figure 3.2C) and inhibited the kinase activity of the wild type receptor 
with an IC50 value of around 0.5 µM (figure 3.3C) which is similar to the value of 0.3 
µM for imatinib (data not shown) (Taylor et al., 2006; Dewar et al., 2005a).   
 
     Osteoclastogenesis of primary human progenitor cells was more sensitive to 
nilotinib (IC50 approx 50 nM) than to imatinib (IC50 greater than 500 nM) (Table 
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3.1), which is in contrast to the similar effects of imatinib and nilotinib upon the other 
assays reported here.  The relatively low IC50 value for the inhibition of 
osteoclastogenesis by nilotinib suggests a target other than FMS.  The Ephrin receptor 
is reported to be particularly sensitive to nilotinib whereas this receptor is resistant to 
imatinib (Melnick et al., 2006).  This could provide a possible explanation for this 
data as the Ephrin receptor is an important receptor for osteoclast formation and 
function (Zhao et al., 2006).  Nilotinib and imatinib showed a similar profile for the 
inhibition of the growth of macrophage colonies from murine bone marrow (figure 
3.5G).  This is in accord with previous reports of the inhibitory effects of imatinib and 
other FMS inhibitors upon macrophage production and function (Dewar et al., 2005b; 
Dewar et al., 2003; Conway et al., 2005; Irvine et al., 2006).     
 
Recently there has been much interest in inhibitors of the FMS receptor which can 
inhibit osteoclastogenesis in vivo (Murray et al., 2003; Ando et al., 2006; Dewar et al., 
2006; El Hajj Dib et al., 2006; Ohno et al., 2006).  I find that nilotinib is more 
effective at inhibiting osteoclastogenesis than imatinib.  There are reports of altered 
bone and mineral metabolism in patients who have been treated with imatinib for 
extended periods at high doses (Berman et al., 2006; Joensuu and Reichardt, 2006; 
Fitter et al., 2007), which implies that this may be a more serious issue if patients 
were to be treated with nilotinib for extended periods. It is necessary to consider that 
nilotinib is a much more effective inhibitor of BCR-ABL than imatinib, and that the 
concentration of nilotinib necessary to inhibit BCR-ABL in vivo may be much lower 
than that necessary to inhibit osteoclastogenesis in vivo.  The plasma levels achieved 
in patients treated for CML with imatinib and nilotinib are 1.5 - 4.5 µM (Kantarjian et 
al., 2006a) and 1.7 - 3.6 µM (Peng et al., 2004a; Peng et al., 2004b) respectively.  
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These concentrations would be expected to inhibit the FMS receptor based on our 
findings, although there is likely to be much more signalling redundancy in vivo so 
this may not necessarily be significant. 
 
There is interest in the literature in finding FMS inhibitors to treat diseases where 
macrophages, osteoclasts and microglia are implicated.  These cell types are involved 
in a variety of diseases including macrophage mediated diseases such as metastasis 
(Pollard, 2004; Irvine et al., 2006) and renal disease (Zoja et al., 2006; Le Meur et al., 
2002), neurological diseases where microglia are implicated (Aldskogius, 2001; Perry, 
2004) and both metastatic and inflammatory bone diseases where osteoclasts are 
involved (El Hajj Dib et al., 2006; Mundy, 2002; Murray et al., 2003).  The extensive 
range of diseases in which the FMS receptor is implicated support the requirement for 
many new FMS inhibitors.  Imatinib and nilotinib therefore form a strong platform for 
development of further FMS inhibitors, and their optimisation for specific therapeutic 
applications. 
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CHAPTER 4. Dasatinib inhibition of the FMS receptor and tumour associated 
macrophages and osteoclasts. 
 
4.1. Introduction 
4.1.1. Dasatinib 
Since the success of targeting ABL in BCR-ABL  positive leukaemias, there has been 
much interest in developing new inhibitors which target a broader range of imatinib 
resistant mutations of BCR-ABL (see section 1.4 for more detail).  Dasatinib (BMS-
354825, Sprycel) is a second generation BCR-ABL kinase inhibitor which also has 
activity against various other kinases, including most of the SRC family kinases, KIT, 
Ephrin receptor (EPH) and PDGFR (Lombardo et al., 2004; Shah et al., 2004; Fabian 
et al., 2005; Schittenhelm et al., 2006).  Dasatinib has a broader spectrum of activity 
against ABL mutations compared to imatinib and is able to inhibit  to all of the 
common imatinib resistant Abl mutants with the exception of the T315I mutation, 
which also confers resistance to imatinib and nilotinib (Shah et al., 2004). 
 
Dasatinib inhibits  the KIT D816V receptor, which is resistant to both imatinib and 
nilotinib and so gives exciting treatment possibilities for systemic mastocytosis where 
KIT D816V is an important oncogenic mutation (Shah et al., 2006; Pardanani et al., 
2003).   Dasatinib is active against  a larger range of kinase mutants partly due to its 
ability to bind to both the active and inactive forms of the kinase domain, so unlike 
imatinib, dasatinib binding is unaffected by mutations which force the kinase into its 
active position (Mol et al., 2004b; Tokarski et al., 2006).  As a result dasatinib has 
less molecular restrictions for binding and so targets many more kinases than imatinib 
(Karaman et al., 2008).  Regardless of dasatinib’s apparent promiscuity, clinical trials 
have shown that it is tolerated reasonably well by patients and dasatinib has now been 
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approved for use in patients with CML or acute lymphoblastic leukaemia (ALL) who 
have developed imatinib resistance or intolerance (Kantarjian et al., 2006b).  
Dasatinib is therefore an interesting drug with other potential clinical applications.  
 
4.1.2. The tumour microenvironment 
It has recently become clear that tumours are not independent of their surroundings 
and that their immediate microenvironment has wide ranging effects on both tumour 
phenotype and disease prognosis (Albini and Sporn, 2007; Kuppers, 2004).  A major 
contributor to the tumour micro-environment is the tumour associated macrophage 
(TAM) (Condeelis and Pollard, 2006; Allavena et al., 2007). Macrophage infiltration 
of solid tumours and tumour microenvironment often correlates with poor prognosis 
and an aggressive disease (Takanami et al., 1999; Condeelis and Pollard, 2006; Yao et 
al., 2001; Tsutsui et al., 2005).  As a result, TAMs are a valid therapeutic target 
intended to complement traditional regimes in treating solid tumours (Joyce, 2005).   
 
A number of different approaches have already been investigated to specifically target 
TAMs.  These include a natural inhibitor, Yondelis (Trabectidine) which is derived 
from the marine tunicate E. turbinate and interferes with transcription and inhibits 
macrophage differentiation in vitro (Allavena et al., 2005), a DNA-based vaccine 
against leguimain, which is over-expressed on the surface of macrophages (Luo et al., 
2006) and zoledronic acid, which inhibits MMP-9 production by macrophages 
(Giraudo et al., 2004). 
 
Tumours are also known in turn to influence their microenvironment.  Osteolytic bone 
lesions are often associated with tumour metastasis to the bone marrow, causing 
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excessive osteoclastogenesis and bone absorption (Mancino et al., 2001; Roato et al., 
2005; Johnson et al., 1989).   Notably, in multiple myeloma, where bone metastasis is 
particularly common, osteolytic lesions only occur in areas directly associated with 
myeloma cells (Roodman, 2001) and in metastatic breast cancer, the main mediator of 
bone metastasis is thought to be a parathyroid hormone-related protein which is 
secreted from tumour cells and stimulates osteoblasts to release increased levels of 
RANKL, thereby stimulating local osteoclastogenesis (Mundy, 2002; Powell et al., 
1991).  Currently, the main therapy for bone metastasis is the use of bisphosphonates 
which reduce osteoclast activity by causing apoptosis and in some cases cause 
dangerous side effects such as renal toxicity (Diel et al., 2007).  There are also various 
new compounds progressing through clinical trials for osteolytic bone metastasis, 
mainly targeting the RANK pathway (Mundy, 2002). 
 
Since the FMS receptor activity is essential for macrophage and osteoclast 
differentiation and survival (Wiktor-Jedrzejczak et al., 1990), I hypothesized that 
FMS may be a valuable therapeutic target for diseases where these cell types are 
involved.  Here I show that dasatinib targets the FMS receptor at low nanomolar 
concentrations (IC50 = 0.5 nM) in various cell based assays.  I have also investigated 
the potential of dasatinib to inhibit the differentiation and survival of tumour 
associated macrophages and osteoclasts using ovarian cancer ascites as a source of 
haematopoetic cells from the tumour microenvironment and have shown dasatinib to 
be a potent inhibitor of both of these cell types in vitro.   
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4.2. Results  
4.2.1. Dasatinib inhibits the FMS receptor in Rat-2 fibroblasts and FDC-P1 
haematopoetic cell lines. 
The murine haematopoetic cell lines FDC-P1, FD c-fms and FD FMSD802V were 
used initially to establish that FMS is sensitive to dasatinib (assays also described in 
chapter 3). Fig 4.1A shows that dasatinib inhibited M-CSF stimulated growth of FD 
c-fms cells with an IC50 value of 0.5 nM, as calculated from figure 4.1A, circles.  The 
D802V mutation of FMS confers resistance to imatinib (see figure 3.1) (Taylor et al., 
2006) but not to dasatinib (Fig 4.1A; triangles) and has a similar IC50 to the wild type 
receptor.  This is in accordance with previous reports that KITD816V is sensitive to 
dasatinib (Schittenhelm et al., 2006; Shah et al., 2006).  As expected, IL-3 stimulated 
growth of FD c-fms cells was unaffected by dasatinib (Fig 4.1A; diamonds). 
      
Figure 4.1B shows that Rat-2 fibroblasts that express the oncogene V-Fms have a 
transformed morphology (Rettenmier et al., 1987a),  and this was suppressed by 1 nM 
dasatinib (Fig 4.1C).  Consequently, dasatinib has a potent inhibitory effect upon 
FMS signalling in fibroblasts as well as haematopoietic cell lines.     
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Figure 4.1.  Dasatinib inhibits growth of the FDcfms haematopoetic cell line by 
M-CSF and inhibits v-fms induced fibroblast transformation. (A) All cells were 
seeded at 5 x 104 cells/ml in RPMI and 10% FCS and cells expressing c-fms were 
grown with 10 ng/ml IL-3 (diamonds) or 5000 U/ml M-CSF (circles) and cells 
expressing oncogenic FMSD802V were grown without IL-3 or M-CSF (triangles) 
with the indicated concentrations of  Dasatinib.    Viable cell numbers were counted 
after 5 days. (B, C) Giemsa staining of Rat-2 V Fms fibroblasts (B) and Rat-2 V Fms 
treatment for 24 hours with 1 nM Dasatinib (C). Scale bar = 200 µm. 
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Figure 4.2 A, B show that 1 nM dasatinib inhibited the in vitro kinase activity of FMS 
and FMS D802VY708F receptors, but was ineffective against a T663I FMS receptor  
so establishing that dasatinib is a potent inhibitor of wild type and oncogenic FMS but 
not of FMS with a mutation in the Thr 663 ‘gatekeeper residue’ .  This is in 
accordance with reports that the equivalent mutations of ABL (T315I) and KIT 
(T670I) also confer resistance to dasatinib (Guo et al., 2007; Bradeen et al., 2006).  
Figure 4.2B shows densitometry readings of the in vitro kinase assays. 
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Figure 4.2.  Dasatinib inhibits FMS kinase activity in vitro. (A) In vitro kinase 
assays of immunoprecipitated FMS (A, upper panel), FMSD802VY708F (A, middle 
pannel) or FMS T663I (A, lower panel).  FMS was immunoprecipitated from Rat-2 
fibroblasts expressing wild type FMS, FMS D802VY708F or FMS T633I using a 
rabbit polyclonal antibody against the C-terminal tail (Ab792) and the purified 
receptor was pretreated with the indicated concentrations of dasatinib for 30 minutes.  
In vitro kinase activity was assessed by incubating samples with gamma P32 labelled 
ATP.  (B) Densitometry readings of the in vitro kinase assays (see A).   
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I have also confirmed these findings by analysing whether dasatinib can inhibit the 
phosphorylation of the FMS receptor and the phosphorylation of downstream 
signalling molecules p42/p44 MAPK and Akt in response to M-CSF stimulation (Fig 
4.3A-E).   Figure 4.3A shows that stimulation of Rat-2 cfms fibroblasts with M-CSF 
caused phosphorylation of the mature form of the receptor.  High molecular weight 
smearing is due to ubiquitination (Taylor et al., 2006).  Phosphorylation of FMS was 
inhibited entirely at 0.5 nM dasatinib, whereas the mutant receptor FMS T663I was 
resistant  (Fig 4.3B).   Dasatinib inhibited both M-CSF induced p42/44 MAPK (Fig 
4.3C) and Akt (Fig 4.3D) phosphorylation with a large effect at concentrations as low 
as 0.1 nM.  Figure 4.3E confirms that FMST633I is resistant to dasatinib, which does 
not inhibit M-CSF induced Akt phosphorylation by this receptor.  The appropriate 
non-phosphorylated protein loading controls are shown in the lower panel of figures 
4.3A-E. 
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Figure 4.3.  Dasatinib inhibits FMS signalling.  Rat-2 fibroblasts that express  FMS 
(A, C, D) or FMS T663I (B, E) were pre-treated with the indicated concentrations of 
dasatinib for 3 hours before 5000 U/ml M-CSF was added for 5 mins. Total lysates 
were analysed by western blotting with an antibody specific for either FMS 
phosphotyrosine 708 (A, B, upper panel), Phospho-p42/44 MAPK (C, upper panel), 
Phospho-Akt (D, E, upper panel). The same western blot samples were also  blotted 
with an antibody specific to the FMS receptor (A. B, lower panel), total p42/44 
MAPK (C, Lower panel) or total Akt (D,E lower panel) to show even loading.  
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4.2.2. Model of dasatinib binding to the FMS kinase domain. 
Figure 4.4 models the binding of dasatinib to the ATP-binding pocket of the FMS 
kinase domain (Walter et al., 2007).   In this model the hydrogen-bonding between 
dasatinib and the hinge region of FMS is similar to the known hydrogen bonding 
between dasatinib and the kinase domain of Abl and includes a hydrogen bond with 
the key gatekeeper residue, Thr 663 (Fig 4.4B).  The activation loop of FMS is 
modelled in its active position in order to illustrate that dasatinib would be expected to 
bind to the active as well as the inactive FMS kinase structures. Modelling courtesy of 
C. Mol.     
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Figure 4.4  Model of dasatinib binding in the ATP pocket of FMS (A).  Kinase 
domain of FMS with the C-helix (orange), activation loop (green) and dasatinib as a 
stick model (B)  Detail of the hydrogen-bonding between dasatinib and the hinge 
region of the kinase domain of FMS indicated by the dotted lines.  Modelling 
courtesy of C. Mol.  
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4.2.3. Dasatinib inhibits the production of normal human macrophages and 
ovarian tumour associated macrophages. 
I next assessed the effect of dasatinib upon the production of primary macrophages 
from ovarian tumour ascites samples.  Figure 4.5A and B are courtesy of C.Hayford 
and S. Ghaem-Maghami and shows a representative FACS scatter of an ascites 
sample, which typically contains a population of lymphocytes and a larger population 
of large granular cells (circled).  This population was gated to include only the 
granular population (4.5A; circle).  On average, about 80% of  these granular cells 
were CD14 positive ( Fig 4-5B) (Milliken et al., 2002) and therefore represent a 
population of cells of the monocytic lineage (n=10) (Ziegler-Heitbrock and Ulevitch, 
1993). 
 
 Mature TAMs could be produced from this material, shown in figure 4.5C by CD68 
staining (red) and as described previously (Hagemann et al., 2006; Allavena et al., 
2005).  This process was almost completely inhibited by 1 nM dasatinib (4.5D).  A 
comparison of the three panels of Fig 4C (CD68, DAPI and merged) shows that all of 
the cells present in this assay are macrophages and so a pure population was 
successfully obtained (4.5C,D; middle and right panel).  As expected, the secondary 
antibody only control failed to stain any cells (data not shown).   
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Figure 4.5. Dasatinib inhibits the production and survival of tumour-associated 
macrophages from ovarian cancer ascites. (A, B) An ascites sample from an 
ovarian cancer patient was stained for extracellular CD14 and analysed by FACS.  (A) 
FACS scatter plots of ovarian cancer ascites samples showing large granular cell 
population (black circle).  (B) Gated percentage of CD14+ monocyte cells from this 
population of large granular cells. Red = unstained cells, blue = CD14 stained cells. 
Similar results were obtained for all samples (n = 10).  (C)  Macrophages produced in 
response to M-CSF stimulation of an ovarian tumour ascites samples.  Cells were 
cultured in alpha MEM with 10% FCS and 5000 U/ml M-CSF with the indicated 
concentrations of Dasatinib for 1 week. Macrophage counts were based on CD68 
staining. Similar results were obtained for all tested samples (n=5). (C,D) 
Representative photographs of TAMs derived from ovarian cancer ascites.  TAMs 
untreated (C) or  treated with 5 nM dasatinib for 24 hours (D)  CD68 staining (red) 
DAPI (blue), scale bar = 100 µm.  (A,B) Courtesy of C. Hayford and S. Ghaem-
Maghami. 
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TAM production was highly dependent on M-CSF addition to the growth media and 
very few macrophages were produced in its absence (4.6A, B).   Figure 4.6A shows 
that dasatinib potently inhibited the production of tumour-associated macrophages 
from ovarian cancer ascites samples (n = 7) with an IC50 value of less than 1 nM 
(figure 4.6A).  As expected, TAM production was also sensitive to imatinib (figure 
4.6B) with an IC50 value of less than 1 µM (figure 4.6B) which is similar to the 
concentrations required for imatinib inhibition of FMS (see figure 3.1). 
 
I also assayed the ability of dasatinib to induce TAM death and found that treatment 
with 5 nM dasatinib killed the vast majority of mature TAMs within 24 hours with an 
IC50 value of around 1 nM (figure 4.6C).  As expected, dasatinib also inhibited the 
production of colonies of macrophages from normal peripheral blood with complete 
inhibition at less than 10 nM (data not shown).    
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Figure 4.6. Dasatinib and imatinib inhibit the production and survival of 
tumour-associated macrophages from ovarian cancer ascites.  (A,B)  
Macrophages produced in response to M-CSF stimulation of ovarian tumour ascites 
samples.  Cells were cultured in alpha MEM with 10% FCS and 5000 U/ml M-CSF 
with the indicated concentrations of Dasatinib (A) or imatinib (B) for 1 week. 
Macrophage counts were based on CD68 staining. Similar results were obtained for 
all tested samples (n=5).  (C) TAM death assay.  Mature macrophages derived from 
an ovarian cancer ascites sample were cultured with dasatinib for 24 hours in the 
presence of M-CSF and live cells were counted based on CD68 staining.  Similar 
results were obtained for all tested samples (n=3).    
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I next investigated the effect of dasatinib on both normal osteoclastogenesis and 
osteoclastogenesis from ovarian cancer ascites.  Normal osteoclastogenesis was 
modelled using peripheral blood from patients who have given blood for the purpose 
of bone marrow transplantation.  These patients have been given G-CSF and therefore 
their peripheral blood is enriched with haematopoietic cells from the bone marrow 
(Gordon et al., 2006).   
 
Table 4.1 and figures 4.7 D, E show that 1 nM dasatinib treatment largely inhibited 
the production of osteoclasts from both normal peripheral blood and from ovarian 
tumour ascites samples and that it was completely inhibited at 10 nM.  Normal 
osteoclastogenesis was assayed in the presence of M-CSF and RANKL and was 
inhibited by dasatinib with an IC50 value of around 0.5 nM.   No osteoclasts were 
formed in the absence of these growth factors as they are both essential for 
osteoclastogenesis (data not shown) (Kodama et al., 1991a; Kodama et al., 1991b; 
Kong et al., 1999; Lacey et al., 1998). 
 
 
 
 
 
 
 
 
 
 
7.9   ± 2.2 2.6    ±  1.6 1.0 
0 0 10 
50.9 ± 7.5 13.9  ±  0.2 0.1 
41.6 ± 3.9 10.2  ±  1.7 0.5 
24.0 ± 1.3 28.5  ± 3.0 0 
Tumour-associated 
osteoclasts (per mm2) 
 
- M-CSF - RANKL 
Osteoclasts from 
normal peripheral blood 
(per mm2) 
+M-CSF + RANKL 
Dasatinib (nM) 
Table 4.1. Osteoclastogenesis from normal mobilised peripheral blood and from 
ovarian cancer ascites samples treated with various concentrations of dasatinib. 
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 Tumour associated osteoclastogenesis showed a similar sensitivity to dasatinib (Table 
4.1) but  more surprisingly appeared in the in the absence of both recombinant M-CSF 
and RANKL.     This is in accordance with a previous report of ‘spontaneous’ 
osteoclastogenesis from peripheral blood of patients with various solid tumours. 
(Roato et al., 2005).  Figure 4.7A shows a typical photograph of ovarian tumour 
associated osteoclasts with a distinctive actin ring (4.7A; red), large vacuoles shown 
by tubulin staining (4.7A; green) and DAPI stained multiple nuclei (4.7A; blue) 
(Yoshida et al., 1989).  Figure 4.7B shows a typical photograph of normal osteoclasts 
which have been stained for tartrate-resistant acid phosphatase (TRAP).  TRAP is 
used as a marker enzyme for osteoclast differentiation and has a function in 
cartilage/bone resorption (Minkin, 1982). Figure 4.7C shows that production of these 
osteoclasts was mostly inhibited at 1 nM dasatinib.   
 
For reasons that are not yet clear, I found that very low concentrations of dasatinib 
(0.1 and 0.5 nM) enhanced the production of tumour-associated osteoclasts.  This is 
illustrated in both figure 4.7E and table 4.1.   Table 4.2 shows that osteoclast 
production from ovarian cancer ascites was much less sensitive to imatinib than 
normal osteoclastogenesis.   This indicates that tumour associated osteoclasts are 
physiologically different to normal osteoclasts and that they are not dependent on 
FMS activity. 
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Figure 4.7. Osteoclast production from both normal mobilised peripheral blood 
and ovarian cancer ascites is inhibited by dasatinib.  (A) Representative 
photograph of ovarian cancer derived ascites osteoclasts which have been grown in 
alpha 10 for 3 weeks.  (B,C) Representative photographs of normal mobilised 
peripheral blood derived osteoclasts which were grown in alpha 10 + 5000 U/ml M-
CSF + 60ng/ml RANKL for 3 weeks with (B) or without (A) 1 µM dasatinib.  (D, E)  
Quantification of osteoclastogenesis assays expressed as percentage for either normal 
mobilised peripheral blood (D) or ovarian ascites (|E)  As indicated cultures were 
grown in the presence or absence of M-CSF (5000 U/ml) or RANKL (60 ng/ml).  Cell 
numbers are based on osteoclasts being TRAP positive and having 3 or more nuclei.  
Similar results were achieved for each sample (n=5). 
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Spontaneous osteoclastogenesis was also observed in a sample of pleural effusion 
fluid from a breast cancer patient (figure 4.8).  This could also be inhibited by 
dasatinib (figure 4.8A) at similar concentrations to ovarian tumour samples.  This 
sample was also sensitive to imatinib (figure 4.8B), unlike osteoclasts derived from 
ovarian tumour ascites (table 4.2).  This observation could not be repeated as we have 
not yet received further pleural effusion samples. 
 
 
 
 
 
 
 
 
 
 
% tumour associated 
osteoclast production  
 
-M-CSF -RANKL 
 
% Normal 
osteoclastogenesis 
 
+ M-CSF + RANKL 
Imatinib (μM) 
118.1 ±  5.1 
 
51.4   ± 14.5 
3.0   ± 1.5 
 
0 
1 
 
2 
 
101.3 ±  16.7 89.3 ± 7.0 0.5 
100    ±  11.5 100  ± 16.0 0 
Table 4.1. Osteoclastogenesis from normal mobilised peripheral blood and from 
ovarian cancer ascites samples treated with various concentrations of imatinib. 
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Figure 4.8. Imatinib and dasatinib inhibit osteoclast production from a breast 
cancer pleural effusion.   Pleural effusion fluid was allowed to adhere to tissue 
culture plastic overnight then cultured with or without 60 ng/ml RANKL + 5000 U/ml 
M-CSF with various concentrations of dasatinib (A) or imatinib (B) for 2 weeks.  
Cells were then fixed and stained for TRAP and TRAP positive cells with 3 or more 
nuclei were counted.  Each experiment was done in triplicate (n=1). 
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I also started a preliminary investigation into whether dasatinib inhibits 
osteoclastogenesis in vivo in patients who are being treated with dasatinib for CML.  
The patients in this study were being treated with dasatinib after developing resistance 
to imatinib treatment previously.  We were provided with 2 bone trephines taken 
before dasatinib treatment and 2 taken after dasatinib treatment for each of 6 patients.   
Figures 4.9A, B show typical trephine sections from before (4.9A) and after (4.9B) 
dasatinib treatment.  Ten random bone measurements from each section were taken 
and figure 4.9C shows average bone thickness before (4.9C; black) and after (4.9C; 
stripy) dasatinib treatment.   We found no significant effect of dasatinib on bone 
thickness in this study although a more extensive study would be useful as we did not 
have access to any patient samples which were either normal and untreated or 
untreated CML patients. 
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Figure 4.9.   Dasatinib has no effect on bone trephine thickness of CML patients 
treated with dasatinib for at least 1 year in patients who were previously treated 
with imatinib.  (A,B) Representative photographs of bone trephines from a patient 
before (A) or after (B) dasatinib treatment with 10 random measurements shown.  (C) 
Mean trephine thickness was calculated by blindly measuring bone sections at 10 
random points on each trephine and the mean width is shown either before or after 
dasatinib treatment for at least 1 year.  Two trephines were measured both before and 
after dasatinib treatment.  Scale bar = 2mm 
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There is no current literature stating patient serum levels of dasatinib which are 
achieved in vivo.  I therefore designed a system which allows these levels to be 
estimated.  I assayed this by adding serum from patients who are currently being 
treated with either dasatinib or imatinib to the K562 cell line which is dependent on 
BCR/ABL activity for survival.  I first standardised this experiment by adding 
dasatinib and imatinib at known concentrations to test the sensitivity of K562 cells to 
these drugs. Figure 4.10 shows that imatinib (figure 4.10A) and dasatinib (figure 
4.10B) inhibited the K562 cell line with IC50 values of 100nM and 0.04 nM 
respectively.  Figure 4.11 shows K562 cells were slightly more sensitive to dasatinib 
serum than to imatinib serum.  The average IC50 values for K562 cell growth 
inhibition by patient serum calculated from figure 4.11 was 0.54 ± 0.17% serum for 
dasatinib and 1.62 ± 0.13 % serum for imatinib treated patients.  A total of 6 patients 
who are being treated with dasatinib were assayed with doses ranging from 50 mg – 
70mg twice daily and 7 patients who were being treated with imatinib were assayed 
with doses ranging from 400 mg to 600 mg once daily. 
 
These results can be used to infer the patient serum levels of these drugs by 
comparing the IC50 values obtained from figure 4.10 for both dasatinib and imatinib 
inhibition of K562 cells (0.04 nM and 100 nM respectively) to the IC50 value 
obtained in figure 4.11 for the amount of patient serum which is required to inhibit the 
same cell line (0.54 % and 1.62 % respectively).  From these figures the patient serum 
levels can be estimated to be around 6.2 µM for imatinib and 7.4 nM for dasatinib. 
The serum level estimated here for imatinib is compatible with those found previously 
in patients treated with imatinib which was recorded as 1.5 - 4.5 µM (Druker et al., 
2001). 
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Figure 4.10. Imatinib and dasatinib inhibit BCR-ABL stimulated growth in the 
K562 cell line. K562 cells were seeded at 5 x 104 cells/ml in RPMI and FCS with the 
indicated concentrations of either imatinib (A) or dasatinib (B).  Viable cell numbers 
were counted after 5 days of culture and mean cell number per ml is shown.  Each 
experiment was done in triplicate and the error bars represent the SEM. 
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Figure 4.11. Comparison of inhibition of K562 cells by CML patient serum after standard doses of either 
imatinib or dasatinib.  Peripheral blood serum was obtained with informed consent from patients who were being 
treated for CML with either imatinib (blue lines) or dasatinib (black lines).  Untreated controls are shown in red.  
K562 cells were seeded at 5 x 104 cells/ml in RPMI and FCS with the indicated concentrations of patient serum and 
counted after 5 days of culture (n=14).  Each experiment was done in triplicate and SEM is shown for each sample 
(error bars). 
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4.3. Discussion   
We found dasatinib to be a potent inhibitor of FMS receptor phosphorylation, 
signalling and FMS induced fibroblast transformation (figures 4.1-4.3).  In support of 
this, the FMS mutation T663I confers resistance to dasatinib (figure 4.2 and 4.3 B,E).  
The equivalent mutation to this of ABL, T315I, is commonly found in CML patients 
who have developed resistance to dasatinib (Bradeen et al., 2006).  We have also 
modelled dasatinib binding to the ATP pocket of FMS and this model is consistent 
with the requirement of Thr 663 to stabilise dasatinib binding through hydrogen 
bonding (figure 4.4, courtesy of C. Mol.). 
 
Tumour associated macrophages were generated readily from ovarian cancer ascites 
samples, making them an ideal source of TAMs for this study.  Ovarian cancer ascites 
is in intimate contact with the tumour and contains various immune cells as well as 
tumour cells.  Tumour associated macrophages isolated from this material have 
previously been shown to display characteristics of M2 activated macrophages and 
are therefore an ideal model of TAMs from solid tumours (Milliken et al., 2002; Sica 
et al., 2000; Hagemann et al., 2006).   Both dasatinib and imatinib inhibited the 
production of TAMs in our assays at concentrations consistent with inhibition of FMS 
(IC50 < 0.5 nM for dasatinib and < 0.5 µM for imatinib) (figure 4.6).  Dasatinib 
treatment also inducted death of mature macrophages, confirming the potency of 
dasatinib against macrophages in vitro. 
 
Osteoclasts could also be easily generated from this material, and in fact arose 
‘spontaneously’ when no growth factors were added to the media (figure 4.7 and table 
4.1).  This is in agreement with a another report of spontaneous osteoclastogenesis 
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from peripheral blood of patients with various solid tumours (Roato et al., 2005).  In 
this study, the author suggests that the spontaneous osteoclastogenesis observed may 
be due to TNF-alpha stimulation and in accordance with this TNF-alpha and RANKL 
are known to synergise strongly to stimulate osteoclastogenesis (Fuller et al., 2002; 
Lam et al., 2000).  
 
M-CSF stimulation was an important factor for normal osteoclastogenesis, and 
accordingly, no osteoclasts formed in its absence or in the presence of FMS inhibitors 
such as imatinib and nilotinib (see table 3.1) as expected (Hodge et al., 2007; Amano 
et al., 1998; Fuller et al., 1993).   Furthermore, both imatinib and nilotinib stimulate 
apoptosis of normal mature osteoclasts (see figure 3.6).  In contrast to this, FMS 
signalling was an apparently unimportant factor for ovarian tumour associated 
osteoclasts as they were resistant to imatinib (Table 4.2).  This indicates that the 
osteoclasts formed from ovarian cancer ascites and those formed from peripheral 
blood mononuclear cells are phenotypically distinct.  The tumour associated 
osteoclasts were however sensitive to dasatinib and this inhibitory affect was 
therefore likely to be though inhibition of an unknown kinase (figure 4.7E).  Src and 
ephrin receptors are  possible candidates as both of these kinases are sensitive to 
dasatinib and are important in osteoclastogenesis (Zhao et al., 2006; Soriano et al., 
1991; Karaman et al., 2008).  Spontaneous osteoclastogenesis seen in the breast 
cancer samples was inhibited by both imatinib and dasatinib at concentrations 
consistent with FMS inhibition (figure 4.8).  This study is unfortunately incomplete 
due to the rarity of these samples.  
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Osteoclasts have well established roles in bone metastasis and therefore the finding 
that dasatinib inhibits osteoclast production in vivo may have great therapeutic value 
in the complementary treatment of cancers that often metastasise to the bone such as 
breast cancer and multiple myeloma (Roato et al., 2005; Mundy, 2002; Akhtari et al., 
2007). There is already some evidence that FMS inhibitors may target osteoclasts in 
vivo.  One report shows altered bone and mineral metabolism in patients treated with 
high doses of imatinib (Berman et al., 2006) and more recently,  bone thickening was 
also shown in patient bone trephine samples (Fitter et al., 2007).   
 
Macrophage inhibitors could have a significant impact on solid tumour treatment due 
to the strong association of tumour associated macrophages and tumour metastasis, 
angiogenesis and aggression (Hagemann et al., 2006; Pollard, 2004; Condeelis and 
Pollard, 2006).  Dasatinib may also be useful in treating many inflammatory diseases 
where macrophages and osteoclasts are inappropriately activated such as renal 
inflammatory disease and osteoarthritis (Le Meur et al., 2002; Teitelbaum, 2006; 
Kitaura et al., 2005; Gravallese, 2002; Hirayama et al., 2002). The potential 
therapeutic application of macrophage and osteoclast inhibitors is therefore wide 
ranging and dasatinib forms a good model for development of this type of inhibitor. 
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CHAPTER 5. Kinase inhibitors as research tools. 
 
5.1 Introduction 
In this chapter I establish that the Flt-3 inhibitor, Tandutinib (MLN518; CT53518) 
also targets the FMS receptor and discuss the therapeutic applications of this finding.  
I also explore the use of kinase inhibitors of FMS, such as tandutinib, as research 
tools to study the mechanisms of FMS receptor phosphorylation and downregulation 
and give evidence that two tyrosine residues which were previously identified as 
autophosphorylation sites can be phosphorylated by another kinase.  I confirm that 
receptor kinase activity is not required for downregulation of the FMSE633H receptor 
and that it is most probably a change in structure that promotes accelerated 
degradation of the FMS receptor (Uden et al., 1999).   
 
5.2 Results 
5.2.1 Tandutinib is an effective inhibitor of FMS signalling, osteoclastogenesis 
and macrophage formation 
 
Tandutinib is a promising quinazoline-based tyrosine kinase inhibitor that is currently 
in phase II clinical trails for treatment of acute myeloid leukaemia where it targets the 
Flt-3 receptor (DeAngelo et al., 2006).  Flt-3 is constitutively activated by internal 
tandem duplications in up to 30% of AML patients and a further 5-10% of patients 
have oncogenic mutations of Asp835 of the kinase domain (Reilly, 2002).   Flt-3 is 
closely related to the KIT, PDGF and FMS receptors and both KIT and PDGF 
receptors are targets of tandutinib with IC50 values of 170 and 200 nM respectively 
for in vitro kinase assays (Kelly et al., 2002).   
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In this section I report that tandutinib is an effective inhibitor of the FMS receptor and 
of both macrophages and osteoclasts in vitro.  The inhibitory effect of tandutinib was 
assessed in the FD-cfms or FD FMSD802V cell lines which are dependent on 
signalling from either FMS, FMS D802V or IL-3 for proliferation and survival 
(similar assays were used in chapters 3 and 4).  Figure 5.1 shows that tandutinib is an 
effective inhibitor of the FMS receptor (5.1A; circles) but not of FMSD802V (5.1A; 
triangles).  This is in accordance with a  previous report that the equivalent mutation 
of D835 of Flt-3 confers resistance to tandutinib (Clark et al., 2004). The IC50 for 
FMS inhibition of tandutinib was calculated as 0.4 µM from figure 5.1A.  Growth of 
this cell line in response to IL-3 stimulation was unaffected by tandutinib, confirming 
specificity of tandutinib to the FMS signalling pathway (5.1A; diamonds).   The 
sensitivity of FMS to tandutinib was also confirmed in a fibroblast transformation 
assay with Rat-2 fibroblasts which ectopically express v-fms (Baker et al., 1994) 
(5.1B,C) and the transformed morphology of these cells was inhibited at 1 µM 
tandutinib (5.1C) (assay described previously in Chapters 3 and 4).   
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Figure 5.1.  Tandutinib inhibits M-CSF induced proliferation and survival of 
FD-cfms cells and v-fms induced fibroblast transformation  (A) FDC-P1 
haematopoietic cells that express FMS were seeded at 5 x 104 cells in either 10 ng/ml 
IL-3 (diamonds) or 5000 U/ml M-CSF (circles) with the indicated concentrations of 
tandutinib.   Similarly, FDC-P1 cells that express the oncogenic receptor FMS D802V 
were cultured with tandutinib in the absence of both M-CSF and IL-3 (triangles). 
Viable cell numbers were counted 5 days later.  (B, C) Rat-2 V Fms fibroblasts 
stained with Giemsa following growth in the absence (1B) or presence of 1 µM 
tandutinib (1C).  
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 Figures 5.2A and B confirm that tandutinib is an inhibitor of FMS phosphorylation 
(5.2A) and that phosphorylation of FMS D802VY708F was resistant to tandutinib 
(5.2B).  The phosphorylation of the FMS receptor was fully inhibited at 0.25 µM 
tandutinib which is consistent with the IC50 value observed in figure 5.1A for 
inhibition of cell growth.  Figure 5.2C shows that tandutinib also inhibited the in vitro 
kinase activity of the FMS receptor and that the oncogenic FMS D802V mutation 
conferred resistance. Densitometry readings of these assays are shown in figure 5.2D.  
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Figure 5.2. Tandutinib inhibits FMS receptor phosphorylation and kinase 
activity and FMS D802VY708F confers resistance.  (A)  Tandutinib inhibits M-
CSF induced phosphorylation of tyrosine 708 (upper panel), Total FMS receptor is 
shown as a loading control (FMS Ab 792)(lower panel).  (B) The oncogenic receptor 
FMS D802VY708F confers resistance to tandutinib shown by phosphorylation at 
tyrosine 723 (upper panel).  Total loading of this receptor is shown (lower panel).  (C) 
FMS (upper panel) and FMS D802VY708F (lower panel) in vitro kinase assay 
showing the effect of tandutinib (D) Graph of (C). 
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Tandutinib inhibited human osteoclastogenesis from mononuclear cells (as described 
in chapter 3). Figure 5.3A shows a comparison of imatinib and tandutinib inhibition 
of osteoclast production in vitro and shows that tandutinib inhibited osteoclast 
production slightly more potently than imatinib with an IC50 value of approximately 
400 nM compared to an IC50 of approximately 800 nM for imatinib.   Figure 5.3B 
confirms the inhibition of osteoclasts by tandutinib and show that the resorption of 
dentine slices was completely inhibited by both imatinib and tandutinib at 1 µM.  
Figure 5.3C shows that tandutinib also inhibits macrophage colony formation from 
mouse bone marrow cells with an IC50 value of 0.5 µM which is similar to IC50 
values shown figures 5.1 and 5.2 for FMS receptor inhibition.  No macrophage 
colonies formed in the absence of M-CSF from this material, as expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 137 
300
350
0
50
100
150
200
250
400
0 200 400 600 800 1000
Inhibitor (nM)
TR
A
P 
Po
sit
iv
e 
Ce
lls
tandutinib
Imatinib
200000
0
400000
600000
800000
1000000
1200000
1400000
1600000
2GF 2GF+ 1 µm
tandutinib
2GF+ 1 µm
imatinib
Pi
t A
re
a 
(µ
m
²)
.
A
B
C
Co
lo
n
y 
n
u
m
be
r
0
2
4
6
8
10
12
14
16
18
M-CSF 0.5µM 1µM - M-CSF
tandutinib
Imatinib
Osteoclast Production
Osteoclast Pit Formation
Macrophage Colony Formation
 
 
Figure 5.3.  Tandutinib and imatinib inhibit osteoclastogensis, osteoclast pit 
formation and macrophage colony formation.  (A)  Normal mobilised peripheral 
blood was cultured for 3 weeks with 5000 U/ml M-CSF and 40 ng/ml RANKL with 
the indicated concentrations of imatinib or tandutinib. (B) Normal mobilised 
peripheral blood was cultured as described above on dentine slices and pit formation 
was measured after 3 weeks.  (C)  Murine bone marrow cultured in methylecellulose 
with 5000 U/ml M-CSF and imatinib or tandutinib for 2 weeks and macrophage 
colonies were counted. 
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5.2.2 Kinase inhibitors as research tools 
5.2.2.1 Anomalous effects of kinase inhibitors upon receptor phosphorylation 
 
I have also assayed the phosphorylation status of FMS tyrosines 723 and 708 when 
the receptor is exposed to various kinase inhibitors.  Figure 5.4A (upper panel) shows 
that nilotinib was a highly effective inhibitor of FMS phosphorylation at tyrosine 723 
with total inhibition at concentrations higher than 0.25 µM.  Contrary to this, 
phosphorylation of the FMS receptor at tyrosine 708 was highly resistant to nilotinib 
with an IC50 value of greater than 4 µM (figure 5.4A, lower panel).   Tandutinib had 
an opposite effect on FMS phosphorylation to nilotinib.  Phosphorylation of FMS 
tyrosine 723 is resistant to tandutinib up to at least 5 µM (figure 5.4B; upper panel), 
whereas phosphorylation of tyrosine 708 was inhibited at 0.5 µM tandutinib (figure 
5.4B; lower panel).  Receptor ubiquitination was inhibited at 0.5 µM tandutinib in 
both assays, shown by high molecular receptor smearing (figure 5.4A,B, upper 
panels).  
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Figure 5.4. Nilotinib and tandutinib have unexpected effects on FMS receptor 
phosphorylation sites.  Western blots of total lysate from Rat-2 cfms cells treated 
with either nilotinib (A) or tandutinib (B).   Rat-2 cfms fibroblasts were pre-treated 
with the appropriate inhibitor and stimulated with 5000 U/ml M-CSF for 5 mins 
before being analysed with an antibody to either phospho-FMS tyrosine 723 (A,B; 
upper panel) or phospho-FMS tyrosine 708 (A, B; middle panel).  Either ponseau 
stained membrane showing total protein loading (A; lower panel) or total FMS 
receptor (Ab792) (B-E) is shown as a loading control.   
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Dasatinib had a similar effect on receptor phosphorylation to tandutinib.  
Phosphorylation of FMS tyrosine 723 was more resistant to dasatinib than 
phosphorylation of tyrosine 708 and was not completely inhibited at concentrations as 
high as 10 nM (figure 5.5A; upper panel).  Conversely, phosphorylation of tyrosine 
708 was very sensitive to dasatinib treatment and was completely inhibited at 0.5 nM 
(figure 5.5A; middle panel).  Similarly, figure 5.5B (upper panel) shows that 
phosphorylation of FMSD802VY708F at tyrosine 723 is highly resistant to dasatinib 
and 60 nM dasatinib is required for complete inhibition of tyrosine 723 whereas in 
vitro kinase activity of FMS D802VY708F was very sensitive to dasatinib with an 
IC50 value of around 1 nM (see chapter 4, figure 4.2).   A mutation of the 
‘gatekeeper’ residue FMS threonine 663 to isoleucine confers resistance to dasatinib 
(see chapter 4; figures 4.3 and 4.3) and consistently, phosphorylation of tyrosines 723 
and 708 is also resistant to dasatinib (figure 5.5C).  These results have been repeated 
at least 3 times. 
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Figure 5.5. Dasatinib inhibits FMS receptor phosphorylation at tyrosine 708 but 
phosphorylation of tyrosine 723 is less sensitive.  Phosphorylation of the FMS 
mutant T663I is resistant to dasatinib.  (A) Rat-2cfms fibroblasts were pretreated 
with dasatinib for 2 hours and stimulated with M-CSF for 5 mins then total lysates 
were immunoblotted for either FMS phospho-tyrosine 723 (A; upper panel) or FMS 
phospho-tyrosine 708 (A; middle panel).  Total FMS receptor is shown as a loading 
control (FMS792 Ab) (A; lower panel).  (B) Rat-2  FMS D802VY708F fibroblasts 
were treated with dasatinib for 2 hours and immunoblotted for either FMS phospho-
tyrosine 723 (B; upper panel) or total FMS receptor as a loading control (FMS792 Ab) 
(B; lower panel).  (C) Rat-2  FMS T663I fibroblasts were pretreated with dasatinib for 
2 hours and stimulated with M-CSF for 5 mins.  Total lysates were immunoblotted for 
FMS phospho-tyrosine 708 (C; upper panel) or FMS Phospho-723 (C; lower panel).  
Total FMS receptor is shown as a loading control (FMS 792 Ab) (C; middle panel).  
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Figure 5.6A compares the effect of imatinib upon the growth of FDC-P1 cells 
expressing the wild type FMS receptor and two FMS receptor mutants; FMS Y569A, 
which is a mutation of the juxtamembrane region, and FMS Y569AY809F, which is a 
double mutation of the juxtamembrane region and the activation loop. This data is 
courtesy of J. Taylor.  The wild type receptor was sensitive to imatinib with an IC50 
value of slightly less than 1 µM as expected (Taylor et al., 2006). The juxtamembrane 
region mutation, FMS Y569A was more sensitive to imatinib than the wild type 
receptor with an almost total inhibition at 1 µM.  This is in accordance with a 
previous observation that imatinib binding to the KIT receptor is slightly obstructed 
by the juxtamembrane region (Mol et al., 2004a).  This mutation of the FMS 
juxtamembrane region may therefore shift this region slightly to enable stronger 
imatinib binding.  The double mutant, FMS Y569AY809F has a similar sensitivity to 
imatinib compared to the wild type receptor.  This may be explained by a slight 
hindrance to imatinib binding due to a shift in the conformation of FMS towards a 
more activated state due to the second mutation of the activation loop (Mol et al., 
2004a).   The oncogenic receptor FMS D802V confers resistance to imatinib in this 
assay, so confirming that the inhibition seen here is due to specific inhibition of the 
receptor function.   
 
In light of the inhibitory effect of imatinib on these receptor mutants, I have also 
examined the effect of imatinib on the phosphorylation of FMS Y723 in each of these 
mutant receptors.   The phosphorylation of wild type FMS Y723 is inhibited by 
imatinib, although total inhibition occurs at slightly higher concentrations than 
expected (Taylor et al., 2006) (figure 5.6B).  The two receptor mutations, FMS 
Y569A and FMS Y569AY809F are oncogenic mutations and therefore are 
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constitutively phosphorylated on both the immature and mature form of the receptor 
(figure 5.6C and D, first lane).  Surprisingly, only the phosphorylation of the 
immature band of FMS Y569A is inhibited by imatinib, and the phosphorylation of 
the mature band appears to be resistant to imatinib (figure 5.6C), and this resistance is 
in contrast to the cell proliferation data shown in figure 5.6A.  Furthermore, the 
double mutant receptor, FMS Y569AY809F appears to be fully resistant to imatinib, 
also in contrast to the cell proliferation data shown (compare figure 5.6A and 5.6D). 
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Figure 5.6. Imatinib inhibits FMS, FMS Y569A and FMS Y569AY809F  induced 
cell proliferation but their phosphorylation on tyrosine 723 is less sensitive. (A) 
FDC-P1 cells expressing the wildtype or mutant forms of  FMS were plated at 5x105 
cells/ml in medium free of IL-3 with 5x105 U/ml M-CSF and with 1 µM or 3 µM 
imatinib. The cells were counted after a week of growth and triplicate assays were 
averaged. (B-D) Rat-2  fibroblasts expressing either wild type FMS (B), FMS Y569A 
(C) or FMS Y569A Y809F were pre-treated with the indicated concentrations of 
imatinib for 2 hours and stimulated with 5000 U/ml M-CSF for 5 minutes if 
appropriate.  Cell lysates were immunoblotted for either FMS phospho-tyrosine 723 
(B-D; upper panel) or FMS (Ab 792)(B-D; lower panel). (A) Courtesy of J. Taylor. 
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5.2.2.2 Receptor downregulation 
Another interest in developing these inhibitors is that they provide new opportunities 
to study general mechanisms of FMS activation and downregulation.  Receptor 
downregulation is usually considered to be a product of receptor internalization and 
receptor degradation.  For most receptors, this process is rapidly enhanced by ligand 
binding, therefore ensuring that the ligand only stimulates a transient signal to the cell. 
The FMS receptor downregulates constitutively in the absence of ligand binding with 
a half life of approximately 1.5-3 hours depending on cell type (Rettenmier et al., 
1987b).  Upon ligand binding, the receptor internalises more rapidly and is either 
degraded or recycled (Manger et al., 1984).   
 
It has been reported that tyrosine kinase activity is required for this second, ligand 
dependent internalisation.  The main evidence for this is a kinase inactive mutant 
K616A.  This mutant receptor internalizes constitutively at the same rate as the wild 
type receptor stimulated by M-CSF and is not degraded (Carlberg et al., 1991).  K616 
is a lysine residue in the ß3 strand and is highly conserved amongst kinases and a 
mutation to alanine is widely reported to inhibit downregulation and is considered to 
be evidence that receptor tyrosine kinase activity is required for ligand induced 
downregulation.  This lysine mutation has been made in many other kinases including 
the EGF receptor (K721A) (Honegger et al., 1987), the PDGF receptor (K634A) 
(Sorkin et al., 1991), the HGF receptor (K589A) (Jeffers et al., 1997) and the insulin 
receptor (K1018A) (Russell et al., 1987).    
 
In contrast to this, Uden et al (1998) have described various FMS kinase inactive 
receptors which are not impaired for degradation upon M-CSF stimulation.  The 
 146 
mutant FMS receptor FMS E633H is kinase inactive and is not ubiquitinated in 
response to M-CSF (N.Dibb unpublished) but does downregulate in a similar manner 
to the wild type receptor (Uden et al., 1999).  This indicates that the accelerated 
downregulation which is stimulated by M-CSF is induced by structural changes and is 
independent of intrinsic kinase activity.   The FMS K616A mutant receptor has 
presumably suffered a structural change which has resulted in a receptor which is 
unable to undertake the changes in conformation necessary for both kinase activity 
and downregulation.  In support of this, there is a family of atypical receptor tyrosine 
kinases which are unable to autophosphorylate but are capable of activating 
downstream signalling molecules such as MAPK upon ligand binding.    These 
receptors include Mep (EphB6) (Gurniak and Berg, 1996),  Colon carcinoma kinase-4 
(Cck4) (Mossie et al., 1995) and H-Ryk (Katso et al., 1999).  Further, a mutation of 
the conserved lysine residue mentioned previously (K616 in FMS) to alanine (K334A 
in H-Ryk) inactivates these receptors, leaving them unable to signal, supporting the 
hypothesis that this mutation impairs structural changes in the receptor  (Katso et al., 
1999).   
 
I have investigated the effect of the kinase inhibitors identified here on the 
downregulation of the FMS receptor.  When FMS is stimulated with M-CSF it 
downregulates at an accelerated rate and this is shown in figure 5.7A as a decrease in 
amount of the higher molecular weight mature receptor compared to the smaller 
immature from of the receptor together with an overall decrease in total amount of 
receptor (compare first and second lane, figure 5.7A) (Uden et al., 1999; Taylor et al., 
2006).  This effect on downregulation is inhibited by imatinib at concentrations 
similar to those required to inhibit other aspects of FMS activity (see chapter 3).   
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Dasatinib also inhibited M-CSF induced FMS downregulation in both Rat-2 cfms 
fibroblasts (figure 5.7B) and in primary macrophage cultures (figure 5.7C).   
 
The mutant FMS receptor, FMS D802V  is very unstable and downregulates 
constitutively in the absence of M-CSF at such an accelerated rate that little of the 
receptor reaches the cell surface (Morley et al., 1999).  As a result the receptor is 
difficult to see by western blotting unless the receptor has suffered a second mutation 
of Tyr 708 to Phe.  This mutant partially stabilizes the immature form of the receptor 
but the mature form of the receptor appears to be degraded at a similar speed to the 
wild type receptor when stimulated by M-CSF (Morley et al., 1999).  Figure 5.7D 
shows that the ratio of mature FMS receptor to immature receptor is low in Rat-2 
D802VY708 cells (figure 5.6D; lane1) and the mature form of the receptor was 
stabilized at low nanomolar concentrations of dasatinib (figure 5.7D) indicating some 
inhibition of mature receptor turnover.   
 
When the more unstable FMS D802V is overexpressed it can be seen by western 
blotting more easily, this is shown in figure 5.7E (lane 1) in the cell line FMS D802V 
clone 8.  This unstable mutant receptor was also further stabilized by dasatinib at low 
nanomolar concentrations (figure 5.7E).  This was confirmed in figure 5.7F with the 
Rat-2  FMS D802V cell line which does not over express this receptor and is 
therefore difficult to see by western blotting (5.7F, lane 1). This receptor was not 
stabilized by nilotinib (figure 5.7F; lanes 2, 3) or tandutinib (figure 5.7F; lanes 4,5) 
but was slightly stabilized by dasatinib (figure 5.7F; lanes 6,7) at 1 nM and 5 nM.  
The FMS receptor with the mutation T663I is not stabilized by dasatinib using a 
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similar assay (figure 5.7G), confirming that this receptor mutation confers resistance 
to dasatinib and that the FMS receptor stabilization seen by dasatinib is due to a direct 
effect on the receptor. 
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Figure 5.7. Imatinib and Dasatinib inhibit M-CSF induced downregulation of the 
wild type receptor in rat-2cfms fibroblast cells and in primary macrophages.  
Dasatinib also stabilises the mutant receptors D802VY708F and D802V.  The 
FMS T663I mutation is not stabilized by dasatinib.   (A) Bac1.2F5 macrophages 
were starved of M-CSF for 24 hours, then pretreated with imatinib for 1 hour before 
being re-stimulated with 5000 U/ml M-CSF for 1 hour. (B) Rat-2 cfms fibroblasts 
were pretreated with the indicated concentrations of dasatinib for 1 hour and 
stimulated with M-CSF for 1 hour. (C) Primary mature macrophages from ovarian 
cancer ascites were cultured in M-CSF and treated with dasatinib for 2 hours.  (D,E) 
Rat-2  FMSD802VY708F fibroblasts (D) or Rat-2  FMS D802V cl8 fibroblasts (E) 
were treated with dasatinib for 2 hours.  (F) Rat-2  FMS D802V cells were treated 
with the indicated concentrations of either nilotinib, tandutinib or dasatinib for 2 
hours. (G) Rat-2  FMS T663I cells were treated with the indicated concentrations of 
dasatinib for 1 hour and then stimulated with M-CSF for 1 hour.  All lysates were 
immunoblotted with an antibody against the C-terminus of the FMS receptor (Ab792).  
Ponseau stained nitrocellulose membrane shows even loading in (F).  
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Figure 5.8 shows that the Src kinase inhibitor SU6656 (figure 5.8A) and the pan-
kinase inhibitor staurosporine (figure 5.8E) also target the FMS receptor.  FMS 
receptor phosphorylation was inhibited by SU6656 with an IC50 value of 
approximately 1 µM (figure 5.8A) and in accordance with figure 5.7, SU6656 also 
inhibits M-CSF induced receptor degradation at similar concentrations to those 
required to inhibit other aspects of receptor activity (figure 5.8B).  SU6656 also 
targets FMS D802VY708F with a similar IC50 to the wild type receptor (figure 5.8C; 
upper panel) and accordingly stabilises the mature form of the mutant receptor (figure 
5.8C; lower panel).  In confirmation of this, SU6656 inhibits the accelerated 
degradation of the particularly unstable FMSD802V receptor and stabilizes both the 
mature and immature receptor (figure 5.8D).  Staurosporine was also an effective 
inhibitor of FMS phosphorylation with an IC50 value of around 20 nM (figure 5.8E) 
and figure 5.8F shows that staurosporine inhibited the accelerated FMS turnover 
induced by M-CSF at similar concentrations to those that were required to inhibit 
phosphorylation (figure 5.8E). 
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Figure 5.8.  The Src kinase inhibitor SU6656 and the pan-kinase inhibitor 
staurosporine also target the FMS receptor and inhibit both phosphorylation 
and receptor degradation of FMS and FMS D802V.  (A) Rat-2 cfms fibroblasts 
were treated with the indicted concentrations of SU6656 and stimulated with 5000 
U/ml M-CSF for 5 mins.  Immunoprecipitated receptor was then immunoblotted with 
an antibody against total phosphorylated tyrosine (PY99). (B) Rat-2 cfms fibroblasts 
were pretreated with the indicated concentrations of SU6656 for 1 hour then 
stimulated with M-CSF for 1 hour and immunoblotted for total FMS receptor. (C)  
Rat-2FMS D802VY708F cells are treated with SU6656 for 2 hours and 
immunoblotted for either FMS phospho-723 (C, upper panel) or total FMS receptor 
(C, lower panel). (D)  Rat-2 D802V cells were treated for 2 hours with SU5565 and 
immunoblotted for total FMS receptor (D, upper panel), D; lower panel shows total 
protein loading on nitrocellulose membrane.  (E) Rat-2 cfms cells were pre-treated 
with the indicated concentrations of staurosporine for 2 hours and stimulated with M-
CSF for 5 minutes before being immunoblotted for FMS phospho-tyrosine 723 (E, 
upper panel) or for total FMS receptor (E, lower panel).  (F) Rat-2 cfms fibroblasts 
were pretreated with various concentrations of staurosporine for 1 hour and stimulated 
with M-CSF for 1 hour then immunoblotted with an antibody FMS antibody Ab 792. 
(A) Courtesy of J. Taylor. 
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Figure 5.9A shows immunofluorescence staining of FMS in N9 microglia cells.  In 
these cells, FMS had a clear cell surface localisation, creating a halo around the cell.  
Figure 5.9B shows that M-CSF stimulation caused a movement of the receptor into 
internal vesicles.  A similar effect has been reported previously for the KIT receptor 
(Jahn et al., 2002).   This can also be observed in Rat-2 cfms fibroblasts which 
express the wild type FMS receptor (figure 5.9 C,D).  The FMS K616A kinase 
inactive mutant receptor did not appear to localise into equivalent vesicles upon 
stimulation with M-CSF and had an evenly distributed cell surface appearance with 
little vesicles localisation both before (figure 5.9E) and after M-CSF stimulation 
(figure 5.9F).  This is in accordance with a previous report and confirms that this 
mutant receptor does not internalise in response to M-CSF (Carlberg et al., 1991).  I 
also investigated a second kinase inactive receptor, FMS E633H (Uden et al., 1999).   
In contrast to FMS K616A, this mutant receptor appeared similar to the wild type 
receptor and the majority of cell surface receptor moved to internal vesicles with M-
CSF stimulation for 15 minutes (figure 5.9H).  This is in accordance with Uden et al 
(1999) and shows that this kinase inactive receptor internalises in response to M-CSF.  
Figure 5.9I,J shows that the FMS staining with this antibody does not cross react with 
any other cell component in Rat-2 fibroblasts.  
 153 
 
C D
E F
G H
No Treatment 15 mins M-CSF
Rat2 cfms
Rat2
FMSK616A
Rat2
FMSE633H
JI
Rat2
fibroblasts
FMS DAPI
N9 microglia
A B
 
Figure 5.9 
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Figure 5.9 The wild type FMS receptor and the kinase inactive FMS receptor 
FMS E633H , but not the kinase inactive receptor FMS K616A downregulate 
into intracellular vesicles in response to M-CSF. (A,B) N9 microglia cells treated 
with or without M-CSF for 15 mins.  Cell were probed with a FMS antibody specific 
to the N-terminus of the receptor (AFS-98) and visualised with an alexa flour 488 
conjugated secondary antibody.  (C-H) Rat-2  fibroblasts expressing either wild type 
FMS (C-D) or the FMS mutants K616A (E-F) or FMS E633H (G-H) were stimulated 
with M-CSF for 15 minutes (D,F,H) or were not treated (C,E,G).  Cells were fixed 
and probed with an antibody specific to the FMS receptor N-terminus (3-4A4) and  
visualised with an alexa flour 488 conjugated secondary antibody. (G) Rat-2  
fibroblasts immunostained for the FMS receptor (negative control) (H) DAPI staining 
of G. Ruler = 50 µm. 
 
 
It has been demonstrated previously that the lysosome inhibitor methylamine inhibits  
the constitutive degradation of FMS but does not have an apparent effect on the 
accelerated, ligand inducible degradation, indicating that FMS downregulates down 
two distinct pathways (N. Dibb, unpublished) (Seglen et al., 1979). This effect on the 
constitutive pathway is confirmed in figure 5.10A which shows that methylamine 
caused a build up of receptor as assayed by western blotting.  Figure 5.10 confirms 
this data by immunofluorescence staining of FMS in Rat-2 cfms fibroblasts and shows 
that the constitutive degradation of both the wild type receptor (figure 5.10; B-D) and 
the kinase inactive mutant receptor FMS E633H (figure 5.10; E-G) are inhibited by 
methylamine.   Both the mutant and wild type receptor aggregated in large vesicles 
close to the centre of the cell, with the most striking accumulation after 4 hours of 
methylamine treatment at 10 mM (figure 5.10 D,G).   
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Figure 5.10 
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Figure 5.10. The wild type FMS receptor and the kinase inactive receptor FMS 
E633H both aggregate into intracellular vesicles when incubated with the 
lysosome inhibitor methylamine. (A) Methylamine was incubated with Rat-2cfms 
cells at the indicated concentrations for 3 hours and immunoblotted for the FMS 
receptor using an antibody against the c-terminus (Ab 792).  (B-G) 10 mM 
methylamine was added to either Rat-2 cfms (B-D) or Rat-2 E633H (E-G) fibroblasts 
and incubated at  37°C for 0 hours (B,E) 1hour (C, F) or 4 hours (D,G). Cells were 
then fixed and probed with an antibody specific for the N-terminus of the FMS 
receptor (3-4A4).  An Alexa-Fluor 488 secondary antibody was used for visualisation. 
Ruler = 50 µM 
 
 
I next investigated the effect of methylamine on the ligand inducible pathway, with 
the aim to deduce whether the wild type and mutant receptor follow similar 
downregulation pathways.  Figure 5.11 A,B confirm that untreated Rat-2 cfms cells 
had a dispersed, cell surface appearance (figure 5.11A) and that M-CSF induced 
aggregation of the FMS receptor into internal vesicles (figure 5.11B).  Figure 5.11C, 
and  5.12C confirms that when the cells are pretreated with methylamine, internal 
FMS containing vesicles appear in the centre of the cell, although dispersed, cell 
surface receptor is also visible (figure 5.11C, 5.12C).   Stimulation with M-CSF 
causes the more dispersed FMS receptor on the cell surface to disappear, indicating 
that methylamine does not inhibit the internalisation of the receptor from the surface 
(figure 5.11D, 5.12D).  The FMS E633H receptor appears to downregulate in a 
similar, methylamine insensitive way in response to M-CSF stimulation (figure 5.11; 
E-H, 5.12; E-H) indicating that both the wild type receptor and FMSE633H 
downregulate in response to M-CSF via similar pathways. Figure 5.12 shows more 
detailed, higher magnification photographs of figure 5.11 
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Figure 5.11. M-CSF induced aggregation of the FMS receptor into internal 
vesicles and this is not inhibited by 10 mM methylamine . Rat-2 cfms (A-D) or 
Rat-2  FMS E633H cells (E-H) were treated with 10 mM methylamine for 3 hours 
before stimulation with M-CSF for 15 minutes (B, D, F, H) and  were then fixed and 
probed with an antibody specific for the N-terminus of the FMS receptor (3-4A4)  An 
Alexa-Fluor 488 secondary antibody was used for visualisation. Ruler = 50 µM 
Figure 5.11 
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Figure 5.12. Higher magnification view of figure 11. Rat-2 cfms (A-D) or Rat-2  
FMS E633H cells (E-H) were treated with 10 mM methylamine for 3 hours before 
stimulation with M-CSF for 15 minutes (B, D, F, H) and  were then fixed and probed 
with an antibody specific for the N-terminus of the FMS receptor (3-4A4)  An Alexa-
Fluor 488 secondary antibody was used for visualisation. Ruler = 50 µM 
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Figure 5.13A confirms that the kinase inactive receptor FMSE633H is not 
phosphorylated on tyrosine 723 as expected (Uden et al., 1999) and figure 5.13B 
(lanes 1 and 2) confirms that this receptor is degraded upon stimulation with M-CSF 
in Rat-2  FMSE633H cells.   This receptor degradation was inhibited effectively by 
both dasatinib (5.13B; lanes 3-6) and imatinib (5.13C).  This provides further 
evidence that neither kinase activity, nor ubiquitination are necessary for degradation 
in this receptor.   
MCSF                                     - +              +             +               +   
Dasatinib (nM)                       0               0             60        120           250
FMS E633H
MCSF                                  - +            +           +            +           + 
imatinib (µM)                      0            0           0.5         1  2           4 
FMS E633H
C
B
A
WT                   E633H
MCSF                                       - +              - +
Phospho-FMS PY723
 
 
 
 
Figure 5.13. Both dasatinib and imatinib  inhibit M-CSF induced degradation of 
the kinase inactive mutant receptor FMS E633H. (A) Rat-2 cfms and Rat-2  
FMSE633H cells were stimulated with M-CSF for 5 minutes , lysed and western 
blotted with an antibody specific to FMS phosphotyrosine 723.  (B,C) Rat-2  
FMSE633H cells were pretreated with either dasatinib (C) or imatinib (D) for 1 hour 
then stimulated with M-CSF for 1 hour.  Cell lysates were immunoblotted for total 
FMS receptor.  
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5.3 Discussion 
5.3.1 Tandutinib  
I found tandutinib to be a potent inhibitor of FMS receptor phosphorylation, 
signalling and FMS induced fibroblast transformation (figures 5.1-5.2).  In support of 
this, the FMS mutation D802V confers resistance to tandutinib (figure 5.1 and 5.2B-
D).  Tandutinib also inhibits in vitro osteoclast and macrophage colony formation at 
similar concentrations to FMS inhibition (figure 5.3).  This opens new possibilities for 
treating diseases with tandutinib where cell types which are dependent on FMS 
signalling are implicated. 
 
 The concentration of tandutinib required to inhibit the FMS receptor, macrophage 
colony formation and osteoclastogenesis in vitro is less than the plasma trough levels 
of around 2 micromolar observed in patients who are treated with tandutinib 
(DeAngelo et al., 2006).  This raises the possibility of some inhibitory effect of 
tandutinib upon these processes; however it should be noted that the inhibitory effects 
of tandutinib and imatinib upon FMS are similar in vitro (see chapter 3) and that 
imatinib is very well tolerated by patients and is a well established treatment and so 
may be a better choice as a therapeutic FMS inhibitor.    Nevertheless, tandutinib also 
has the potential to be developed as an inhibitor of the wide range of diseases that are 
known to be dependent upon FMS expression. 
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5.3.2 FMS kinase inhibitors as research tools 
5.3.2.1 Anomalous FMS phosphorylation 
 
Tyrosine kinase inhibitors of FMS are useful research tools and have previously been 
unavailable to the lack of specificity for the FMS receptor of many of the pan kinase 
inhibitors that are available.  I have shown in figures 5.4 - 5.6 that in the presence of 
the various FMS kinase inhibitors established here, at least one FMS phosphorylation 
site remains phosphorylated when other aspects of receptor activity are inhibited, 
including in vitro kinase activity.  What is more surprising is that different kinase 
inhibitors allow different tyrosine residues to be phosphorylated.  For example, figure 
5.4A shows that phosphorylation of FMS tyrosine 723 is extremely sensitive to 
nilotinib, whereas figure 5.4B shows that the same tyrosine is resistant to tandutinib 
and conversely, phosphorylation of FMS tyrosine 708 is resistant to nilotinib but 
sensitive to tandutinib.  This seems to be evidence that at least one other kinase is able 
to phosphorylate FMS tyrosines 723 and 708, although it is unclear whether this 
second kinase is necessary for phosphorylation of these residues. 
 
Both tyrosines 708 and 723 were previously thought to be FMS autophosphorylation 
sites although these experiments were carried out in vitro and the authors 
acknowledge that these results are not necessarily relevant in vivo (van der Geer and 
Hunter, 1990; Tapley et al., 1990; Reedijk et al., 1992).  Tyrosine 723 is thought to 
bind to the p85 subunit of phosphatidylinositol 3'-kinase (PI3 Kinase) once it has been 
phosphorylated, allowing downstream signalling to AKT (Reedijk et al., 1992).  In 
my experiments, tyrosine 723 is phosphorylated in the presence of tandutinib and 
dasatinib, but downstream phosphorylation of AKT is inhibited along with FMS 
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kinase activity (Chapter 4, figure 4.3).  It would be useful to know whether p85 still 
binds to FMS when these inhibitors are bound. 
 
At present it is not clear what the physiological relevance of these findings are and 
they need to be tested further.  These results do show however that the 
phosphorylation state of the receptor is not necessarily an appropriate marker of 
receptor activity in this type of inhibitor assay. 
 
5.3.2.2 FMS downregulation 
I have also shown preliminary results that various FMS inhibitors, including imatinib 
can inhibit M-CSF inducible FMS degradation.  Imatinib is thought to bind to only 
the inactive form of the FMS and KIT receptors and as a result, mutant receptors 
which are permanently in an active conformation confer resistance to imatinib (Mol et 
al., 2004a; Mol et al., 2004b).  It is therefore expected that imatinib would inhibit 
downregulation of the wild type receptor as an active conformation is thought to be 
required to trigger accelerated, M-CSF induced downregulation of FMS (Uden et al., 
1999).  The FMSE633H mutant receptor is kinase inactive and downregulates in 
response to M-CSF and this is evidence the accelerated degradation is due to a change 
in structure of FMS upon M-CSF stimulation and not due to FMS kinase activity. It 
therefore seems possible that there could be a kinase inhibitor that binds to the active 
form of the receptor which would not inhibit M-CSF induced downregulation.  Our 
structural model of dasatinib binding to FMS predicts that dasatinib may bind to the 
active conformation of FMS (Chapter 4, figure 4.4).  This is supported by dasatinib 
inhibition of FMSD802V and FMSD802VY708F (Chapter 4, figure 4.1 and 4.2) as 
these particular mutant are thought to force the kinase domain into a permanently 
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activated conformation (Mol et al., 2004a; Mol et al., 2004b).  It was therefore 
surprising that dasatinib inhibited M-CSF stimulated FMS downregulation (figure 
5.7B) and that it also stabilised both FMS D802VY708F (figure 5.7D) and FMS 
D802V (figure 5.7E,F).   FMS T633I confers resistance to dasatinib, and as expected 
dasatinib does not stabilise this receptor confirming that stabilisation of the wild type 
receptor is due to a direct effect of the inhibitor on the receptor (figure 5.7.G).  A 
second FMS and FMSD802V kinase inhibitor, SU6656 (figure 5.8A) confirms these 
results because it stabilised M-CSF induced degradation of the wild type receptor 
(figure 5.8B) and also stabilised FMSD802V and FMSD802VY708F (figure 5.8 C,D).  
These results may indicate that that the kinase inhibitors themselves inhibit a 
structural change which is required for downregulation, such as dimerization. 
 
The main evidence available that FMS kinase activity is not required for 
downregulation are the various kinase inactive FMS mutant receptors, including 
FMSE633H  which still downregulate in response to M-CSF (Uden et al., 1999).  I 
confirmed that FMSE633H internalises in response to M-CSF (figure 5.9A-H) in a 
similar, methylamine independent way to the wild type receptor (figure 5.10-5.12) 
and also confirmed that FMSK616A does not downregulate in this assay as reported 
previously (5.9E-F) (Carlberg et al., 1991).  I have also shown that both the wild type 
receptor and FMSE633H are both constitutively downregulated by pathways which 
are sensitive to the lysosome inhibitor methylamine (figure 5.10). 
 
  Interestingly, both imatinib and dasatinib inhibit the degradation of FMSE633H in 
response to M-CSF (figure 5.14B,C).  This indicates that imatinib and dasatinib 
inhibit the M-CSF inducible downregulation of the wild type receptor and the 
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FMSE633H receptor by inducing or inhibiting a change in receptor structure, and is 
further evidence that kinase activity is not required for FMS downregulation. 
 
5.3.3 Conclusion 
 
FMS kinase inhibitors are useful research tools to study the general mechanisms of 
FMS activity and structure and here I have used imatinib and dasatinib to further 
establish that kinase activity and ubiquitination are not necessary for downregulation 
of this receptor and that downregualtion is likely to be controlled by changes in 
receptor structure.  I have also shown that other kinases are able to phosphorylate 
FMS on two residues in the kinase insert region, although the physiological relevance 
of this finding is unclear.  This needs to be developed further but could lead to the 
identification of secondary drug targets for signalling by the PDGF receptor family. 
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CHAPTER 6. GENERAL  DISCUSSION 
 
The FMS receptor is a member of the PDGF receptor family of receptor tyrosine 
kinases and is mainly expressed on cells of the monocyte lineage where it is important 
for differentiation, activation and survival of macrophages, osteoclasts and microglia 
(Cecchini et al., 1994; Michaelson et al., 1996; Wiktor-Jedrzejczak et al., 1982; 
Wegiel et al., 1998).  FMS is therefore a potential target for treatment of a wide 
variety of diseases in which these cell types are implicated, including inflammatory 
diseases, tumour metastasis and osteolytic bone cancer (Dewar et al., 2006; Murray et 
al., 2003; Ando et al., 2006; Lin et al., 2002; Nowicki et al., 1996; Ohno et al., 2008).  
Before this project began, there were no available small molecule inhibitors of the 
FMS receptor and my initial aim was to identify some such inhibitors and investigate 
their use both as potential therapeutic agents and as tools to study FMS receptor 
activity in vitro. 
 
6.1 FMS receptor kinase inhibitors 
 
There has recently been much success in developing small molecule inhibitors which 
specifically target tyrosine kinases.  Many of these inhibitors have FDA approval and 
are routinely used to treat their intended malignancy (see introduction, table 1.2).  
These inhibitors are however not always totally specific for the kinase which they 
were initially designed to inhibit.  Because many of these kinase inhibitors are 
tolerated extremely well by patients, this strongly indicates that these inhibitors may 
be useful in treating diseases where other kinases are implicated if these secondary 
targets are identified and are targeted at therapeutically relevant concentrations.   
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I therefore screened various clinically relevant kinase inhibitors which would be 
expected to also target the FMS receptor and identified four inhibitors which target 
FMS at clinically relevant concentrations, these are imatinib, nilotinib, tandutinib and 
dasatinib (Brownlow et al., 2008a; Brownlow et al., 2008b; Taylor et al., 2006).    
 
Osteoclasts are causally implicated in osteolytic bone cancer, osteoarthritis and 
osteoporosis.  I therefore investigated whether the inhibitors which I had identified 
had the potential to inhibit osteoclastogenesis.   I have shown that in fact all of these 
inhibitors prevent osteoclast formation from normal mobilised peripheral blood at 
similar concentrations to those at which they target the FMS receptor.  This is with the 
exception of nilotinib which was a much more potent inhibitor of osteoclastogenesis 
than of FMS indicating that nilotinib targets another kinase at low concentrations 
which is important for osteoclastogenesis (see table 6.1 for summary of results).   
Since the start of this study, bone thickening has been reported in patients who have 
been taking relatively high doses of imatinib for long periods, supporting the potential 
of imatinib to inhibit osteoclast formation in vivo and the potential of FMS inhibitors 
to target osteoclasts (Berman et al., 2006; Joensuu and Reichardt, 2006; Fitter et al., 
2007).   
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7.4 nM
(unpublished, 
figure 3.11)
2 µM 
(DeAngelo et al., 
2006)
1.7 – 3.6 µM 
(Weisberg et al, 
2006)
1.5 -5 µM 
(Druker et al., 2001).
Plasma levels
0.5 nM
400 nM
250 nM
600 nM
IC50 
FMS
Dasatinib
Tandutinib
Nilotinib
Imatinib
Inhibitor
0.1-.0.5 nM
400 nM
50 nM
650 nM
IC50
Osteoclastogenesis
0.1-0.5 nM
Not tested
Not tested
600 nM
IC50 tumour 
associated 
macrophages
1 nM
Not tested
Not tested
< 1000 nM
IC50 spontaneous, 
tumour associated 
Osteoclasts
0.1-1 nM
500 nM
500 nM
500 nM
IC50
Macrophage 
colony 
formation
Table 6.1. Summary of kinase inhibitor IC50 values. 
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I have also shown that dasatinib, but not imatinib inhibits spontaneous 
osteoclastogenesis from ovarian cancer ascites samples (table 4.2). These osteoclasts 
were slightly different to normal osteoclasts as they were produced without the 
requirement for recombinant M-CSF and RANKL.  The reasons for this are unclear 
but it is presumably due to the presence of another growth factor or cytokine which 
they have been exposed to in vivo or that is being released from another cell type in 
this culture system.  This finding may not be physiologically relevant as metastasis to 
the bone is reported extremely rarely in ovarian cancer patients (Kingston et al., 2001).   
It would be interesting to further develop these results and also to apply them to an in 
vitro model of bone metastasis from breast cancer, which is much more common than 
bone metastasis from ovarian cancer (Akhtari et al., 2007; Roodman, 2001).  Figure 
4.8 shows preliminary results that osteoclasts developed from breast cancer pleural 
effusion fluid in the absence of recombinant M-CSF and RANKL and that these 
osteoclasts were sensitive to both imatinib and dasatinib, but I was unable to repeat 
these results due to a lack of material available during the course of my project.   
 
Macrophages are thought to be important inflammatory cells of the tumour 
microenvironment and are heavily implicated in the progression of various solid 
tumours including ovarian cancer and breast cancer (Condeelis and Pollard, 2006; 
Pollard, 2004; Allavena et al., 2007; Luo et al., 2006).  These tumour associated 
macrophages are thought to assume a wound healing, M2 macrophage type phenotype 
in the tumour microenvironment in response to the many immunosuppressive 
cytokines and growth factors. (Hagemann et al., 2006; Mantovani et al., 2002). 
Importantly, M-CSF is often found at high levels in this environment in both ovarian 
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cancer and breast cancer, and is a strong prognostic indicator of poor outcome 
(Kacinski, 1997; Kacinski, 1995).  M-CSF recruits large numbers of macrophages and 
these cells are thought to support tumour growth by stimulating angiogenesis and also 
to support tumour metastasis (Allavena et al., 2007).  I therefore investigated whether 
these inhibitors have the potential to target macrophages.  I have shown that all four 
of the inhibitors reported here target murine macrophage colony formation and that 
both imatinib and dasatinib inhibit tumour associated macrophage production from 
ovarian cancer ascites fluid in vitro (figures 3.5, 4.6, 5.3) 
 
The most interesting of these inhibitors was dasatinib as it is such a potent inhibitor of 
FMS with an IC50 value of 0.5 nM (figure 4.1).  The plasma levels of dasatinib 
achieved in patients has not yet been reported so I designed an in vitro assay to 
estimate the plasma  levels achieved in patients who are taking dasatinib to treat CML 
(figure 4.11).  The average patient plasma level for dasatinib was estimated to be 7.4 
nM (as calculated from figures 4.10 and 4.11).  The therapeutic potential of each of 
these four inhibitors can now be compared based on the difference between the 
plasma  levels and the concentration of inhibitor required to inhibit FMS, assuming 
that the bigger the difference between the two values, the more likely the inhibitor is 
to effectively inhibit FMS in vivo.   
 
Table 6.1 summarises the IC50 values for all of the assays discussed here.  It seems 
that dasatinib is the most potent inhibitor of FMS as the plasma concentration is 
approximately 14 times greater than the concentrations required to inhibit FMS, 
compared to around 5 times for imatinib, 11 times for nilotinib and 5 times for 
tandutinib.  Nilotinib may however be a more potent inhibitor of osteoclastogenesis as 
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normal osteoclasts were extremely sensitive to nilotinib in these assays with an IC50 
value of 50 nM which is around 56 times more potent than the plasma levels of 1.7-
3.6 which are reported (table 6.1) (Weisberg et al., 2006).   
 
The macrophages produced in culture are highly dependent on M-CSF stimulation as 
no macrophages were produced in the absence of exogenous M-CSF.  This is a 
slightly artificial system because, although high concentrations of M-CSF have been 
consistently reported in the tumour microenvironment of breast cancer and ovarian 
cancer, there may also be other cytokines and growth factors which could support 
macrophage survival or differentiation in the absence of FMS signalling (Burke et al., 
1996; Kacinski, 1997; Smith et al., 1995; Kacinski, 1995).  These other cytokines may 
also polarise the macrophages to display a different phenotype in the absence of FMS 
signalling.  It is therefore unclear what the outcome of inhibiting the FMS receptor 
would be in vivo. 
 
This problem could be addressed by developing a more realistic model of the tumour 
microenvironment.  One way to do this is to use an animal model of ovarian cancer to 
further test these inhibitors.  This is an expensive and time consuming route and it is 
currently unclear whether any of the mouse models of ovarian cancer which are 
currently available fully represent a host-tumour interaction which can be translated to 
humans (Foulkes, 2002).  Another solution would be to attempt to develop an in vitro 
culture system that contains a more comparable mixture of growth factors and 
cytokines to the normal tumour microenvironment and to test these inhibitors on the 
macrophages produced in this system.  This could be achieved by either creating a co-
culture system with primary tumour cells and macrophages or more simply, and 
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perhaps more realistically, to supplement the growth media of macrophages in culture 
with ascites solution periodically.   
 
6.2 Inhibitors as research tools 
6.2.1. Phosphorylation of the kinase insert region 
 
The identification of new FMS inhibitors has proven useful in investigating some 
aspects of FMS activity in vitro.  It has also yielded some surprising results, in 
particular the observation that phosphorylation of tyrosines 723 and 708 of the kinase 
insert region are differently affected by each of the four kinase inhibitors that I 
investigated at concentrations at which the receptor kinase activity is inhibited.  This 
data is summarised in table 6.2. 
 
Table 6.2.  Summary of phosphorylation site data (from figures 5.4-5.6). 
Inhibitor Inhibition of tyrosine 723 Inhibition of tyrosine 708 
Nilotinib Yes No 
Tandutinib No Yes 
Imatinib Less sensitive Not tested 
Dasatinib Less sensitive No 
 
 
This indicates that at least one other kinase is able to phosphorylate the FMS receptor 
when bound to the kinase inhibitors (Table 6.2).  What is more surprising is that 
different inhibitors (ie nilotinib and tandutinib) have different effects on the 
phosphorylation of the kinase insert region. 
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One possible hypothesis which may explain these surprising results is that these 
kinase inhibitors could be stabilizing the kinase in several semi-activated structural 
states.   It is already known that the crystal structure of imatinib bound to the KIT 
receptor does not perfectly align with either the crystal structure of the active or 
inactive form of the receptor (figure 5.15) and that the structure of KIT bound to 
imatinib  is  intermediate between the active and inactive receptor (Mol et al., 2004; 
figure 5.16).  This could mean that the anomalous phosphorylation of the FMS 
receptor seen in the presence of inhibitors happens because the inhibitors stabilise  a 
partially active structure of FMS in which tyrosines 708 or 723 are accessible for  
phosphorylation by another kinase(s).   
 
It can be seen from the crystal structure of the KIT receptor that the juxtamembrane 
region of KIT is phosphorylated in trans by another receptor monomer as two of the 
tyrosines (tyrosines 568 and 570) in this region were phosphorylated in the crystal 
structure and one of these residues (tyrosine 568) was caught in the act of becoming 
phosphorylated (Mol et al., 2003).  In this structure none of the other tyrosines were 
phosphorylated, which implies that phosphorylation of the juxtamembrane region may 
precede the phosphorylation of the other tyrosines including those in the activation 
loop and the kinase insert region.  This is supported by various experiments carried 
out by the Stanley group who show that the phosphorylation of different tyrosines of 
the FMS receptor occurs sequentially rather than simultaneously (Li and Stanley, 
1991; Yeung and Stanley, 2003).  It is therefore possible that the trans 
phosphorylation of the juxtamembrane region stabilises the active structure and this 
stabilisation is required for access to the kinase insert region by another kinase.  These 
kinase inhibitors may therefore stabilise the kinase in various semi-activated states 
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allowing differential access to the kinase insert region depending in the structure of 
the inhibitor.  This could be tested by looking for association of binding proteins with 
the kinase insert region in the presence of these inhibitors as it would be predicted that 
these sites should be exposed for binding only in the presence of these kinase 
inhibitors or M-CSF. 
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Inactive KIT aligned with
imatinib bound KIT
Active KIT aligned with
imatinib bound KIT
Aligned structures
Non-aligned structures
Figure 6.1 
Figure 6.1  The crystal structure of imatinib bound to the KIT receptor does not fully align with either the receptor in its active or inactive 
form. The following receptor structures were aligned from NCBI using the CN3D program: inactive KIT receptor (1t45) and imatinib bound KIT 
receptor (1t46) (A), active KIT receptor and  imatinib bound KIT receptor 1t46 (B).  Red colouring shows closely aligned structures and grey 
colouring shows non-aligned structures. 
A B
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Inactive KIT Imatinib bound KIT Active KIT
Figure 6.2  The structure of imatinib bound to the KIT receptor may be an intermediate step between the active and inactive 
receptor states.  The following receptor structures were retrieved from NCBI using the CN3D program: inactive KTI receptor 1t45 (A), 
imatinib bound to the KIT receptor 1t46 (B) and the active KIT receptor 1PKG(C) and orientated to equivalent positions by aligning the 3 
structures before recording their images  individually.
A B C
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6.2.2. FMS receptor downregulation 
 
During the course of this project I have created an immunofluorescence assay to study 
downregulation of the wild type FMS receptor and various mutant receptors and I 
have used this assay to confirm the previous finding that the FMSE633H kinase 
inactive mutant receptor downregulates in response to M-CSF (figure 5.9).  It would 
now be useful to characterize carefully the endocytosis pathways of the wild type 
receptor and the kinase inactive receptors in order to fully establish whether the two 
receptors are being trafficked through similar pathways.  I have also shown that 
various kinase inhibitors of the FMS receptor inhibit the downregulation of both the 
wild type receptor and the kinase inactive FMS E633H receptor (figure 5.7, 5.8, 5.13).  
This was an interesting finding as it gave further evidence that it is a structural change 
in the receptor which is required for downregulation rather than kinase activation.  
This could be further characterised by using dimerisation assays to check whether the 
kinase inhibitors used here prevent dimerisation. It would also be interesting to further 
investigate whether there are any kinase inhibitors which inhibit kinase activity but 
allow downregulation of the receptor in response to M-CSF and to elucidate whether 
our downregulation results can be applied to the whole of the PDGF receptor family. 
 
6.3. Conclusions 
 
I have established that imatinib, tandutinib, nilotinib and dasatinib are inhibitors of the 
FMS receptor as tested in various biochemical and cell based assays.  All of these 
inhibitors prevented differentiation of human macrophages and osteoclasts in vitro 
and dasatinib and imatinib both inhibited production of tumour associated 
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macrophages from ovarian cancer ascites.  Dasatinib is the most potent of these 
inhibitors and is present in patient serum at biologically active concentrations which 
would be expected to target FMS in vivo.   Together, these kinase inhibitors provide a 
strong platform for the development of agents which specifically target the FMS 
receptor and could be an important progression in the targeting of the tumour 
microenvironment. 
 
I have also provided evidence that the FMS receptor is phosphorylated on the kinase 
insert region by at least one other kinase in the absence of receptor kinase activity, 
this project could be developed further to identify the kinase responsible.  I have also 
confirmed previous findings that the kinase inactive receptor FMSE633H 
downregulates in response to M-CSF and have used the kinase inhibitors identified in 
this project to support a structural explanation for receptor downregulation. 
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